No definition available.
Melanocytic naevi of lower limb, including hip
EFO MESH Endpoint Browser PheWeb
CD2_BENIGN_MELANOCYTIC_LOWERLIMB
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
1861 |
4. Check minimum number of eventsNone |
1861 |
5. Include endpointsNone |
1861 |
6. Filter based on genotype QC (FinnGen only) |
1824 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D22
- Name in latin
- Naevus melanocyticus (cutis) coxae
Similar endpoints
↥List of similar endpoints to
Melanocytic naevi of lower limb, including hip
based on the number of shared cases.
Similar with more cases:
- Melanocytic naevi
- Benign neoplasms
- Neoplasms
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 10634 | 6739 | 3862 |
| Only index persons | 9877 | 6347 | 3530 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.16 | 0.19 | 0.11 |
| Only index persons | 0.20 | 0.23 | 0.13 |
| Median age at first event (years) | |||
| Whole population | 39.83 | 41.13 | 37.49 |
| Only index persons | 41.39 | 42.30 | 39.75 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1824 | 1251 | 573 |
| Unadjusted period prevalence (%) | 0.39 | 0.44 | 0.26 |
| Median age at first event (years) | 52.32 | 49.06 | 59.44 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 1861
- Matched controls
- 18610
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
8.6
310.4
460
681
QDE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in lower limb
61.9
307.7
792
220
D22.5
ICD-10 Finland
Melanocytic naevi of trunk
9.9
307.7
487
646
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
10.1
307.7
622
883
D22.7
ICD-10 Finland
Melanocytic naevi of lower limb, including hip
3886.3
307.7
1781
106
D22.9
ICD-10 Finland
Melanocytic naevi, unspecified
7.2
201.5
335
551
C43.72
ICD-10 Finland
Malignant melanoma of the lower extremity including the hip: 'superficial spreading' type
56.2
178.3
101
19
D48.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Skin
6.0
159.8
318
620
QCE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in upper limb
10.6
148.1
168
172
XQ845
NOMESCO Finland
Dermatoscopy
11.8
145.6
153
140
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
4.8
125.3
322
778
QDE99
NOMESCO Finland
Other excision or repair of lesion of skin of lower limb
27.8
124.7
85
32
C43.52
ICD-10 Finland
Malignant melanoma on the torso: 'superficial spreading' type
21.5
122.1
92
45
XQ848
NOMESCO Finland
Dermatological photography
7.8
118.4
172
240
L57.0
ICD-10 Finland
Actinic keratosis
4.3
115.7
350
957
TQW99
NOMESCO Finland
Other minor procedure on skin
5.7
105.5
212
412
D03.7
ICD-10 Finland
Melanoma in situ of lower limb, including hip
59.8
103.5
58
10
R23.8
ICD-10 Finland
Other and unspecified skin changes
3.0
101.6
645
2806
8720/3-C44.7
ICD-O-3
Malignant melanoma, NOS, of skin of lower limb and hip
31.0
96.0
63
21
QBA25
NOMESCO Finland
Destruction of lesion of skin of trunk
9.7
91.2
109
119
C43.70
ICD-10 Finland
Malignant melanoma of the lower extremity including the hip without histology
26.9
87.2
60
23
2167A
ICD-9 Finland
Benign neoplasm of skin, Skin of lower limb, including hip[ALARAAJAN IHON BEN KASV,NAEVUS PIGMENTOSUS]
+∞
87.2
83
*
D22.6
ICD-10 Finland
Melanocytic naevi of upper limb, including shoulder
8.9
84.4
107
126
8720/3-C44.9
ICD-O-3
Malignant melanoma, NOS, of skin, NOS
13.9
80.5
75
56
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
6.8
79.0
127
197
C43.50
ICD-10 Finland
Malignant melanoma of the torso without histology
22.7
72.3
53
24
C43.59
ICD-10 Finland
Malignant melanoma of the trunk other or unspecified histology
25.7
71.4
50
20
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
6.3
67.9
118
198
C43.79
ICD-10 Finland
Malignant melanoma of the lower extremity including hip or other unspecified histology
31.4
65.7
43
14
QAA25
NOMESCO Finland
Destruction of lesion of head or neck
6.9
64.9
102
154
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
4.0
64.4
200
548
9733
FHL
Excision of skin change in operating room or anesthesia
9.2
63.5
78
88
D03.5
ICD-10 Finland
Melanoma in situ of trunk
21.4
61.3
46
22
QXE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in uspecified region
13.9
58.1
54
40
C44.71
ICD-10 Finland
Basocellular carcinoma of the skin of the lower extremity including the hip
12.2
57.6
58
49
127
Kela drug reimbursment
Transplant complication
8.3
57.0
76
95
L82
ICD-10 Finland
Seborrhoeic keratosis
2.5
56.3
461
2188
D22
ICD-10 Finland
Melanocytic naevi
3.6
55.1
201
613
S18
ICPC
Laceration/cut
2.1
53.9
1001
6602
C44.61
ICD-10 Finland
Basocellular carcinoma of the skin of the upper extremity including the shoulder
10.5
52.1
58
57
D22.3
ICD-10 Finland
Melanocytic naevi of other and unspecified parts of face
5.4
49.5
101
197
XQ846
NOMESCO Finland
Digital dermatoscopy and registration of nevi
68.1
46.3
53
8
C43.62
ICD-10 Finland
Malignant melanoma of upper extremity including shoulder: 'superficial spreading' type
16.6
46.2
39
24
8720/2-C44.9
ICD-O-3
Melanoma in situ of skin, NOS
18.0
45.6
37
21
L04AA06
ATC
mycophenolic acid; systemic
6.1
45.3
80
136
ZXC50
NOMESCO Finland
Cryotherapy
5.0
44.5
99
208
D04.7
ICD-10 Finland
Carcinoma in situ: Skin of lower limb, including hip
15.5
43.5
38
25
8720/3-C44.5
ICD-O-3
Malignant melanoma, NOS, of skin of trunk
12.3
42.0
42
35
QAA05
NOMESCO Finland
Incision for biopsy of skin of head or neck
5.5
41.6
82
155
S82
ICPC
Naevus/mole
2.3
39.3
363
1787
D23.7
ICD-10 Finland
Benign neoplasm: Skin of lower limb, including hip
7.1
39.1
59
85
QBE99
NOMESCO Finland
Other excision or repair of lesion of skin of trunk
6.0
39.0
70
121
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
5.2
38.3
80
159
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
3.2
37.9
161
537
PJA12
NOMESCO Finland
Sentinel node biopsy
2.7
36.6
214
851
Z94.0
ICD-10 Finland
Kidney transplant status
7.7
34.9
49
65
8743/3-C44.9
ICD-O-3
Low cumulative sun damage melanoma of skin, NOS
14.1
34.8
32
23
D04.3
ICD-10 Finland
Carcinoma in situ: Skin of other and unspecified parts of face
5.5
34.6
68
128
ZZR00
NOMESCO Finland
Flap of skin
5.2
34.1
71
141
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
10.8
34.1
37
35
ZXC15
NOMESCO Finland
Use of photodynamic technique
6.9
31.5
49
73
C44.41
ICD-10 Finland
Basocellular carcinoma of the skin of the scalp and neck
5.6
31.4
60
110
Z2221
NOMESCO Finland
Medical doctor
1.9
30.9
568
3551
L04AD02
ATC
tacrolimus; systemic
7.1
29.7
45
65
QCA25
NOMESCO Finland
Destruction of lesion of skin of upper limb
10.5
28.1
31
30
L04AA01
ATC
[U] ciclosporin
6.3
27.5
46
74
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
7.8
26.8
37
48
C44.30
ICD-10 Finland
Malignant tumor of the skin on another or unspecified part of the face without histology
7.0
25.5
39
57
L81.4
ICD-10 Finland
Other melanin hyperpigmentation
7.4
25.5
37
51
ZZA00
NOMESCO Finland
Split skin graft
3.9
24.1
73
195
L04AX01
ATC
azathioprine; systemic
3.1
23.9
104
351
D04.6
ICD-10 Finland
Carcinoma in situ: Skin of upper limb, including shoulder
9.2
23.9
29
32
B07.9
ICD-10 Finland
Verruca simplex
3.1
23.8
101
336
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
4.5
23.2
57
130
ZXC20
NOMESCO Finland
Use of chemical agents
4.7
22.7
52
112
L04AD01
ATC
ciclosporin; systemic
4.4
22.6
57
133
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
6.9
22.1
34
50
8090/3-C44.5
ICD-O-3
Basal cell carcinoma, NOS, of skin of trunk
5.2
22.0
45
88
D06BB10
ATC
imiquimod; topical
2.6
21.8
128
508
E0000UV, ,
ATC
1.6
21.6
810
6023
D22.4
ICD-10 Finland
Melanocytic naevi of scalp and neck
4.3
21.2
54
127
S77
ICPC
Malignant neoplasm of skin
6.0
20.9
37
63
C43.71
ICD-10 Finland
Malignant melanoma of the lower extremity including the hip originating in lentigo maligna
77.7
20.7
23
*
ZQZ00
NOMESCO Finland
Treatment of several skin areas
16.0
20.6
33
21
D03.6
ICD-10 Finland
Melanoma in situ of upper limb, including shoulder
42.2
20.5
25
6
S21
ICPC
Skin texture symptom/complaint
1.9
20.0
310
1809
A12AA04
ATC
calcium carbonate; oral
4.9
19.9
44
92
ZXD10
NOMESCO Finland
Scheduled procedure
1.6
19.6
668
4823
ZXE10
NOMESCO Finland
More than one and less than three hours
1.6
19.5
631
4500
QDA25
NOMESCO Finland
Destruction of lesion of skin of lower limb
14.8
19.4
32
22
SPAT1153
SPAT
Removal of sutures
1.6
19.2
548
3784
D04.5
ICD-10 Finland
Carcinoma in situ: Skin of trunk
7.3
19.1
28
39
C43.73
ICD-10 Finland
Malignant melanoma of the lower extremity including the hip nodular
28.1
18.7
25
9
C43.60
ICD-10 Finland
Malignant melanoma of the upper extremity including the shoulder without histology
21.1
18.6
27
13
TQW80
NOMESCO Finland
Local dermatologic skincare
3.5
18.6
65
192
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
6.2
18.1
31
51
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
2.6
18.1
104
408
S29
ICPC
Skin symptom/complaint other
1.7
18.0
399
2577
C43
ICD-10 Finland
Malignant melanoma of skin
24.3
17.3
24
10
Z49.1
ICD-10 Finland
Extracorporeal dialysis
5.2
17.2
35
68
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
3.9
17.2
50
130
ZXA05
NOMESCO Finland
Left side
1.7
16.9
407
2681
8720/3-C44.6
ICD-O-3
Malignant melanoma, NOS, of skin of upper limb and shoulder
19.5
16.9
25
13
L91.0
ICD-10 Finland
Hypertrophic scar
4.3
16.7
43
102
R22.4
ICD-10 Finland
Localized swelling, mass and lump, lower limb
3.2
16.7
68
221
C44.81
ICD-10 Finland
Overall basocellular carcinoma of the skin
14.4
16.3
27
19
Z3231
NOMESCO Finland
Registered nurse
1.6
16.2
483
3349
C43.7
ICD-10 Finland
Malignant neoplasm: Malignant melanoma of lower limb, including hip
16.9
16.1
25
15
TQW40, ,
SPAT
1.9
15.6
207
1144
C43.69
ICD-10 Finland
Malignant melanoma of the upper extremity including shoulder other or unspecified histology
22.2
15.5
22
10
R4110
NOMESCO Finland
Physiotherapy
1.6
15.5
492
3457
A11CC03
ATC
alfacalcidol; systemic
3.5
15.4
53
155
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
2.5
14.9
94
386
L30.9
ICD-10 Finland
Dermatitis, unspecified
1.6
14.5
404
2746
C43.99
ICD-10 Finland
Unspecified localization of malignant melanoma of the skin other or unspecified histology
17.1
14.3
22
13
L01BC02
ATC
fluorouracil; systemic, topical
6.2
14.2
24
39
R22.0
ICD-10 Finland
Localized swelling, mass and lump, head
2.8
14.2
73
271
QB9S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in torso, unspecified
6.3
13.8
23
37
D04.4
ICD-10 Finland
Carcinoma in situ: Skin of scalp and neck
6.3
13.8
23
37
ZXE00
NOMESCO Finland
One hour or less
1.5
13.6
683
5262
QDA99
NOMESCO Finland
Other local destruction of skin of lower limb
16.3
13.5
21
13
ZXA00
NOMESCO Finland
Right side
1.6
13.2
425
2980
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
4.6
13.1
31
69
B03XA01
ATC
erythropoietin; parenteral
5.5
13.1
25
46
137
Kela drug reimbursment
Uraemia requiring dialysis
5.3
13.0
26
50
C43.51
ICD-10 Finland
Malignant melanoma of the trunk originating in lentigo maligna
28.6
13.0
17
6
QDE00
NOMESCO Finland
Excision of loose skin or fold of skin from lower limb
70.4
12.6
14
*
J01MA02
ATC
ciprofloxacin; systemic
1.5
12.5
629
4825
8090/3-C44.7
ICD-O-3
Basal cell carcinoma, NOS, of skin of lower limb and hip
13.3
12.4
21
16
TK800
NOMESCO Finland
Hemodialysis
3.4
12.4
43
127
D18.0
ICD-10 Finland
Haemangioma, any site
2.9
12.3
57
200
D23.5
ICD-10 Finland
Benign neoplasm: Skin of trunk
2.8
12.2
59
212
S52
ICPC
Skin, Exc/remov/biopsy/destruc/debrid/caut
6.1
12.1
21
35
WX408
NOMESCO Finland
General anesthesy, balanced
1.5
12.1
435
3117
N18.0
ICD-10 Finland
End-stage renal disease
5.3
12.0
24
46
C43.61
ICD-10 Finland
Malignant melanoma of the upper extremity including the shoulder originating in lentigo maligna
47.0
11.9
14
*
J01DB01
ATC
cefalexin; oral
1.5
11.9
1507
13660
UJF32
NOMESCO Finland
Coloscopy
1.5
11.8
427
3061
C43.42
ICD-10 Finland
Malignant melanoma of the scalp and neck: 'superficial spreading' type
30.2
11.6
15
5
TQW40
NOMESCO Finland
Remowal of suture of skin
2.0
11.5
130
680
8070/3-C44.9
ICD-O-3
Squamous cell carcinoma, NOS, of skin, NOS
4.0
11.5
32
81
C43.53
ICD-10 Finland
Malignant melanoma of the torso nodular
13.7
11.5
19
14
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.4
11.5
778
6279
D23.3
ICD-10 Finland
Benign neoplasm: Skin of other and unspecified parts of face
2.7
11.4
60
226
S54
ICPC
Skin, Repair/fix-suture/cast/prosth device
2.5
11.4
69
279
WX402
NOMESCO Finland
General anaesthesia
1.5
11.3
408
2921
8743/3-C44.7
ICD-O-3
Low cumulative sun damage melanoma of skin of lower limb and hip
35.2
11.3
14
*
J02AC01
ATC
fluconazole; systemic
1.4
11.1
731
5861
Q82.58
ICD-10 Finland
Congenital non-neoplastic naevus
4.2
10.8
28
67
EP1AE
NOMESCO Finland
Neck ultrasound examination
2.0
10.7
114
583
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
1.4
10.4
548
4211
Z94.4
ICD-10 Finland
Liver transplant status
12.1
10.3
18
15
D22.0
ICD-10 Finland
Melanocytic naevi of lip
12.1
10.3
18
15
D03.31
ICD-10 Finland
Melanoma in situ in another or unspecified part of the face
10.7
10.3
19
18
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
1.8
10.1
167
986
DHB00
NOMESCO Finland
Excision of lesion of external nose
4.4
10.1
25
58
8090/3-C44.6
ICD-O-3
Basal cell carcinoma, NOS, of skin of upper limb and shoulder
11.3
10.1
18
16
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
4.6
10.0
23
50
C43.39
ICD-10 Finland
Malignant melanoma of another or unspecified part of the face other or unspecified histology
16.8
9.9
15
9
KA1AE
NOMESCO Finland
Kidney ultrasound examination
2.8
9.8
49
180
DAB00
NOMESCO Finland
Excision of lesion of auricle
4.6
9.8
23
51
QAA50
NOMESCO Finland
Cryotherapy of skin of head or neck
7.4
9.7
22
30
8742/2-C44.9
ICD-O-3
Lentigo maligna of skin, NOS
13.4
9.7
16
12
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
1.6
9.7
225
1456
8743/3-C44.5
ICD-O-3
Low cumulative sun damage melanoma of skin of trunk
55.3
9.7
11
*
D23.9
ICD-10 Finland
Benign neoplasm: Skin, unspecified
2.6
9.6
54
211
QBA10
NOMESCO Finland
Incision of skin of trunk
4.0
9.6
27
69
Z3226
NOMESCO Finland
Physiotherapist
1.5
9.6
298
2062
ZXA10
NOMESCO Finland
Bilateral
1.5
9.5
289
1991
S26
ICPC
Fear of cancer of skin
3.6
9.4
30
84
I78.1
ICD-10 Finland
Naevus, non-neoplastic
2.8
9.4
47
173
C44.62
ICD-10 Finland
Spinocellular carcinoma of the skin of the upper extremity including the shoulder
12.4
9.4
16
13
N18.8
ICD-10 Finland
Other chronic renal failure
3.2
9.3
36
114
R22.2
ICD-10 Finland
Localized swelling, mass and lump, trunk
2.2
9.2
73
334
Z49.0
ICD-10 Finland
Preparatory care for dialysis
4.8
9.1
20
42
ZX108
NOMESCO Finland
Inhalation
4.8
9.1
20
42
C43.49
ICD-10 Finland
Malignant melanoma of the scalp and neck other or unspecified histology
36.9
9.0
11
*
C44
ICD-10 Finland
Other malignant neoplasms of skin
12.6
8.9
15
12
TPH04
NOMESCO Finland
Cathetrisation of vein
1.5
8.9
360
2627
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.4
8.9
649
5244
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
1.8
8.8
128
727
UJF30
NOMESCO Finland
Ileoscopy through colon
1.7
8.8
180
1126
QDA10
NOMESCO Finland
Incision of skin of lower limb
4.7
8.8
20
43
QCE99
NOMESCO Finland
Other excision or repair of lesion of skin of upper limb
7.2
8.7
20
28
PJD55
NOMESCO Finland
Block dissection of inguinal lymph nodes
14.1
8.7
14
10
5AB14, ,
NOMESCO Finland
16.4
8.6
13
8
A06AC01
ATC
ispaghula (psylla seeds); oral
1.4
8.5
429
3253
C44.50
ICD-10 Finland
Malignant tumor of the skin on the torso without histology
9.0
8.5
17
19
Z01.4
ICD-10 Finland
Gynaecological examination (general)(routine)
1.5
8.5
329
2377
R22.9
ICD-10 Finland
Localized swelling, mass and lump, unspecified
1.7
8.4
163
1007
D03.4
ICD-10 Finland
Melanoma in situ of scalp and neck
+∞
8.3
8
*
C44.60
ICD-10 Finland
Malignant tumor of the skin of the upper extremity including the shoulder without histology
+∞
8.3
8
*
J31.0
ICD-10 Finland
Chronic rhinitis
1.7
8.3
159
978
Z31.5
ICD-10 Finland
Genetic counselling
1.9
8.3
108
594
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
1.6
8.2
185
1188
N02BE01
ATC
paracetamol; systemic, rectal
1.5
8.1
1601
14978
R22.3
ICD-10 Finland
Localized swelling, mass and lump, upper limb
2.6
8.1
45
175
1509
Kela drug reimbursment
Dabrafenib (adjuvant treatment)
33.5
8.1
10
*
3024
Kela drug reimbursment
Dabrafenib and trametinib (adjuvant treatment)
33.5
8.1
10
*
L04AA05
ATC
[U] tacrolimus
17.2
8.1
12
7
ZXE20
NOMESCO Finland
More than three and less than five hours
1.6
8.1
204
1346
JN4BD
NOMESCO Finland
Extensive body CT
1.7
8.1
151
924
D23.6
ICD-10 Finland
Benign neoplasm: Skin of upper limb, including shoulder
3.7
8.0
25
69
D06BX02
ATC
ingenol mebutate; topical
3.9
8.0
23
60
QAE99
NOMESCO Finland
Other excision or repair surgery of skin and subcutaneous tissue in head and neck
2.7
8.0
40
148
QXA50
NOMESCO Finland
Skin cryotherapy, unspecified location
4.5
7.9
19
43
L72.1
ICD-10 Finland
Trichilemmal cyst
1.8
7.9
120
693
QXE99
NOMESCO Finland
Other excision or repair of unspecified region of skin
15.1
7.7
12
8
B03XA02
ATC
darbepoetin alfa; parenteral
2.7
7.7
39
145
WX404
NOMESCO Finland
Intravenous generell anesthesy
1.4
7.6
336
2483
S08
ICPC
Skin colour change
1.9
7.6
94
508
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.3
7.6
693
5753
QDE15
NOMESCO Finland
Excision of other superficial lesion of skin in lower limb
18.4
7.6
11
6
C44.70
ICD-10 Finland
Malignant tumor of the skin of the lower extremity including the hip without histology
25.1
7.6
10
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
2.0
7.6
80
410
D01AE16
ATC
amorolfine; topical
1.6
7.5
178
1155
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
3.3
7.5
28
87
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
1.4
7.5
363
2727
D07XC01
ATC
betamethasone; topical
1.6
7.5
185
1214
SPAT1141
SPAT
Excision of skin or mucous membrane lesion
2.1
7.4
71
351
L98.4
ICD-10 Finland
Chronic ulcer of skin, not elsewhere classified
2.8
7.4
36
131
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
1.9
7.4
93
506
D04.9
ICD-10 Finland
Carcinoma in situ: Skin, unspecified
7.7
7.4
16
21
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
6.0
7.4
19
32
G03CA03
ATC
estradiol; nasal, systemic, rectal, transdermal, vaginal
1.3
7.4
751
6325
A02BC05
ATC
esomeprazole; systemic
1.3
7.3
662
5482
C43.5
ICD-10 Finland
Malignant neoplasm: Malignant melanoma of trunk
6.9
7.3
17
25
Z08.9
ICD-10 Finland
Follow-up examination after unspecified treatment for malignant neoplasm
6.9
7.3
17
25
UJH02
NOMESCO Finland
Anoscopy
2.1
7.3
69
340
SPAT1144
SPAT
Treatment of reopened or infected surgical wound
1.8
7.3
107
612
UKC02
NOMESCO Finland
Cystoscopy
1.5
7.2
210
1430
R50.9
ICD-10 Finland
Fever, unspecified
1.5
7.2
254
1801
A02BC01
ATC
omeprazole; systemic
1.4
7.1
424
3295
C43.6
ICD-10 Finland
Malignant neoplasm: Malignant melanoma of upper limb, including shoulder
20.1
7.1
10
5
R60.9
ICD-10 Finland
Oedema, unspecified
1.9
7.1
92
505
I84.2
ICD-10 Finland
Internal hemorrhoids without complication
1.8
7.1
108
624
D07AC01
ATC
betamethasone; topical
1.3
7.0
597
4894
D02AX
ATC
Other emollients and protectives
2.2
6.9
56
260
QBB10
NOMESCO Finland
Major dressing of wound of skin of trunk
2.1
6.8
65
321
JJC00
NOMESCO Finland
Allogenic transplantation of liver
11.0
6.8
12
11
J05AB01
ATC
aciclovir; systemic
1.4
6.8
371
2844
L01EC02
ATC
dabrafenib; oral
40.2
6.8
8
*
8742/3-C44.9
ICD-O-3
Lentigo maligna melanoma of skin, NOS
40.2
6.8
8
*
A12AA12
ATC
[U] calcium acetate
16.7
6.7
10
6
Z71.8
ICD-10 Finland
Other specified counselling
1.3
6.7
609
5030
R4120
NOMESCO Finland
Occupational therapy
1.7
6.7
109
642
KA9AE
NOMESCO Finland
Ultrasound examination transplanted kidney
7.2
6.7
15
21
C43.74
ICD-10 Finland
Malignant melanoma of the lower extremity including the hip acral
22.6
6.7
9
*
C43.00
ICD-10 Finland
Malignant melanoma of the lip without histology
22.6
6.7
9
*
D07AB08
ATC
desonide; topical
1.5
6.7
180
1205
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.3
6.7
450
3563
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
1.8
6.6
93
524
QDE20
NOMESCO Finland
Excision and repair of scar or web of skin of lower limb
8.7
6.6
13
15
ZX120
NOMESCO Finland
Intravenous
1.6
6.5
146
936
QBE15
NOMESCO Finland
Excision of other superficial lesion of skin of trunk
6.9
6.5
15
22
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
1.5
6.5
214
1494
WX002
NOMESCO Finland
Sedation and analgesia
1.4
6.5
292
2163
Z48.0
ICD-10 Finland
Attention to surgical dressings and sutures
2.1
6.5
55
260
K83.0
ICD-10 Finland
Cholangitis
3.1
6.5
26
85
L40.0
ICD-10 Finland
Psoriasis vulgaris
2.0
6.5
67
342
C44.91
ICD-10 Finland
Unspecified localization of basocellular carcinoma of the skin
5.7
6.4
17
30
SHA02
NOMESCO Finland
Stomatognathic treatment, basic
1.6
6.4
138
875
XKD00
NOMESCO Finland
Uroflowmetry
1.5
6.4
176
1182
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
1.6
6.4
164
1085
JJ9AE
NOMESCO Finland
Ultrasound examination of liver transplant
14.4
6.4
10
7
C43.31
ICD-10 Finland
Malignant melanoma of another or unspecified part of the face originating in lentigo maligna
14.4
6.4
10
7
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
1.6
6.4
158
1038
C44.52
ICD-10 Finland
Spinocellular carcinoma of the skin on the torso
6.6
6.3
15
23
Z01.8
ICD-10 Finland
Other specified special examinations
1.4
6.3
373
2892
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
5.5
6.3
17
31
F45.8
ICD-10 Finland
Other somatoform disorders
1.6
6.3
134
849
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.3
6.3
513
4172
D07BA04
ATC
hydrocortisone and antiseptics; topical
1.6
6.3
165
1099
S81.8
ICD-10 Finland
Open wound of other parts of lower leg
2.1
6.2
53
251
WX702
NOMESCO Finland
Supraglottic ventilation device
1.8
6.2
94
543
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
1.7
6.2
109
657
H02AB09
ATC
hydrocortisone; systemic
2.4
6.2
42
181
R42
ICD-10 Finland
Dizziness and giddiness
1.4
6.2
355
2740
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
1.5
6.1
176
1194
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
1.9
6.1
73
391
SHA03
NOMESCO Finland
Stomatognathic treatment, demanding
2.0
6.1
63
321
Z2446
NOMESCO Finland
Social worker
1.7
6.1
112
683
QX3HE
NOMESCO Finland
Ultrsound examination of lesion close to skin
2.7
6.1
32
122
D02AE01
ATC
carbamide; topical
1.7
6.1
103
615
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Melanocytic naevi of lower limb, including hip
D22.7 [45566673]
D22.7 [45566673]
2.5e+00
4.2e+00
—
1.0e+50
1.0e+50
6.7e+00
4.4e+00
cases:1.05%
controls:0.08%
cases:1.87%
controls:0.03%
—
—
cases:96.09%
controls:0.00%
cases:19.60%
controls:0.00%
cases:19.63%
controls:0.03%
cases:10.11%
controls:0.14%
19
15
1795
18090
34
5
1780
18100
—
1743
0
71
18105
355
0
1456
18057
343
5
1404
17355
151
21
1342
14714
Neoplasm of uncertain or unknown behaviour: Skin
D48.5 [45586113]
D48.5 [45586113]
2.0e+00
3.1e+00
3.7e+00
—
3.6e+00
2.9e+00
2.1e+00
cases:4.19%
controls:0.56%
cases:3.97%
controls:0.19%
cases:1.82%
controls:0.04%
—
—
cases:0.99%
controls:0.03%
cases:2.98%
controls:0.17%
cases:5.63%
controls:0.76%
76
102
1738
18003
72
34
1742
18071
33
8
1781
18097
—
18
5
1793
18052
52
30
1695
17330
84
112
1409
14623
mycophenolic acid; oral, parenteral
L04AA06 [21603896]
L04AA06 [21603896]
2.4e+00
2.6e+00
3.0e+00
—
2.2e+00
2.7e+00
2.4e+00
cases:2.70%
controls:0.26%
cases:2.92%
controls:0.23%
cases:1.16%
controls:0.06%
—
—
cases:0.83%
controls:0.09%
cases:3.09%
controls:0.21%
cases:3.55%
controls:0.32%
49
47
1765
18058
53
41
1761
18064
21
11
1793
18094
—
15
16
1796
18041
54
37
1693
17323
53
47
1440
14688
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
1.5e+00
2.3e+00
3.3e+00
—
3.6e+00
2.7e+00
1.7e+00
cases:25.58%
controls:7.00%
cases:22.99%
controls:2.83%
cases:12.13%
controls:0.50%
—
—
cases:17.67%
controls:0.60%
cases:30.80%
controls:2.82%
cases:30.81%
controls:7.60%
464
1267
1350
16838
417
513
1397
17592
220
91
1594
18014
—
320
108
1491
17949
538
489
1209
16871
460
1120
1033
13615
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
1.3e+00
2.3e+00
3.3e+00
1.0e+50
4.1e+00
2.6e+00
1.5e+00
cases:9.54%
controls:2.72%
cases:8.27%
controls:0.90%
cases:3.42%
controls:0.13%
cases:16.04%
controls:0.00%
cases:6.29%
controls:0.11%
cases:11.05%
controls:0.90%
cases:11.59%
controls:2.92%
173
493
1641
17612
150
163
1664
17942
62
23
1752
18082
291
0
1523
18105
114
20
1697
18037
193
157
1554
17203
173
430
1320
14305
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
TQX10 [2001310152]
2.5e+00
3.6e+00
—
—
3.1e+00
3.1e+00
2.6e+00
cases:9.15%
controls:0.84%
cases:6.28%
controls:0.18%
—
—
—
—
cases:0.72%
controls:0.03%
cases:4.87%
controls:0.23%
cases:8.98%
controls:0.75%
166
152
1648
17953
114
33
1700
18072
—
—
13
6
1798
18051
85
40
1662
17320
134
110
1359
14625
Excision of other lesion extending through all layers of skin in lower limb
QDE10 [2001309980]
QDE10 [2001309980]
2.8e+00
3.4e+00
1.0e+50
1.0e+50
—
4.8e+00
3.1e+00
cases:3.03%
controls:0.19%
cases:1.98%
controls:0.07%
cases:1.16%
controls:0.00%
cases:26.74%
controls:0.00%
—
—
cases:7.27%
controls:0.06%
cases:3.62%
controls:0.18%
55
34
1759
18071
36
12
1778
18093
21
0
1793
18105
485
0
1329
18105
—
127
11
1620
17349
54
26
1439
14709
Basocellular carcinoma of the skin on another or unspecified part of the face
C44.31 [2000500792]
C44.31 [2000500792]
1.6e+00
2.5e+00
2.2e+00
1.0e+50
3.5e+00
2.4e+00
1.8e+00
cases:2.87%
controls:0.59%
cases:2.59%
controls:0.23%
cases:0.77%
controls:0.09%
cases:2.43%
controls:0.00%
cases:1.60%
controls:0.05%
cases:2.98%
controls:0.28%
cases:4.29%
controls:0.71%
52
106
1762
17999
47
41
1767
18064
14
16
1800
18089
44
0
1770
18105
29
9
1782
18048
52
49
1695
17311
64
105
1429
14630
Kidney transplant status
Z94.0 [45566477]
Z94.0 [45566477]
2.1e+00
2.2e+00
2.7e+00
—
2.2e+00
2.2e+00
2.4e+00
cases:1.98%
controls:0.24%
cases:2.04%
controls:0.23%
cases:0.94%
controls:0.06%
—
—
cases:0.66%
controls:0.07%
cases:2.06%
controls:0.22%
cases:2.55%
controls:0.23%
36
44
1778
18061
37
42
1777
18063
17
11
1797
18094
—
12
13
1799
18044
36
39
1711
17321
38
34
1455
14701
Basocellular carcinoma of the skin on the torso
C44.51 [2000500800]
C44.51 [2000500800]
2.2e+00
2.7e+00
2.3e+00
1.0e+50
3.3e+00
3.1e+00
2.4e+00
cases:2.65%
controls:0.31%
cases:1.49%
controls:0.10%
cases:0.28%
controls:0.03%
cases:1.71%
controls:0.00%
cases:0.72%
controls:0.03%
cases:2.29%
controls:0.11%
cases:2.75%
controls:0.26%
48
56
1766
18049
27
19
1787
18086
5
5
1809
18100
31
0
1783
18105
13
5
1798
18052
40
19
1707
17341
41
39
1452
14696
ciclosporin; oral, parenteral
L04AD01 [21603924]
L04AD01 [21603924]
2.1e+00
2.5e+00
2.7e+00
—
1.7e+00
2.3e+00
2.2e+00
cases:2.21%
controls:0.28%
cases:2.09%
controls:0.18%
cases:0.50%
controls:0.03%
—
—
cases:0.55%
controls:0.11%
cases:2.06%
controls:0.21%
cases:2.14%
controls:0.24%
40
51
1774
18054
38
33
1776
18072
9
6
1805
18099
—
10
19
1801
18038
36
36
1711
17324
32
36
1461
14699
tacrolimus; oral, parenteral
L04AD02 [21603925]
L04AD02 [21603925]
2.1e+00
2.2e+00
2.2e+00
—
1.9e+00
2.3e+00
2.2e+00
cases:1.49%
controls:0.19%
cases:1.71%
controls:0.19%
cases:0.66%
controls:0.08%
—
—
cases:0.72%
controls:0.11%
cases:1.72%
controls:0.18%
cases:1.88%
controls:0.20%
27
34
1787
18071
31
34
1783
18071
12
14
1802
18091
—
13
19
1798
18038
30
31
1717
17329
28
30
1465
14705
Pathology report gross observation
24419-4 [3002256]
24419-4 [3002256]
9.5e-01
1.7e+00
2.7e+00
1.0e+50
4.2e+00
2.2e+00
1.2e+00
cases:6.01%
controls:2.41%
cases:3.75%
controls:0.73%
cases:1.32%
controls:0.09%
cases:8.71%
controls:0.00%
cases:2.26%
controls:0.03%
cases:5.90%
controls:0.70%
cases:6.76%
controls:2.16%
109
437
1705
17668
68
133
1746
17972
24
17
1790
18088
158
0
1656
18105
41
6
1770
18051
103
121
1644
17239
101
318
1392
14417
Actinic keratosis
L57.0 [45591640]
L57.0 [45591640]
1.8e+00
2.3e+00
3.0e+00
1.0e+50
1.6e+00
2.2e+00
1.9e+00
cases:6.78%
controls:1.19%
cases:5.35%
controls:0.55%
cases:1.98%
controls:0.10%
cases:5.02%
controls:0.00%
cases:0.44%
controls:0.09%
cases:5.38%
controls:0.60%
cases:8.57%
controls:1.35%
123
216
1691
17889
97
99
1717
18006
36
19
1778
18086
91
0
1723
18105
8
16
1803
18041
94
104
1653
17256
128
199
1365
14536
Malignant melanoma of the lower extremity including the hip: 'superficial spreading' type
C43.72 [2000500763]
C43.72 [2000500763]
3.9e+00
—
—
1.0e+50
1.0e+50
4.6e+00
4.1e+00
cases:1.38%
controls:0.03%
—
—
—
—
cases:1.27%
controls:0.00%
cases:1.71%
controls:0.00%
cases:3.21%
controls:0.03%
cases:2.88%
controls:0.05%
25
5
1789
18100
—
—
23
0
1791
18105
31
0
1780
18057
56
6
1691
17354
43
7
1450
14728
Basocellular carcinoma of the skin of the lower extremity including the hip
C44.71 [2000500808]
C44.71 [2000500808]
2.3e+00
3.1e+00
1.0e+50
1.0e+50
—
3.5e+00
3.1e+00
cases:0.72%
controls:0.07%
cases:0.61%
controls:0.03%
cases:0.28%
controls:0.00%
cases:0.94%
controls:0.00%
—
—
cases:0.97%
controls:0.03%
cases:1.07%
controls:0.05%
13
13
1801
18092
11
5
1803
18100
5
0
1809
18105
17
0
1797
18105
—
17
5
1730
17355
16
7
1477
14728
Dermatoscopy
XQ845 [2001310108]
XQ845 [2001310108]
2.8e+00
3.3e+00
—
1.0e+50
—
3.3e+00
2.6e+00
cases:1.82%
controls:0.12%
cases:1.87%
controls:0.07%
—
—
cases:3.31%
controls:0.00%
—
—
cases:1.66%
controls:0.06%
cases:2.88%
controls:0.22%
33
21
1781
18084
34
13
1780
18092
—
60
0
1754
18105
—
29
11
1718
17349
43
33
1450
14702
Tacrolimus [Mass/volume] in Blood
11253-2 [3026250]
11253-2 [3026250]
1.7e+00
1.8e+00
2.4e+00
—
1.8e+00
2.0e+00
2.1e+00
cases:0.94%
controls:0.17%
cases:0.94%
controls:0.16%
cases:0.61%
controls:0.06%
—
—
cases:0.39%
controls:0.07%
cases:1.14%
controls:0.15%
cases:1.61%
controls:0.20%
17
30
1797
18075
17
29
1797
18076
11
10
1803
18095
—
7
12
1804
18045
20
26
1727
17334
24
29
1469
14706
Dermatological photography
XQ848 [2001310110]
XQ848 [2001310110]
2.4e+00
3.8e+00
1.0e+50
1.0e+50
—
3.3e+00
2.1e+00
cases:2.81%
controls:0.25%
cases:2.76%
controls:0.07%
cases:0.99%
controls:0.00%
cases:3.03%
controls:0.00%
—
—
cases:1.77%
controls:0.07%
cases:2.55%
controls:0.33%
51
46
1763
18059
50
12
1764
18093
18
0
1796
18105
55
0
1759
18105
—
31
12
1716
17348
38
48
1455
14687
Melanocytic naevi of trunk
D22.5 [45542688]
D22.5 [45542688]
2.3e+00
3.1e+00
—
1.0e+50
—
3.2e+00
2.4e+00
cases:6.50%
controls:0.70%
cases:4.91%
controls:0.22%
—
—
cases:6.17%
controls:0.00%
—
—
cases:5.09%
controls:0.21%
cases:8.57%
controls:0.82%
118
126
1696
17979
89
40
1725
18065
—
112
0
1702
18105
—
89
37
1658
17323
128
121
1365
14614
Excision of other lesion extending through all layers of skin in upper limb
QCE10 [2001309914]
QCE10 [2001309914]
2.4e+00
3.6e+00
—
1.0e+50
1.0e+50
2.7e+00
2.3e+00
cases:2.59%
controls:0.23%
cases:0.99%
controls:0.03%
—
—
cases:1.76%
controls:0.00%
cases:0.28%
controls:0.00%
cases:0.57%
controls:0.04%
cases:1.47%
controls:0.15%
47
42
1767
18063
18
5
1796
18100
—
32
0
1782
18105
5
0
1806
18057
10
7
1737
17353
22
22
1471
14713
Removal of sutures
SPAT1153 [2001700254]
SPAT1153 [2001700254]
5.4e-01
1.3e+00
3.0e+00
—
4.0e+00
1.4e+00
6.2e-01
cases:8.93%
controls:5.41%
cases:5.13%
controls:1.46%
cases:2.21%
controls:0.11%
—
—
cases:6.63%
controls:0.13%
cases:4.52%
controls:1.17%
cases:7.90%
controls:4.42%
162
979
1652
17126
93
264
1721
17841
40
20
1774
18085
—
120
24
1691
18033
79
203
1668
17157
118
651
1375
14084
Other and unspecified skin changes
R23.8 [45573020]
R23.8 [45573020]
1.1e+00
2.3e+00
3.4e+00
—
1.8e+00
1.1e+00
1.0e+00
cases:6.50%
controls:2.20%
cases:7.94%
controls:0.87%
cases:2.37%
controls:0.08%
—
—
cases:0.61%
controls:0.11%
cases:2.92%
controls:1.01%
cases:9.98%
controls:3.77%
118
399
1696
17706
144
158
1670
17947
43
14
1771
18091
—
11
19
1800
18038
51
175
1696
17185
149
555
1344
14180
Excision of other lesion extending through all layers of skin of trunk
QBE10 [2001309853]
QBE10 [2001309853]
2.3e+00
3.3e+00
1.0e+50
1.0e+50
—
2.7e+00
2.3e+00
cases:5.79%
controls:0.62%
cases:3.91%
controls:0.15%
cases:0.77%
controls:0.00%
cases:5.62%
controls:0.00%
—
—
cases:2.98%
controls:0.20%
cases:4.96%
controls:0.51%
105
112
1709
17993
71
27
1743
18078
14
0
1800
18105
102
0
1712
18105
—
52
34
1695
17326
74
75
1419
14660
Malignant melanoma on the torso: 'superficial spreading' type
C43.52 [2000500751]
C43.52 [2000500751]
3.3e+00
3.7e+00
—
1.0e+50
—
—
3.6e+00
cases:1.87%
controls:0.07%
cases:2.04%
controls:0.05%
—
—
cases:1.60%
controls:0.00%
—
—
—
—
cases:2.48%
controls:0.07%
34
13
1780
18092
37
9
1777
18096
—
29
0
1785
18105
—
—
37
10
1456
14725
Outpatient Visit
OP [9202]
OP [9202]
5.0e-01
7.2e-01
9.0e-01
5.8e+00
1.2e+00
7.9e-01
6.0e-01
cases:80.43%
controls:71.43%
cases:66.98%
controls:49.62%
cases:23.21%
controls:10.90%
cases:59.26%
controls:0.45%
cases:27.83%
controls:10.25%
cases:67.89%
controls:48.95%
cases:86.07%
controls:77.14%
1459
12933
355
5172
1215
8983
599
9122
421
1974
1393
16131
1075
81
739
18024
504
1851
1307
16206
1186
8498
561
8862
1285
11366
208
3369
Melanocytic naevi, unspecified
D22.9 [45571603]
D22.9 [45571603]
2.3e+00
3.2e+00
—
1.0e+50
—
2.8e+00
2.2e+00
cases:4.24%
controls:0.46%
cases:4.41%
controls:0.18%
—
—
cases:0.55%
controls:0.00%
—
—
cases:2.92%
controls:0.18%
cases:5.63%
controls:0.66%
77
83
1737
18022
80
33
1734
18072
—
10
0
1804
18105
—
51
32
1696
17328
84
97
1409
14638
Immunohistochemistry procedure
117617002 [4035726]
117617002 [4035726]
7.8e-01
1.7e+00
2.7e+00
—
2.5e+00
1.8e+00
9.5e-01
cases:3.42%
controls:1.60%
cases:2.59%
controls:0.47%
cases:0.72%
controls:0.05%
—
—
cases:0.33%
controls:0.03%
cases:1.77%
controls:0.31%
cases:2.41%
controls:0.95%
62
289
1752
17816
47
85
1767
18020
13
9
1801
18096
—
6
5
1805
18052
31
54
1716
17306
36
140
1457
14595
Oncology Clinic/Center
261QX0200X [38004268]
261QX0200X [38004268]
1.2e+00
1.9e+00
2.5e+00
1.0e+50
3.3e+00
7.2e-01
7.3e-01
cases:14.22%
controls:4.70%
cases:8.54%
controls:1.40%
cases:2.09%
controls:0.17%
cases:2.21%
controls:0.00%
cases:2.26%
controls:0.09%
cases:2.12%
controls:1.04%
cases:7.77%
controls:3.90%
258
851
1556
17254
155
253
1659
17852
38
31
1776
18074
40
0
1774
18105
41
16
1770
18041
37
181
1710
17179
116
574
1377
14161
TACROLIMUS - yes
TACROLIMUS-1 [2002330222]
TACROLIMUS-1 [2002330222]
2.0e+00
2.7e+00
—
—
—
2.9e+00
2.6e+00
cases:0.72%
controls:0.09%
cases:0.72%
controls:0.05%
—
—
—
—
—
—
cases:0.74%
controls:0.04%
cases:0.87%
controls:0.07%
13
17
1801
18088
13
9
1801
18096
—
—
—
13
7
1734
17353
13
10
1480
14725
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
7.3e-01
1.8e+00
3.0e+00
—
2.4e+00
1.3e+00
9.9e-01
cases:16.70%
controls:8.79%
cases:15.38%
controls:3.04%
cases:5.13%
controls:0.27%
—
—
cases:3.31%
controls:0.32%
cases:9.79%
controls:2.95%
cases:20.16%
controls:8.58%
303
1591
1511
16514
279
550
1535
17555
93
48
1721
18057
—
60
57
1751
18000
171
512
1576
16848
301
1264
1192
13471
Laceration/cut
S18 [2002000983]
S18 [2002000983]
5.1e-01
1.3e+00
2.3e+00
—
3.5e+00
1.5e+00
8.2e-01
cases:12.24%
controls:7.74%
cases:8.82%
controls:2.60%
cases:3.64%
controls:0.39%
—
—
cases:12.76%
controls:0.43%
cases:10.36%
controls:2.53%
cases:18.22%
controls:8.92%
222
1402
1592
16703
160
470
1654
17635
66
71
1748
18034
—
231
78
1580
17979
181
439
1566
16921
272
1315
1221
13420
Carcinoma in situ: Skin of other and unspecified parts of face
D04.3 [45586080]
D04.3 [45586080]
1.7e+00
3.0e+00
—
—
—
2.8e+00
2.3e+00
cases:0.94%
controls:0.17%
cases:0.99%
controls:0.05%
—
—
—
—
—
—
cases:0.92%
controls:0.06%
cases:1.21%
controls:0.12%
17
30
1797
18075
18
9
1796
18096
—
—
—
16
10
1731
17350
18
18
1475
14717
Destruction of lesion of skin of trunk
QBA25 [2001309832]
QBA25 [2001309832]
2.1e+00
2.5e+00
—
1.0e+50
—
2.8e+00
2.4e+00
cases:1.38%
controls:0.18%
cases:0.88%
controls:0.07%
—
—
cases:0.66%
controls:0.00%
—
—
cases:1.03%
controls:0.06%
cases:1.67%
controls:0.16%
25
32
1789
18073
16
13
1798
18092
—
12
0
1802
18105
—
18
11
1729
17349
25
23
1468
14712
Nephrology
39 [38004479]
39 [38004479]
1.3e+00
1.6e+00
1.9e+00
—
1.5e+00
1.8e+00
1.4e+00
cases:3.03%
controls:0.85%
cases:2.76%
controls:0.57%
cases:1.16%
controls:0.17%
—
—
cases:0.83%
controls:0.19%
cases:3.49%
controls:0.59%
cases:3.88%
controls:0.99%
55
153
1759
17952
50
104
1764
18001
21
31
1793
18074
—
15
35
1796
18022
61
103
1686
17257
58
146
1435
14589
Destruction of lesion of head or neck
QAA25 [2001309763]
QAA25 [2001309763]
2.1e+00
2.8e+00
—
1.0e+50
—
2.6e+00
1.9e+00
cases:1.43%
controls:0.18%
cases:1.21%
controls:0.08%
—
—
cases:0.61%
controls:0.00%
—
—
cases:1.09%
controls:0.08%
cases:1.54%
controls:0.24%
26
33
1788
18072
22
14
1792
18091
—
11
0
1803
18105
—
19
14
1728
17346
23
35
1470
14700
cycloSPORINE [Mass/volume] in Blood
3520-4 [3010375]
3520-4 [3010375]
1.8e+00
2.6e+00
—
—
2.3e+00
2.4e+00
2.4e+00
cases:0.83%
controls:0.14%
cases:0.83%
controls:0.06%
—
—
—
—
cases:0.28%
controls:0.03%
cases:0.86%
controls:0.07%
cases:1.34%
controls:0.13%
15
26
1799
18079
15
11
1799
18094
—
—
5
5
1806
18052
15
13
1732
17347
20
19
1473
14716
ANTIHYPERTENSIVE_DRUG - yes
ANTIHYPERTENSIVE_DRUG-1 [2002330215]
ANTIHYPERTENSIVE_DRUG-1 [2002330215]
2.1e+00
2.5e+00
—
—
—
2.2e+00
2.3e+00
cases:1.87%
controls:0.24%
cases:1.60%
controls:0.13%
—
—
—
—
—
—
cases:1.37%
controls:0.15%
cases:2.01%
controls:0.20%
34
44
1780
18061
29
24
1785
18081
—
—
—
24
26
1723
17334
30
30
1463
14705
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
7.7e-01
1.5e+00
1.5e+00
—
2.1e+00
1.8e+00
1.3e+00
cases:9.65%
controls:4.72%
cases:5.02%
controls:1.12%
cases:0.77%
controls:0.17%
—
—
cases:1.05%
controls:0.13%
cases:4.75%
controls:0.86%
cases:7.77%
controls:2.23%
175
855
1639
17250
91
202
1723
17903
14
31
1800
18074
—
19
23
1792
18034
83
149
1664
17211
116
329
1377
14406
Other minor procedure on skin
TQW99 [2001310150]
TQW99 [2001310150]
2.1e+00
2.3e+00
—
1.0e+50
—
2.9e+00
1.7e+00
cases:3.25%
controls:0.41%
cases:1.05%
controls:0.10%
—
—
cases:1.87%
controls:0.00%
—
—
cases:1.60%
controls:0.09%
cases:2.08%
controls:0.39%
59
74
1755
18031
19
19
1795
18086
—
34
0
1780
18105
—
28
16
1719
17344
31
57
1462
14678
Seborrhoeic keratosis
L82 [45548208]
L82 [45548208]
1.1e+00
1.3e+00
2.5e+00
—
1.8e+00
1.2e+00
1.1e+00
cases:5.02%
controls:1.80%
cases:2.76%
controls:0.77%
cases:1.16%
controls:0.10%
—
—
cases:0.66%
controls:0.11%
cases:2.58%
controls:0.78%
cases:7.97%
controls:2.83%
91
325
1723
17780
50
139
1764
17966
21
18
1793
18087
—
12
20
1799
18037
45
136
1702
17224
119
417
1374
14318
Outpatient Hospital
22 [8756]
22 [8756]
2.6e-01
4.7e-01
8.1e-01
5.0e+00
1.1e+00
6.7e-01
5.3e-01
cases:27.62%
controls:22.78%
cases:9.43%
controls:6.10%
cases:1.54%
controls:0.69%
cases:4.02%
controls:0.03%
cases:2.10%
controls:0.71%
cases:10.02%
controls:5.40%
cases:23.17%
controls:15.11%
501
4125
1313
13980
171
1105
1643
17000
28
125
1786
17980
73
5
1741
18100
38
129
1773
17928
175
937
1572
16423
346
2227
1147
12508
Liver transplant status
Z94.4 [45566478]
Z94.4 [45566478]
2.9e+00
3.2e+00
—
1.0e+50
—
—
2.6e+00
cases:0.83%
controls:0.04%
cases:0.77%
controls:0.03%
—
—
cases:0.39%
controls:0.00%
—
—
—
—
cases:0.74%
controls:0.05%
15
8
1799
18097
14
6
1800
18099
—
7
0
1807
18105
—
—
11
8
1482
14727
Hypertrophic scar
L91.0 [45548222]
L91.0 [45548222]
1.6e+00
2.3e+00
—
—
—
2.2e+00
2.6e+00
cases:0.55%
controls:0.11%
cases:0.39%
controls:0.04%
—
—
—
—
—
—
cases:0.46%
controls:0.05%
cases:0.80%
controls:0.06%
10
20
1804
18085
7
7
1807
18098
—
—
—
8
9
1739
17351
12
9
1481
14726
Basocellular carcinoma of the skin of the upper extremity including the shoulder
C44.61 [2000500804]
C44.61 [2000500804]
2.6e+00
—
—
1.0e+50
—
3.4e+00
2.7e+00
cases:0.66%
controls:0.05%
—
—
—
—
cases:0.83%
controls:0.00%
—
—
cases:0.86%
controls:0.03%
cases:1.54%
controls:0.11%
12
9
1802
18096
—
—
15
0
1799
18105
—
15
5
1732
17355
23
16
1470
14719
Basocellular carcinoma of the skin of the scalp and neck
C44.41 [2000500796]
C44.41 [2000500796]
1.7e+00
2.3e+00
—
1.0e+50
—
2.7e+00
1.8e+00
cases:0.77%
controls:0.14%
cases:0.50%
controls:0.05%
—
—
cases:0.77%
controls:0.00%
—
—
cases:0.92%
controls:0.06%
cases:1.21%
controls:0.20%
14
26
1800
18079
9
9
1805
18096
—
14
0
1800
18105
—
16
11
1731
17349
18
29
1475
14706
Destruction of lesion of skin, site unspecified
QXA25 [2001310041]
QXA25 [2001310041]
1.9e+00
2.2e+00
—
—
—
2.4e+00
2.0e+00
cases:1.54%
controls:0.23%
cases:1.05%
controls:0.12%
—
—
—
—
—
—
cases:1.32%
controls:0.13%
cases:2.68%
controls:0.37%
28
42
1786
18063
19
21
1795
18084
—
—
—
23
22
1724
17338
40
54
1453
14681
Naevus/mole
S82 [2002001046]
S82 [2002001046]
6.7e-01
2.0e+00
2.2e+00
—
2.6e+00
7.3e-01
7.2e-01
cases:2.98%
controls:1.55%
cases:3.97%
controls:0.57%
cases:0.83%
controls:0.09%
—
—
cases:0.72%
controls:0.06%
cases:1.03%
controls:0.50%
cases:4.15%
controls:2.06%
54
281
1760
17824
72
103
1742
18002
15
17
1799
18088
—
13
10
1798
18047
18
87
1729
17273
62
303
1431
14432
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
QAE10 [2001309784]
1.9e+00
2.5e+00
—
1.0e+50
—
2.1e+00
1.7e+00
cases:5.02%
controls:0.82%
cases:2.15%
controls:0.19%
—
—
cases:2.43%
controls:0.00%
—
—
cases:1.95%
controls:0.24%
cases:4.15%
controls:0.81%
91
148
1723
17957
39
34
1775
18071
—
44
0
1770
18105
—
34
41
1713
17319
62
119
1431
14616
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
6.2e-01
1.1e+00
1.8e+00
—
2.2e+00
1.3e+00
9.6e-01
cases:10.20%
controls:5.75%
cases:3.86%
controls:1.30%
cases:0.72%
controls:0.12%
—
—
cases:0.66%
controls:0.07%
cases:3.49%
controls:0.98%
cases:7.23%
controls:2.91%
185
1041
1629
17064
70
236
1744
17869
13
21
1801
18084
—
12
13
1799
18044
61
170
1686
17190
108
429
1385
14306
Ultrasound examination transplanted kidney
KA2AE [2001305644]
KA2AE [2001305644]
2.5e+00
2.6e+00
—
—
—
—
2.9e+00
cases:0.99%
controls:0.08%
cases:0.39%
controls:0.03%
—
—
—
—
—
—
—
—
cases:1.07%
controls:0.06%
18
15
1796
18090
7
5
1807
18100
—
—
—
—
16
9
1477
14726
Skin texture symptom/complaint
S21 [2002000986]
S21 [2002000986]
6.9e-01
1.3e+00
1.8e+00
—
2.4e+00
1.1e+00
6.9e-01
cases:3.53%
controls:1.81%
cases:2.65%
controls:0.71%
cases:0.39%
controls:0.07%
—
—
cases:0.88%
controls:0.08%
cases:1.66%
controls:0.56%
cases:4.22%
controls:2.17%
64
327
1750
17778
48
129
1766
17976
7
12
1807
18093
—
16
15
1795
18042
29
97
1718
17263
63
320
1430
14415
Melanocytic naevi of other and unspecified parts of face
D22.3 [45542687]
D22.3 [45542687]
2.3e+00
3.3e+00
—
1.0e+50
1.0e+50
2.3e+00
1.0e+00
cases:1.05%
controls:0.11%
cases:0.77%
controls:0.03%
—
—
cases:0.99%
controls:0.00%
cases:0.33%
controls:0.00%
cases:0.52%
controls:0.05%
cases:0.54%
controls:0.19%
19
20
1795
18085
14
5
1800
18100
—
18
0
1796
18105
6
0
1805
18057
9
9
1738
17351
8
28
1485
14707
Polycystic kidney, autosomal dominant
Q61.2 [45558415]
Q61.2 [45558415]
1.7e+00
1.9e+00
—
—
—
2.1e+00
1.9e+00
cases:0.55%
controls:0.10%
cases:0.61%
controls:0.09%
—
—
—
—
—
—
cases:0.63%
controls:0.07%
cases:0.60%
controls:0.10%
10
18
1804
18087
11
16
1803
18089
—
—
—
11
13
1736
17347
9
14
1484
14721
Incision for biopsy of skin of head or neck
QAA05 [2001309761]
QAA05 [2001309761]
2.4e+00
3.3e+00
—
1.0e+50
—
—
1.9e+00
cases:1.60%
controls:0.15%
cases:0.72%
controls:0.03%
—
—
cases:0.50%
controls:0.00%
—
—
—
—
cases:1.27%
controls:0.18%
29
28
1785
18077
13
5
1801
18100
—
9
0
1805
18105
—
—
19
27
1474
14708
Melanocytic naevi of upper limb, including shoulder
D22.6 [45590987]
D22.6 [45590987]
2.5e+00
—
—
1.0e+50
—
3.1e+00
2.0e+00
cases:1.10%
controls:0.09%
—
—
—
—
cases:1.76%
controls:0.00%
—
—
cases:0.74%
controls:0.03%
cases:1.14%
controls:0.16%
20
17
1794
18088
—
—
32
0
1782
18105
—
13
6
1734
17354
17
24
1476
14711
Dermatitis, unspecified
L30.9 [45572271]
L30.9 [45572271]
4.9e-01
9.0e-01
2.9e+00
—
1.9e+00
7.2e-01
4.6e-01
cases:3.64%
controls:2.27%
cases:1.93%
controls:0.79%
cases:0.83%
controls:0.04%
—
—
cases:0.50%
controls:0.08%
cases:2.06%
controls:1.01%
cases:4.89%
controls:3.14%
66
411
1748
17694
35
143
1779
17962
15
8
1799
18097
—
9
14
1802
18043
36
176
1711
17184
73
463
1420
14272
Carcinoma in situ: Skin of upper limb, including shoulder
D04.6 [45547572]
D04.6 [45547572]
2.2e+00
—
—
1.0e+50
2.5e+00
2.0e+00
2.5e+00
cases:0.55%
controls:0.06%
—
—
—
—
cases:0.28%
controls:0.00%
cases:0.33%
controls:0.03%
cases:0.29%
controls:0.04%
cases:0.67%
controls:0.05%
10
11
1804
18094
—
—
5
0
1809
18105
6
5
1805
18052
5
7
1742
17353
10
8
1483
14727
Cryotherapy
ZXC50 [2001311370]
ZXC50 [2001311370]
1.8e+00
1.7e+00
—
—
—
1.7e+00
1.9e+00
cases:1.54%
controls:0.26%
cases:0.55%
controls:0.10%
—
—
—
—
—
—
cases:0.74%
controls:0.13%
cases:1.67%
controls:0.26%
28
47
1786
18058
10
18
1804
18087
—
—
—
13
23
1734
17337
25
39
1468
14696
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-6.3e-01
-6.0e-01
-5.4e-01
—
2.8e+00
2.5e+00
3.0e+00
cases:15.82%
controls:26.03%
cases:4.85%
controls:8.52%
cases:0.55%
controls:0.94%
—
—
cases:0.72%
controls:0.04%
cases:5.67%
controls:0.48%
cases:17.41%
controls:1.02%
287
4713
1527
13392
88
1542
1726
16563
10
170
1804
17935
—
13
8
1798
18049
99
84
1648
17276
260
150
1233
14585
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
9.0e-01
1.2e+00
1.4e+00
—
1.3e+00
1.2e+00
9.6e-01
cases:4.47%
controls:1.86%
cases:3.42%
controls:1.01%
cases:0.72%
controls:0.18%
—
—
cases:0.77%
controls:0.20%
cases:3.03%
controls:0.98%
cases:5.89%
controls:2.35%
81
337
1733
17768
62
183
1752
17922
13
33
1801
18072
—
14
37
1797
18020
53
170
1694
17190
88
346
1405
14389
Malignant melanoma of the trunk other or unspecified histology
C43.59 [2000500754]
C43.59 [2000500754]
3.5e+00
—
1.0e+50
1.0e+50
—
—
3.4e+00
cases:0.94%
controls:0.03%
—
—
cases:0.28%
controls:0.00%
cases:0.33%
controls:0.00%
—
—
—
—
cases:1.34%
controls:0.05%
17
5
1797
18100
—
5
0
1809
18105
6
0
1808
18105
—
—
20
7
1473
14728
Melanocytic naevi
D22 [45595739]
D22 [45595739]
1.2e+00
2.8e+00
—
—
—
1.5e+00
1.3e+00
cases:1.54%
controls:0.45%
cases:2.48%
controls:0.15%
—
—
—
—
—
—
cases:0.80%
controls:0.18%
cases:3.08%
controls:0.83%
28
81
1786
18024
45
28
1769
18077
—
—
—
14
32
1733
17328
46
123
1447
14612
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
5.7e-01
8.7e-01
1.4e+00
—
2.0e+00
9.7e-01
9.7e-01
cases:10.42%
controls:6.16%
cases:3.36%
controls:1.43%
cases:0.55%
controls:0.13%
—
—
cases:0.77%
controls:0.11%
cases:3.09%
controls:1.20%
cases:8.51%
controls:3.40%
189
1116
1625
16989
61
259
1753
17846
10
24
1804
18081
—
14
19
1797
18038
54
208
1693
17152
127
501
1366
14234
Tryptase [Mass/volume] in Serum or Plasma
21582-2 [3019420]
21582-2 [3019420]
1.9e+00
2.5e+00
—
—
—
—
2.3e+00
cases:0.50%
controls:0.08%
cases:0.33%
controls:0.03%
—
—
—
—
—
—
—
—
cases:1.07%
controls:0.11%
9
14
1805
18091
6
5
1808
18100
—
—
—
—
16
16
1477
14719
Other extensive ultrasound examination of artery
PG1DE [2001309713]
PG1DE [2001309713]
1.6e+00
1.6e+00
—
—
—
1.9e+00
1.3e+00
cases:1.54%
controls:0.30%
cases:0.66%
controls:0.13%
—
—
—
—
—
—
cases:0.86%
controls:0.13%
cases:1.61%
controls:0.43%
28
55
1786
18050
12
24
1802
18081
—
—
—
15
23
1732
17337
24
63
1469
14672
General Surgery
2 [38004447]
2 [38004447]
4.5e-01
8.5e-01
1.2e+00
—
2.5e+00
1.1e+00
3.9e-01
cases:21.94%
controls:15.16%
cases:9.76%
controls:4.40%
cases:1.98%
controls:0.63%
—
—
cases:5.85%
controls:0.50%
cases:11.10%
controls:4.07%
cases:17.08%
controls:12.25%
398
2745
1416
15360
177
797
1637
17308
36
114
1778
17991
—
106
91
1705
17966
194
706
1553
16654
255
1805
1238
12930
azathioprine; oral, parenteral
L04AX01 [21603927]
L04AX01 [21603927]
1.1e+00
1.1e+00
1.6e+00
—
—
1.2e+00
1.3e+00
cases:2.15%
controls:0.73%
cases:1.65%
controls:0.54%
cases:0.66%
controls:0.14%
—
—
—
—
cases:1.60%
controls:0.51%
cases:2.08%
controls:0.59%
39
132
1775
17973
30
97
1784
18008
12
25
1802
18080
—
—
28
89
1719
17271
31
87
1462
14648
CICLOSPORIN - yes
CICLOSPORIN-1 [2002330221]
CICLOSPORIN-1 [2002330221]
3.0e+00
—
—
—
—
—
3.2e+00
cases:0.99%
controls:0.05%
—
—
—
—
—
—
—
—
—
—
cases:1.00%
controls:0.04%
18
9
1796
18096
—
—
—
—
—
15
6
1478
14729
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
43730-1 [3043849]
1.5e+00
1.5e+00
—
—
—
1.6e+00
1.6e+00
cases:1.21%
controls:0.27%
cases:0.66%
controls:0.14%
—
—
—
—
—
—
cases:0.63%
controls:0.13%
cases:1.47%
controls:0.31%
22
48
1792
18057
12
26
1802
18079
—
—
—
11
23
1736
17337
22
46
1471
14689
Skin Pathology biopsy report
65754-4 [40768443]
65754-4 [40768443]
1.2e+00
2.5e+00
—
1.0e+50
—
1.4e+00
1.1e+00
cases:2.32%
controls:0.74%
cases:2.65%
controls:0.23%
—
—
cases:0.94%
controls:0.00%
—
—
cases:0.80%
controls:0.19%
cases:2.41%
controls:0.80%
42
134
1772
17971
48
42
1766
18063
—
17
0
1797
18105
—
14
33
1733
17327
36
118
1457
14617
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
72493-0 [43055120]
1.5e+00
1.6e+00
1.8e+00
—
1.8e+00
1.5e+00
1.5e+00
cases:1.60%
controls:0.35%
cases:0.88%
controls:0.18%
cases:0.28%
controls:0.04%
—
—
cases:0.28%
controls:0.04%
cases:0.80%
controls:0.17%
cases:1.74%
controls:0.41%
29
64
1785
18041
16
32
1798
18073
5
8
1809
18097
—
5
8
1806
18049
14
30
1733
17330
26
60
1467
14675
Benign neoplasm: Skin of lower limb, including hip
D23.7 [45581295]
D23.7 [45581295]
2.3e+00
2.2e+00
—
—
—
—
1.7e+00
cases:0.39%
controls:0.04%
cases:0.39%
controls:0.04%
—
—
—
—
—
—
—
—
cases:0.60%
controls:0.12%
7
7
1807
18098
7
8
1807
18097
—
—
—
—
9
17
1484
14718
Sentinel node biopsy
PJA12 [2001309627]
PJA12 [2001309627]
1.8e+00
2.0e+00
—
—
1.0e+50
2.3e+00
4.7e-01
cases:3.91%
controls:0.67%
cases:1.76%
controls:0.24%
—
—
—
—
cases:0.50%
controls:0.00%
cases:1.09%
controls:0.12%
cases:0.80%
controls:0.50%
71
121
1743
17984
32
43
1782
18062
—
—
9
0
1802
18057
19
20
1728
17340
12
74
1481
14661
Hematology
82 [38004501]
82 [38004501]
9.2e-01
1.0e+00
1.2e+00
—
1.2e+00
9.2e-01
8.0e-01
cases:2.37%
controls:0.96%
cases:1.76%
controls:0.64%
cases:0.72%
controls:0.23%
—
—
cases:0.72%
controls:0.23%
cases:1.55%
controls:0.62%
cases:2.61%
controls:1.19%
43
173
1771
17932
32
115
1782
17990
13
41
1801
18064
—
13
41
1798
18016
27
108
1720
17252
39
175
1454
14560
Overall basocellular carcinoma of the skin
C44.81 [2000500812]
C44.81 [2000500812]
2.7e+00
—
—
—
—
—
3.3e+00
cases:0.55%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
cases:0.94%
controls:0.03%
10
7
1804
18098
—
—
—
—
—
14
5
1479
14730
Major dressing of wound of skin of lower limb
QDB10 [2001309970]
QDB10 [2001309970]
7.6e-01
5.3e-01
—
—
2.7e+00
2.3e+00
1.1e+00
cases:0.83%
controls:0.39%
cases:0.39%
controls:0.23%
—
—
—
—
cases:0.55%
controls:0.04%
cases:1.26%
controls:0.13%
cases:1.41%
controls:0.50%
15
70
1799
18035
7
41
1807
18064
—
—
10
7
1801
18050
22
23
1725
17337
21
73
1472
14662
alfacalcidol; oral, parenteral
A11CC03 [21600818]
A11CC03 [21600818]
1.7e+00
1.3e+00
—
—
2.0e+00
1.4e+00
1.4e+00
cases:1.38%
controls:0.25%
cases:0.72%
controls:0.20%
—
—
—
—
cases:0.28%
controls:0.04%
cases:0.74%
controls:0.19%
cases:1.14%
controls:0.28%
25
45
1789
18060
13
36
1801
18069
—
—
5
7
1806
18050
13
33
1734
17327
17
41
1476
14694
Psoriasis vulgaris
L40.0 [45543370]
L40.0 [45543370]
8.1e-01
1.3e+00
1.6e+00
1.0e+50
1.5e+00
1.1e+00
9.6e-01
cases:1.27%
controls:0.57%
cases:1.16%
controls:0.32%
cases:0.50%
controls:0.10%
cases:0.72%
controls:0.00%
cases:0.44%
controls:0.09%
cases:0.92%
controls:0.31%
cases:1.67%
controls:0.64%
23
103
1791
18002
21
58
1793
18047
9
18
1805
18087
13
0
1801
18105
8
17
1803
18040
16
53
1731
17307
25
95
1468
14640
Hypertension secondary to other renal disorders
I15.1 [45557535]
I15.1 [45557535]
2.1e+00
2.0e+00
—
—
—
1.8e+00
1.6e+00
cases:0.83%
controls:0.10%
cases:0.44%
controls:0.06%
—
—
—
—
—
—
cases:0.34%
controls:0.06%
cases:0.80%
controls:0.17%
15
18
1799
18087
8
11
1806
18094
—
—
—
6
10
1741
17350
12
25
1481
14710
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
8.9e-02
2.5e-01
6.6e-01
3.8e+00
6.4e-01
2.5e-01
1.0e-01
cases:46.86%
controls:44.66%
cases:47.85%
controls:41.69%
cases:22.22%
controls:12.90%
cases:23.26%
controls:0.70%
cases:20.98%
controls:12.33%
cases:48.88%
controls:42.63%
cases:62.16%
controls:59.72%
850
8085
964
10020
868
7548
946
10557
403
2335
1411
15770
422
126
1392
17979
380
2227
1431
15830
854
7400
893
9960
928
8800
565
5935
Medical Oncology
90 [38004507]
90 [38004507]
8.0e-01
8.6e-01
9.0e-01
1.5e+00
1.0e+00
9.9e-01
9.7e-01
cases:7.66%
controls:3.59%
cases:5.84%
controls:2.56%
cases:2.15%
controls:0.89%
cases:0.28%
controls:0.06%
cases:2.15%
controls:0.79%
cases:6.64%
controls:2.57%
cases:9.38%
controls:3.76%
139
650
1675
17455
106
463
1708
17642
39
161
1775
17944
5
11
1809
18094
39
143
1772
17914
116
447
1631
16913
140
554
1353
14181
Melanocytic naevi of scalp and neck
D22.4 [45590986]
D22.4 [45590986]
1.7e+00
2.1e+00
—
—
—
2.3e+00
1.7e+00
cases:0.55%
controls:0.10%
cases:0.33%
controls:0.04%
—
—
—
—
—
—
cases:0.29%
controls:0.03%
cases:0.60%
controls:0.12%
10
18
1804
18087
6
7
1808
18098
—
—
—
5
5
1742
17355
9
17
1484
14718
imiquimod
D06BB10 [21602092]
D06BB10 [21602092]
1.1e+00
1.5e+00
—
—
—
1.6e+00
1.2e+00
cases:1.49%
controls:0.49%
cases:0.66%
controls:0.15%
—
—
—
—
—
—
cases:0.80%
controls:0.16%
cases:1.81%
controls:0.54%
27
89
1787
18016
12
27
1802
18078
—
—
—
14
27
1733
17333
27
80
1466
14655
Inpatient Hospital
21 [8717]
21 [8717]
1.2e-01
2.7e-01
5.2e-01
4.4e+00
5.2e-01
4.1e-01
3.3e-01
cases:32.14%
controls:29.55%
cases:11.52%
controls:9.01%
cases:1.98%
controls:1.19%
cases:3.14%
controls:0.04%
cases:1.82%
controls:1.09%
cases:11.56%
controls:7.96%
cases:26.93%
controls:21.01%
583
5350
1231
12755
209
1632
1605
16473
36
216
1778
17889
57
7
1757
18098
33
197
1778
17860
202
1382
1545
15978
402
3096
1091
11639
Carcinoma in situ: Skin of scalp and neck
D04.4 [45581275]
D04.4 [45581275]
2.8e+00
—
—
—
—
—
2.6e+00
cases:0.44%
controls:0.03%
—
—
—
—
—
—
—
—
—
—
cases:0.54%
controls:0.04%
8
5
1806
18100
—
—
—
—
—
8
6
1485
14729
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
7.1e-02
1.6e-01
5.3e-01
3.6e+00
9.4e-01
1.9e-01
8.3e-02
cases:66.43%
controls:64.82%
cases:61.69%
controls:57.96%
cases:35.61%
controls:24.62%
cases:35.61%
controls:1.49%
cases:44.28%
controls:23.77%
cases:64.00%
controls:59.57%
cases:77.03%
controls:75.53%
1205
11736
609
6369
1119
10493
695
7612
646
4458
1168
13647
646
269
1168
17836
802
4293
1009
13764
1118
10341
629
7019
1150
11129
343
3606
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
1.6e-01
2.7e-01
3.5e-01
4.7e+00
4.2e-01
2.9e-01
2.5e-01
cases:22.93%
controls:20.26%
cases:9.92%
controls:7.76%
cases:1.38%
controls:0.98%
cases:2.87%
controls:0.03%
cases:1.60%
controls:1.06%
cases:10.07%
controls:7.72%
cases:26.46%
controls:21.97%
416
3668
1398
14437
180
1405
1634
16700
25
177
1789
17928
52
5
1762
18100
29
191
1782
17866
176
1341
1571
16019
395
3237
1098
11498
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
190 [2001600189]
190 [2001600189]
3.0e+00
—
—
—
—
—
2.1e+00
cases:0.66%
controls:0.03%
—
—
—
—
—
—
—
—
—
—
cases:0.40%
controls:0.05%
12
6
1802
18099
—
—
—
—
—
6
7
1487
14728
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
OMOP4822009 [45756830]
4.5e-02
1.0e+00
2.0e+00
—
—
1.2e+00
9.0e-01
cases:1.10%
controls:1.05%
cases:0.94%
controls:0.35%
cases:0.33%
controls:0.04%
—
—
—
—
cases:0.74%
controls:0.22%
cases:1.88%
controls:0.77%
20
191
1794
17914
17
63
1797
18042
6
8
1808
18097
—
—
13
38
1734
17322
28
114
1465
14621
calcium carbonate
A02AC01 [21600065]
A02AC01 [21600065]
2.1e+00
1.3e+00
-1.0e+50
—
—
1.4e+00
1.5e+00
cases:1.43%
controls:0.17%
cases:0.61%
controls:0.17%
cases:0.00%
controls:0.05%
—
—
—
—
cases:0.69%
controls:0.17%
cases:1.21%
controls:0.26%
26
31
1788
18074
11
31
1803
18074
0
9
1814
18096
—
—
12
29
1735
17331
18
39
1475
14696
calcium carbonate; oral
A12AA04 [21600863]
A12AA04 [21600863]
2.1e+00
1.3e+00
-1.0e+50
—
—
1.4e+00
1.5e+00
cases:1.43%
controls:0.17%
cases:0.61%
controls:0.17%
cases:0.00%
controls:0.05%
—
—
—
—
cases:0.69%
controls:0.17%
cases:1.21%
controls:0.26%
26
31
1788
18074
11
31
1803
18074
0
9
1814
18096
—
—
12
29
1735
17331
18
39
1475
14696
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
620-5 [3007853]
4.9e-01
7.7e-01
9.7e-01
—
2.4e+00
9.1e-01
5.1e-01
cases:3.42%
controls:2.12%
cases:1.65%
controls:0.77%
cases:0.28%
controls:0.10%
—
—
cases:0.83%
controls:0.08%
cases:2.00%
controls:0.81%
cases:4.49%
controls:2.74%
62
383
1752
17722
30
140
1784
17965
5
19
1809
18086
—
15
14
1796
18043
35
141
1712
17219
67
404
1426
14331
fusidic acid
D09AA02 [21602265]
D09AA02 [21602265]
6.0e-01
1.0e+00
1.6e+00
1.0e+50
1.7e+00
8.3e-01
7.4e-01
cases:6.50%
controls:3.68%
cases:2.70%
controls:1.01%
cases:0.44%
controls:0.09%
cases:0.66%
controls:0.00%
cases:0.77%
controls:0.14%
cases:2.58%
controls:1.13%
cases:7.84%
controls:3.89%
118
666
1696
17439
49
183
1765
17922
8
17
1806
18088
12
0
1802
18105
14
25
1797
18032
45
197
1702
17163
117
573
1376
14162
fusidic acid; ointment
D06AX01 [21602062]
D06AX01 [21602062]
6.0e-01
1.0e+00
1.6e+00
1.0e+50
1.7e+00
8.3e-01
7.4e-01
cases:6.50%
controls:3.68%
cases:2.70%
controls:1.01%
cases:0.44%
controls:0.09%
cases:0.66%
controls:0.00%
cases:0.77%
controls:0.14%
cases:2.58%
controls:1.13%
cases:7.84%
controls:3.89%
118
666
1696
17439
49
183
1765
17922
8
17
1806
18088
12
0
1802
18105
14
25
1797
18032
45
197
1702
17163
117
573
1376
14162
hydrocortisone buteprate
D07AB11 [21602115]
D07AB11 [21602115]
4.2e-01
8.2e-01
1.4e+00
—
1.2e+00
7.0e-01
3.1e-01
cases:10.47%
controls:7.15%
cases:5.18%
controls:2.36%
cases:0.94%
controls:0.24%
—
—
cases:0.72%
controls:0.22%
cases:4.75%
controls:2.41%
cases:9.98%
controls:7.51%
190
1294
1624
16811
94
427
1720
17678
17
43
1797
18062
—
13
40
1798
18017
83
418
1664
16942
149
1106
1344
13629
hydrocortisone butyrate
D07AB02 [21602106]
D07AB02 [21602106]
4.2e-01
8.2e-01
1.4e+00
—
1.2e+00
7.0e-01
3.1e-01
cases:10.47%
controls:7.15%
cases:5.18%
controls:2.36%
cases:0.94%
controls:0.24%
—
—
cases:0.72%
controls:0.22%
cases:4.75%
controls:2.41%
cases:9.98%
controls:7.51%
190
1294
1624
16811
94
427
1720
17678
17
43
1797
18062
—
13
40
1798
18017
83
418
1664
16942
149
1106
1344
13629
hydrocortisone
D07AA02 [21602102]
D07AA02 [21602102]
4.2e-01
8.2e-01
1.4e+00
—
1.2e+00
7.0e-01
3.1e-01
cases:10.47%
controls:7.15%
cases:5.18%
controls:2.36%
cases:0.94%
controls:0.24%
—
—
cases:0.72%
controls:0.22%
cases:4.75%
controls:2.41%
cases:9.98%
controls:7.51%
190
1294
1624
16811
94
427
1720
17678
17
43
1797
18062
—
13
40
1798
18017
83
418
1664
16942
149
1106
1344
13629
hydrocortisone aceponate
D07AC16 [21602135]
D07AC16 [21602135]
4.2e-01
8.2e-01
1.4e+00
—
1.2e+00
7.0e-01
3.1e-01
cases:10.47%
controls:7.15%
cases:5.18%
controls:2.36%
cases:0.94%
controls:0.24%
—
—
cases:0.72%
controls:0.22%
cases:4.75%
controls:2.41%
cases:9.98%
controls:7.51%
190
1294
1624
16811
94
427
1720
17678
17
43
1797
18062
—
13
40
1798
18017
83
418
1664
16942
149
1106
1344
13629
Destruction of lesion of skin of upper limb
QCA25 [2001309893]
QCA25 [2001309893]
2.5e+00
—
—
—
—
—
2.3e+00
cases:0.61%
controls:0.05%
—
—
—
—
—
—
—
—
—
—
cases:0.40%
controls:0.04%
11
9
1803
18096
—
—
—
—
—
6
6
1487
14729
hydrocortisone
C05AA01 [21601608]
C05AA01 [21601608]
4.1e-01
8.2e-01
1.4e+00
—
1.2e+00
7.0e-01
3.2e-01
cases:10.47%
controls:7.20%
cases:5.24%
controls:2.37%
cases:0.94%
controls:0.24%
—
—
cases:0.72%
controls:0.23%
cases:4.75%
controls:2.41%
cases:10.05%
controls:7.53%
190
1304
1624
16801
95
429
1719
17676
17
43
1797
18062
—
13
41
1798
18016
83
419
1664
16941
150
1110
1343
13625
hydrocortisone
A07EA02 [21600654]
A07EA02 [21600654]
4.1e-01
8.2e-01
1.4e+00
—
1.2e+00
7.0e-01
3.2e-01
cases:10.47%
controls:7.20%
cases:5.24%
controls:2.37%
cases:0.94%
controls:0.24%
—
—
cases:0.72%
controls:0.23%
cases:4.75%
controls:2.41%
cases:10.05%
controls:7.53%
190
1304
1624
16801
95
429
1719
17676
17
43
1797
18062
—
13
41
1798
18016
83
419
1664
16941
150
1110
1343
13625
Dermatographic urticaria
L50.3 [45596376]
L50.3 [45596376]
7.8e-01
2.3e+00
—
—
—
2.5e+00
1.6e+00
cases:0.28%
controls:0.13%
cases:0.33%
controls:0.03%
—
—
—
—
—
—
cases:0.34%
controls:0.03%
cases:0.40%
controls:0.08%
5
23
1809
18082
6
6
1808
18099
—
—
—
6
5
1741
17355
6
12
1487
14723
betamethasone
A07EA04 [21600656]
A07EA04 [21600656]
4.2e-01
8.5e-01
1.0e+00
—
1.4e+00
7.7e-01
3.2e-01
cases:9.37%
controls:6.35%
cases:5.24%
controls:2.30%
cases:0.94%
controls:0.35%
—
—
cases:1.16%
controls:0.28%
cases:4.64%
controls:2.21%
cases:9.24%
controls:6.87%
170
1149
1644
16956
95
416
1719
17689
17
63
1797
18042
—
21
51
1790
18006
81
383
1666
16977
138
1013
1355
13722
betamethasone
D07AC01 [21602120]
D07AC01 [21602120]
4.2e-01
8.5e-01
1.0e+00
—
1.4e+00
7.7e-01
3.2e-01
cases:9.37%
controls:6.35%
cases:5.24%
controls:2.30%
cases:0.94%
controls:0.35%
—
—
cases:1.16%
controls:0.28%
cases:4.64%
controls:2.21%
cases:9.24%
controls:6.87%
170
1149
1644
16956
95
416
1719
17689
17
63
1797
18042
—
21
51
1790
18006
81
383
1666
16977
138
1013
1355
13722
betamethasone
S02BA07 [21605169]
S02BA07 [21605169]
4.2e-01
8.5e-01
1.0e+00
—
1.4e+00
7.7e-01
3.2e-01
cases:9.37%
controls:6.35%
cases:5.24%
controls:2.30%
cases:0.94%
controls:0.35%
—
—
cases:1.16%
controls:0.28%
cases:4.64%
controls:2.21%
cases:9.24%
controls:6.87%
170
1149
1644
16956
95
416
1719
17689
17
63
1797
18042
—
21
51
1790
18006
81
383
1666
16977
138
1013
1355
13722
betamethasone
C05AA05 [21601610]
C05AA05 [21601610]
4.2e-01
8.5e-01
1.0e+00
—
1.4e+00
7.7e-01
3.2e-01
cases:9.37%
controls:6.35%
cases:5.24%
controls:2.30%
cases:0.94%
controls:0.35%
—
—
cases:1.16%
controls:0.28%
cases:4.64%
controls:2.21%
cases:9.24%
controls:6.87%
170
1149
1644
16956
95
416
1719
17689
17
63
1797
18042
—
21
51
1790
18006
81
383
1666
16977
138
1013
1355
13722
Kidney ultrasound examination
KA1AE [2001305627]
KA1AE [2001305627]
1.4e+00
1.7e+00
—
—
—
—
1.7e+00
cases:0.77%
controls:0.19%
cases:0.44%
controls:0.08%
—
—
—
—
—
—
—
—
cases:1.00%
controls:0.19%
14
35
1800
18070
8
15
1806
18090
—
—
—
—
15
28
1478
14707
Carcinoma in situ: Skin of lower limb, including hip
D04.7 [45590975]
D04.7 [45590975]
2.2e+00
—
—
1.0e+50
1.0e+50
—
2.5e+00
cases:0.39%
controls:0.04%
—
—
—
—
cases:0.39%
controls:0.00%
cases:0.33%
controls:0.00%
—
—
cases:0.67%
controls:0.05%
7
8
1807
18097
—
—
7
0
1807
18105
6
0
1805
18057
—
10
8
1483
14727
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
33863-2 [3030366]
1.1e+00
1.2e+00
—
—
—
1.1e+00
1.2e+00
cases:1.54%
controls:0.51%
cases:1.16%
controls:0.35%
—
—
—
—
—
—
cases:0.97%
controls:0.32%
cases:2.88%
controls:0.85%
28
93
1786
18012
21
64
1793
18041
—
—
—
17
55
1730
17305
43
125
1450
14610
Carcinoma in situ: Skin of trunk
D04.5 [45576373]
D04.5 [45576373]
1.8e+00
—
—
1.0e+50
—
2.4e+00
2.2e+00
cases:0.28%
controls:0.04%
—
—
—
—
cases:0.28%
controls:0.00%
—
—
cases:0.52%
controls:0.05%
cases:0.80%
controls:0.09%
5
8
1809
18097
—
—
5
0
1809
18105
—
9
8
1738
17352
12
13
1481
14722
Emergency Room Visit
ER [9203]
ER [9203]
2.2e-01
2.9e-01
3.8e-01
2.8e+00
6.2e-01
3.5e-01
3.2e-01
cases:36.77%
controls:31.83%
cases:13.78%
controls:10.65%
cases:2.04%
controls:1.41%
cases:0.55%
controls:0.03%
cases:2.48%
controls:1.36%
cases:13.51%
controls:9.94%
cases:33.76%
controls:27.06%
667
5763
1147
12342
250
1928
1564
16177
37
255
1777
17850
10
6
1804
18099
45
245
1766
17812
236
1725
1511
15635
504
3988
989
10747
combinations of corticosteroids
D07AB30 [21602118]
D07AB30 [21602118]
4.0e-01
8.0e-01
1.2e+00
—
1.3e+00
6.1e-01
3.5e-01
cases:14.88%
controls:10.52%
cases:7.61%
controls:3.58%
cases:1.27%
controls:0.40%
—
—
cases:1.49%
controls:0.42%
cases:6.12%
controls:3.42%
cases:15.20%
controls:11.20%
270
1904
1544
16201
138
648
1676
17457
23
72
1791
18033
—
27
76
1784
17981
107
594
1640
16766
227
1650
1266
13085
combinations of corticosteroids
D07XB30 [21602188]
D07XB30 [21602188]
4.0e-01
8.0e-01
1.2e+00
—
1.3e+00
6.1e-01
3.5e-01
cases:14.88%
controls:10.52%
cases:7.61%
controls:3.58%
cases:1.27%
controls:0.40%
—
—
cases:1.49%
controls:0.42%
cases:6.12%
controls:3.42%
cases:15.20%
controls:11.20%
270
1904
1544
16201
138
648
1676
17457
23
72
1791
18033
—
27
76
1784
17981
107
594
1640
16766
227
1650
1266
13085
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
2.9e-01
5.0e-01
6.6e-01
—
2.0e+00
6.9e-01
3.0e-01
cases:34.45%
controls:28.32%
cases:13.95%
controls:8.98%
cases:1.98%
controls:1.03%
—
—
cases:6.85%
controls:0.96%
cases:15.46%
controls:8.37%
cases:32.15%
controls:26.02%
625
5128
1189
12977
253
1626
1561
16479
36
187
1778
17918
—
124
173
1687
17884
270
1453
1477
15907
480
3834
1013
10901
Skin, Repair/fix-suture/cast/prosth device
S54 [2002001018]
S54 [2002001018]
7.8e-01
2.4e+00
—
—
—
2.1e+00
4.6e-01
cases:0.55%
controls:0.25%
cases:0.72%
controls:0.07%
—
—
—
—
—
—
cases:0.46%
controls:0.06%
cases:0.54%
controls:0.34%
10
46
1804
18059
13
12
1801
18093
—
—
—
8
10
1739
17350
8
50
1485
14685
Malignant neoplasm of skin
S77 [2002001041]
S77 [2002001041]
2.0e+00
—
—
—
—
—
2.4e+00
cases:0.55%
controls:0.07%
—
—
—
—
—
—
—
—
—
—
cases:0.67%
controls:0.06%
10
13
1804
18092
—
—
—
—
—
10
9
1483
14726
Left side
ZXA05 [2001311347]
ZXA05 [2001311347]
5.3e-01
6.0e-01
2.0e+00
1.0e+50
—
1.2e+00
7.1e-01
cases:5.24%
controls:3.14%
cases:1.43%
controls:0.80%
cases:0.55%
controls:0.08%
cases:0.83%
controls:0.00%
—
—
cases:2.00%
controls:0.61%
cases:3.95%
controls:1.98%
95
568
1719
17537
26
144
1788
17961
10
14
1804
18091
15
0
1799
18105
—
35
106
1712
17254
59
292
1434
14443
Localized swelling, mass and lump, lower limb
R22.4 [45597173]
R22.4 [45597173]
1.4e+00
3.0e+00
—
—
—
—
1.2e+00
cases:0.77%
controls:0.19%
cases:0.66%
controls:0.03%
—
—
—
—
—
—
—
—
cases:0.54%
controls:0.16%
14
35
1800
18070
12
6
1802
18099
—
—
—
—
8
24
1485
14711
Infection following a procedure, not elsewhere classified
T81.4 [45575538]
T81.4 [45575538]
1.2e-01
9.2e-01
—
—
2.6e+00
1.7e+00
6.4e-01
cases:1.27%
controls:1.13%
cases:0.88%
controls:0.35%
—
—
—
—
cases:0.66%
controls:0.05%
cases:1.66%
controls:0.32%
cases:2.01%
controls:1.07%
23
204
1791
17901
16
64
1798
18041
—
—
12
9
1799
18048
29
56
1718
17304
30
158
1463
14577
FISTULA - Fistula
FISTULA-1 [2002330212]
FISTULA-1 [2002330212]
2.3e+00
—
—
—
—
2.1e+00
1.9e+00
cases:0.50%
controls:0.05%
—
—
—
—
—
—
—
—
cases:0.29%
controls:0.03%
cases:0.54%
controls:0.08%
9
9
1805
18096
—
—
—
—
5
6
1742
17354
8
12
1485
14723
Use of photodynamic technique
ZXC15 [2001311365]
ZXC15 [2001311365]
1.7e+00
—
—
—
—
—
2.5e+00
cases:0.66%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
cases:0.80%
controls:0.07%
12
22
1802
18083
—
—
—
—
—
12
10
1481
14725
Ultrsound examination of soft tissue not elsewhere classified
QX2XE [2001310033]
QX2XE [2001310033]
7.9e-01
2.2e+00
—
—
—
1.9e+00
1.3e+00
cases:0.50%
controls:0.23%
cases:0.39%
controls:0.04%
—
—
—
—
—
—
cases:0.40%
controls:0.06%
cases:0.67%
controls:0.19%
9
41
1805
18064
7
8
1807
18097
—
—
—
7
10
1740
17350
10
28
1483
14707
methylprednisolone; oral, parenteral
H02AB04 [21602732]
H02AB04 [21602732]
7.6e-01
1.3e+00
1.2e+00
—
1.5e+00
1.1e+00
9.5e-01
cases:3.64%
controls:1.73%
cases:2.37%
controls:0.68%
cases:0.44%
controls:0.13%
—
—
cases:0.39%
controls:0.08%
cases:2.00%
controls:0.66%
cases:3.68%
controls:1.46%
66
313
1748
17792
43
124
1771
17981
8
24
1806
18081
—
7
15
1804
18042
35
115
1712
17245
55
215
1438
14520
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
3.2e-01
5.8e-01
9.7e-01
—
8.7e-01
6.7e-01
6.7e-01
cases:10.31%
controls:7.69%
cases:7.17%
controls:4.14%
cases:2.26%
controls:0.87%
—
—
cases:2.04%
controls:0.87%
cases:8.13%
controls:4.34%
cases:15.67%
controls:8.67%
187
1393
1627
16712
130
750
1684
17355
41
158
1773
17947
—
37
157
1774
17900
142
754
1605
16606
234
1277
1259
13458
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
7.0e-01
1.3e+00
—
—
—
9.8e-01
1.1e+00
cases:4.19%
controls:2.13%
cases:1.43%
controls:0.40%
—
—
—
—
—
—
cases:0.97%
controls:0.37%
cases:3.22%
controls:1.13%
76
385
1738
17720
26
72
1788
18033
—
—
—
17
64
1730
17296
48
166
1445
14569
Verruca simplex
B07.9 [2000500357]
B07.9 [2000500357]
1.0e+00
1.5e+00
—
1.0e+50
—
1.5e+00
1.5e+00
cases:0.99%
controls:0.36%
cases:0.55%
controls:0.13%
—
—
cases:0.33%
controls:0.00%
—
—
cases:0.46%
controls:0.10%
cases:1.88%
controls:0.43%
18
66
1796
18039
10
23
1804
18082
—
6
0
1808
18105
—
8
17
1739
17343
28
63
1465
14672
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
M01AE01 [21603967]
1.8e-01
3.3e-01
1.4e-01
2.2e+00
6.7e-01
3.0e-01
2.4e-01
cases:40.41%
controls:36.13%
cases:21.06%
controls:16.09%
cases:2.59%
controls:2.27%
cases:0.94%
controls:0.10%
cases:4.09%
controls:2.14%
cases:20.61%
controls:16.16%
cases:42.00%
controls:36.21%
733
6542
1081
11563
382
2913
1432
15192
47
411
1767
17694
17
19
1797
18086
74
386
1737
17671
360
2806
1387
14554
627
5336
866
9399
ibuprofen
R02AX02 [1588667]
R02AX02 [1588667]
1.8e-01
3.3e-01
1.4e-01
2.2e+00
6.7e-01
3.0e-01
2.4e-01
cases:40.41%
controls:36.13%
cases:21.06%
controls:16.09%
cases:2.59%
controls:2.27%
cases:0.94%
controls:0.10%
cases:4.09%
controls:2.14%
cases:20.61%
controls:16.16%
cases:42.00%
controls:36.21%
733
6542
1081
11563
382
2913
1432
15192
47
411
1767
17694
17
19
1797
18086
74
386
1737
17671
360
2806
1387
14554
627
5336
866
9399
Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]
SPAT1144 [2001700245]
3.1e-01
1.1e+00
—
—
2.3e+00
1.6e+00
7.2e-01
cases:0.94%
controls:0.69%
cases:0.61%
controls:0.21%
—
—
—
—
cases:0.33%
controls:0.03%
cases:0.80%
controls:0.16%
cases:1.41%
controls:0.69%
17
125
1797
17980
11
38
1803
18067
—
—
6
6
1805
18051
14
28
1733
17332
21
102
1472
14633
Local dermatologic skincare
TQW80 [2001310149]
TQW80 [2001310149]
1.6e+00
1.2e+00
—
1.0e+50
—
2.3e+00
9.9e-01
cases:0.99%
controls:0.21%
cases:0.28%
controls:0.08%
—
—
cases:0.44%
controls:0.00%
—
—
cases:0.52%
controls:0.05%
cases:0.87%
controls:0.33%
18
38
1796
18067
5
15
1809
18090
—
8
0
1806
18105
—
9
9
1738
17351
13
48
1480
14687
Skin symptom/complaint other
S29 [2002000993]
S29 [2002000993]
2.2e-01
1.2e+00
7.3e-01
—
2.1e+00
5.2e-01
5.3e-01
cases:3.14%
controls:2.53%
cases:2.65%
controls:0.83%
cases:0.28%
controls:0.13%
—
—
cases:0.72%
controls:0.09%
cases:1.37%
controls:0.82%
cases:5.36%
controls:3.22%
57
458
1757
17647
48
150
1766
17955
5
24
1809
18081
—
13
16
1798
18041
24
143
1723
17217
80
474
1413
14261
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
1.2e-01
1.5e-01
2.0e-01
3.1e+00
7.0e-01
1.6e-01
1.3e-01
cases:16.21%
controls:14.62%
cases:9.10%
controls:7.90%
cases:1.65%
controls:1.36%
cases:2.15%
controls:0.10%
cases:2.71%
controls:1.37%
cases:9.39%
controls:8.14%
cases:21.03%
controls:18.91%
294
2647
1520
15458
165
1430
1649
16675
30
246
1784
17859
39
18
1775
18087
49
247
1762
17810
164
1413
1583
15947
314
2787
1179
11948
Use of chemical agents
ZXC20 [2001311366]
ZXC20 [2001311366]
1.9e+00
1.7e+00
—
—
—
—
1.8e+00
cases:0.99%
controls:0.14%
cases:0.28%
controls:0.05%
—
—
—
—
—
—
—
—
cases:0.47%
controls:0.07%
18
26
1796
18079
5
9
1809
18096
—
—
—
—
7
11
1486
14724
darbepoetin alfa; parenteral
B03XA02 [21601134]
B03XA02 [21601134]
1.7e+00
1.4e+00
—
—
—
1.4e+00
2.0e+00
cases:0.72%
controls:0.13%
cases:0.44%
controls:0.10%
—
—
—
—
—
—
cases:0.46%
controls:0.12%
cases:1.00%
controls:0.14%
13
23
1801
18082
8
19
1806
18086
—
—
—
8
20
1739
17340
15
20
1478
14715
Pediatric Medicine
37 [38004477]
37 [38004477]
-3.0e-01
-3.9e-01
—
3.7e+00
3.4e-01
3.0e-02
-4.3e-01
cases:2.43%
controls:3.25%
cases:1.21%
controls:1.77%
—
—
cases:1.16%
controls:0.03%
cases:0.61%
controls:0.43%
cases:1.77%
controls:1.72%
cases:1.54%
controls:2.35%
44
588
1770
17517
22
321
1792
17784
—
21
5
1793
18100
11
78
1800
17979
31
299
1716
17061
23
347
1470
14388
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
3.1e-01
4.9e-01
8.7e-01
—
7.2e-01
7.1e-01
6.3e-01
cases:14.99%
controls:11.49%
cases:10.53%
controls:6.76%
cases:3.20%
controls:1.36%
—
—
cases:2.71%
controls:1.33%
cases:12.71%
controls:6.66%
cases:24.25%
controls:14.50%
272
2081
1542
16024
191
1223
1623
16882
58
247
1756
17858
—
49
241
1762
17816
222
1157
1525
16203
362
2137
1131
12598
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
3.1e-01
4.9e-01
8.8e-01
—
7.2e-01
7.1e-01
6.3e-01
cases:14.94%
controls:11.46%
cases:10.47%
controls:6.71%
cases:3.20%
controls:1.35%
—
—
cases:2.71%
controls:1.33%
cases:12.59%
controls:6.64%
cases:24.05%
controls:14.42%
271
2074
1543
16031
190
1214
1624
16891
58
245
1756
17860
—
49
241
1762
17816
220
1152
1527
16208
359
2125
1134
12610
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
3.0e-01
4.6e-01
8.7e-01
—
7.3e-01
7.0e-01
6.1e-01
cases:15.44%
controls:11.96%
cases:10.58%
controls:6.96%
cases:3.25%
controls:1.39%
—
—
cases:2.82%
controls:1.37%
cases:12.94%
controls:6.88%
cases:24.45%
controls:14.94%
280
2165
1534
15940
192
1261
1622
16844
59
252
1755
17853
—
51
248
1760
17809
226
1195
1521
16165
365
2202
1128
12533
Neck ultrasound examination
EP1AE [2001302284]
EP1AE [2001302284]
8.0e-01
1.6e+00
—
—
—
1.2e+00
1.2e+00
cases:1.43%
controls:0.65%
cases:0.72%
controls:0.14%
—
—
—
—
—
—
cases:0.57%
controls:0.17%
cases:1.74%
controls:0.53%
26
118
1788
17987
13
26
1801
18079
—
—
—
10
29
1737
17331
26
78
1467
14657
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
3.0e-01
4.9e-01
8.3e-01
—
6.8e-01
6.7e-01
6.1e-01
cases:15.60%
controls:12.08%
cases:10.92%
controls:7.01%
cases:3.31%
controls:1.47%
—
—
cases:2.76%
controls:1.42%
cases:12.76%
controls:6.95%
cases:24.58%
controls:15.03%
283
2187
1531
15918
198
1269
1616
16836
60
267
1754
17838
—
50
256
1761
17801
223
1206
1524
16154
367
2214
1126
12521
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
4.3e-01
5.7e-01
1.1e+00
—
6.1e-01
8.1e-01
6.8e-01
cases:11.41%
controls:7.74%
cases:5.13%
controls:2.96%
cases:0.83%
controls:0.28%
—
—
cases:0.61%
controls:0.33%
cases:5.67%
controls:2.62%
cases:13.53%
controls:7.38%
207
1401
1607
16704
93
536
1721
17569
15
51
1799
18054
—
11
60
1800
17997
99
454
1648
16906
202
1087
1291
13648
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
2.9e-01
4.0e-01
8.1e-01
—
7.7e-01
6.6e-01
5.8e-01
cases:14.11%
controls:10.94%
cases:9.10%
controls:6.31%
cases:2.81%
controls:1.26%
—
—
cases:2.54%
controls:1.20%
cases:11.33%
controls:6.22%
cases:21.30%
controls:13.14%
256
1980
1558
16125
165
1143
1649
16962
51
229
1763
17876
—
46
216
1765
17841
198
1080
1549
16280
318
1936
1175
12799
Person consulting for explanation of investigation findings
Z71.2 [45552100]
Z71.2 [45552100]
2.2e-01
6.0e-01
1.7e+00
—
7.9e-01
7.5e-01
4.6e-01
cases:5.68%
controls:4.61%
cases:3.31%
controls:1.85%
cases:1.10%
controls:0.20%
—
—
cases:0.50%
controls:0.23%
cases:3.95%
controls:1.90%
cases:9.31%
controls:6.09%
103
835
1711
17270
60
335
1754
17770
20
37
1794
18068
—
9
41
1802
18016
69
330
1678
17030
139
897
1354
13838
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
2.9e-01
4.0e-01
8.1e-01
—
7.6e-01
6.7e-01
5.8e-01
cases:14.11%
controls:10.99%
cases:9.15%
controls:6.33%
cases:2.81%
controls:1.28%
—
—
cases:2.54%
controls:1.21%
cases:11.45%
controls:6.23%
cases:21.23%
controls:13.13%
256
1989
1558
16116
166
1146
1648
16959
51
231
1763
17874
—
46
218
1765
17839
200
1082
1547
16278
317
1934
1176
12801
Gastroenterology
10 [38004455]
10 [38004455]
4.3e-01
6.2e-01
1.1e+00
—
7.6e-01
6.6e-01
6.4e-01
cases:8.32%
controls:5.58%
cases:4.24%
controls:2.32%
cases:1.43%
controls:0.46%
—
—
cases:0.99%
controls:0.47%
cases:4.69%
controls:2.48%
cases:11.39%
controls:6.35%
151
1011
1663
17094
77
420
1737
17685
26
84
1788
18021
—
18
84
1793
17973
82
430
1665
16930
170
936
1323
13799
Cholangitis
K83.0 [45552955]
K83.0 [45552955]
1.4e+00
1.6e+00
—
—
—
1.4e+00
2.1e+00
cases:0.55%
controls:0.13%
cases:0.39%
controls:0.08%
—
—
—
—
—
—
cases:0.40%
controls:0.10%
cases:1.00%
controls:0.13%
10
24
1804
18081
7
14
1807
18091
—
—
—
7
18
1740
17342
15
19
1478
14716
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
2.9e-01
3.9e-01
8.1e-01
—
7.5e-01
6.5e-01
5.9e-01
cases:14.06%
controls:10.89%
cases:9.10%
controls:6.34%
cases:2.81%
controls:1.26%
—
—
cases:2.54%
controls:1.22%
cases:11.33%
controls:6.23%
cases:21.37%
controls:13.14%
255
1972
1559
16133
165
1148
1649
16957
51
229
1763
17876
—
46
220
1765
17837
198
1081
1549
16279
319
1936
1174
12799
FEV1 percent change
69983-5 [42868472]
69983-5 [42868472]
4.1e-01
8.4e-01
1.8e+00
—
2.1e+00
1.3e+00
1.3e+00
cases:2.59%
controls:1.73%
cases:1.32%
controls:0.57%
cases:0.33%
controls:0.06%
—
—
cases:0.28%
controls:0.03%
cases:1.43%
controls:0.39%
cases:3.42%
controls:0.92%
47
313
1767
17792
24
104
1790
18001
6
10
1808
18095
—
5
6
1806
18051
25
68
1722
17292
51
136
1442
14599
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
4.1e-01
8.4e-01
1.8e+00
—
2.1e+00
1.3e+00
1.3e+00
cases:2.59%
controls:1.73%
cases:1.32%
controls:0.57%
cases:0.33%
controls:0.06%
—
—
cases:0.28%
controls:0.03%
cases:1.43%
controls:0.39%
cases:3.42%
controls:0.92%
47
313
1767
17792
24
104
1790
18001
6
10
1808
18095
—
5
6
1806
18051
25
68
1722
17292
51
136
1442
14599
FEV1 --post bronchodilation
20155-8 [3023550]
20155-8 [3023550]
4.1e-01
8.4e-01
1.8e+00
—
2.1e+00
1.3e+00
1.3e+00
cases:2.59%
controls:1.73%
cases:1.32%
controls:0.57%
cases:0.33%
controls:0.06%
—
—
cases:0.28%
controls:0.03%
cases:1.43%
controls:0.39%
cases:3.42%
controls:0.92%
47
313
1767
17792
24
104
1790
18001
6
10
1808
18095
—
5
6
1806
18051
25
68
1722
17292
51
136
1442
14599
FVC percent change Respiratory system
69982-7 [42868471]
69982-7 [42868471]
4.1e-01
8.4e-01
1.8e+00
—
2.1e+00
1.3e+00
1.3e+00
cases:2.59%
controls:1.73%
cases:1.32%
controls:0.57%
cases:0.33%
controls:0.06%
—
—
cases:0.28%
controls:0.03%
cases:1.43%
controls:0.39%
cases:3.42%
controls:0.92%
47
313
1767
17792
24
104
1790
18001
6
10
1808
18095
—
5
6
1806
18051
25
68
1722
17292
51
136
1442
14599
FEV1/FVC --post bronchodilation
69970-2 [42868459]
69970-2 [42868459]
4.1e-01
8.4e-01
1.8e+00
—
2.1e+00
1.3e+00
1.3e+00
cases:2.59%
controls:1.73%
cases:1.32%
controls:0.57%
cases:0.33%
controls:0.06%
—
—
cases:0.28%
controls:0.03%
cases:1.43%
controls:0.39%
cases:3.42%
controls:0.92%
47
313
1767
17792
24
104
1790
18001
6
10
1808
18095
—
5
6
1806
18051
25
68
1722
17292
51
136
1442
14599
carbamide
D02AE01 [21601975]
D02AE01 [21601975]
8.3e-01
1.1e+00
—
—
—
1.5e+00
1.1e+00
cases:1.49%
controls:0.65%
cases:0.61%
controls:0.19%
—
—
—
—
—
—
cases:0.74%
controls:0.17%
cases:1.47%
controls:0.50%
27
118
1787
17987
11
35
1803
18070
—
—
—
13
29
1734
17331
22
73
1471
14662
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
2.9e-01
3.7e-01
8.0e-01
—
7.5e-01
6.7e-01
5.5e-01
cases:14.61%
controls:11.31%
cases:9.26%
controls:6.57%
cases:2.81%
controls:1.28%
—
—
cases:2.60%
controls:1.24%
cases:11.79%
controls:6.41%
cases:21.43%
controls:13.65%
265
2048
1549
16057
168
1190
1646
16915
51
232
1763
17873
—
47
224
1764
17833
206
1113
1541
16247
320
2011
1173
12724
Intravenous general anesthesia
WX404 [2001310807]
WX404 [2001310807]
4.7e-01
9.0e-01
—
—
—
1.1e+00
1.0e+00
cases:4.91%
controls:3.11%
cases:1.65%
controls:0.68%
—
—
—
—
—
—
cases:1.37%
controls:0.48%
cases:3.75%
controls:1.41%
89
563
1725
17542
30
123
1784
17982
—
—
—
24
84
1723
17276
56
208
1437
14527
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
AA1CG [2001300116]
2.0e-01
1.1e+00
—
—
—
1.1e+00
1.2e+00
cases:1.27%
controls:1.04%
cases:0.88%
controls:0.30%
—
—
—
—
—
—
cases:0.74%
controls:0.25%
cases:2.14%
controls:0.64%
23
189
1791
17916
16
54
1798
18051
—
—
—
13
43
1734
17317
32
94
1461
14641
Basal cell carcinoma, NOS, of skin, NOS
8090/3-C44.9 [44505057]
8090/3-C44.9 [44505057]
1.1e+00
2.4e+00
—
1.0e+50
—
—
7.0e-01
cases:1.43%
controls:0.50%
cases:1.54%
controls:0.15%
—
—
cases:0.50%
controls:0.00%
—
—
—
—
cases:1.07%
controls:0.54%
26
91
1788
18014
28
27
1786
18078
—
9
0
1805
18105
—
—
16
79
1477
14656
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
2.5e-01
3.6e-01
8.2e-01
—
7.2e-01
6.7e-01
5.6e-01
cases:13.73%
controls:11.00%
cases:8.93%
controls:6.41%
cases:2.81%
controls:1.26%
—
—
cases:2.48%
controls:1.23%
cases:11.51%
controls:6.23%
cases:21.17%
controls:13.34%
249
1991
1565
16114
162
1160
1652
16945
51
228
1763
17877
—
45
222
1766
17835
201
1082
1546
16278
316
1966
1177
12769
hydrocortisone
S02BA01 [21605166]
S02BA01 [21605166]
4.0e-01
8.4e-01
1.5e+00
—
8.4e-01
6.3e-01
2.4e-01
cases:9.04%
controls:6.24%
cases:4.52%
controls:2.00%
cases:0.77%
controls:0.18%
—
—
cases:0.50%
controls:0.22%
cases:3.84%
controls:2.07%
cases:8.31%
controls:6.67%
164
1130
1650
16975
82
362
1732
17743
14
32
1800
18073
—
9
39
1802
18018
67
360
1680
17000
124
983
1369
13752
Other excision or repair of lesion of skin of trunk
QBE99 [2001309861]
QBE99 [2001309861]
1.3e+00
—
—
1.0e+50
—
—
2.0e+00
cases:0.61%
controls:0.17%
—
—
—
—
cases:0.88%
controls:0.00%
—
—
—
—
cases:0.47%
controls:0.06%
11
30
1803
18075
—
—
16
0
1798
18105
—
—
7
9
1486
14726
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
22664-7 [3020779]
6.9e-01
9.1e-01
1.3e+00
—
6.3e-01
8.3e-01
9.1e-01
cases:2.98%
controls:1.52%
cases:2.04%
controls:0.83%
cases:0.55%
controls:0.15%
—
—
cases:0.33%
controls:0.18%
cases:2.00%
controls:0.88%
cases:4.76%
controls:1.97%
54
275
1760
17830
37
151
1777
17954
10
27
1804
18078
—
6
32
1805
18025
35
153
1712
17207
71
291
1422
14444
Split skin graft
ZZA00 [2001311610]
ZZA00 [2001311610]
1.8e+00
—
—
—
1.0e+50
—
1.5e+00
cases:0.88%
controls:0.15%
—
—
—
—
—
—
cases:0.33%
controls:0.00%
—
—
cases:0.60%
controls:0.13%
16
27
1798
18078
—
—
—
6
0
1805
18057
—
9
19
1484
14716
FEV1/FVC
19926-5 [3011505]
19926-5 [3011505]
3.9e-01
8.5e-01
1.6e+00
—
2.0e+00
1.1e+00
1.3e+00
cases:2.92%
controls:1.99%
cases:1.54%
controls:0.67%
cases:0.33%
controls:0.07%
—
—
cases:0.28%
controls:0.04%
cases:1.49%
controls:0.48%
cases:3.75%
controls:1.02%
53
360
1761
17745
28
121
1786
17984
6
12
1808
18093
—
5
7
1806
18050
26
84
1721
17276
56
150
1437
14585
FEV1
20150-9 [3024653]
20150-9 [3024653]
3.9e-01
8.5e-01
1.6e+00
—
2.0e+00
1.1e+00
1.3e+00
cases:2.92%
controls:1.99%
cases:1.54%
controls:0.67%
cases:0.33%
controls:0.07%
—
—
cases:0.28%
controls:0.04%
cases:1.49%
controls:0.48%
cases:3.75%
controls:1.02%
53
360
1761
17745
28
121
1786
17984
6
12
1808
18093
—
5
7
1806
18050
26
84
1721
17276
56
150
1437
14585
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
19870-5 [3020158]
3.9e-01
8.5e-01
1.6e+00
—
2.0e+00
1.1e+00
1.3e+00
cases:2.92%
controls:1.99%
cases:1.54%
controls:0.67%
cases:0.33%
controls:0.07%
—
—
cases:0.28%
controls:0.04%
cases:1.49%
controls:0.48%
cases:3.75%
controls:1.02%
53
360
1761
17745
28
121
1786
17984
6
12
1808
18093
—
5
7
1806
18050
26
84
1721
17276
56
150
1437
14585
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
NK6QA [2001308500]
7.5e-01
6.9e-01
—
—
—
1.4e+00
1.1e+00
cases:1.76%
controls:0.85%
cases:0.50%
controls:0.25%
—
—
—
—
—
—
cases:0.69%
controls:0.17%
cases:1.81%
controls:0.60%
32
153
1782
17952
9
45
1805
18060
—
—
—
12
29
1735
17331
27
88
1466
14647
Flap of skin
ZZR00 [2001311677]
ZZR00 [2001311677]
1.6e+00
—
—
1.0e+50
—
—
1.7e+00
cases:0.66%
controls:0.13%
—
—
—
—
cases:0.33%
controls:0.00%
—
—
—
—
cases:0.60%
controls:0.12%
12
24
1802
18081
—
—
6
0
1808
18105
—
—
9
17
1484
14718
tretinoin; ointment
D10AD01 [21602293]
D10AD01 [21602293]
8.3e-01
1.5e+00
—
—
—
7.6e-01
9.6e-01
cases:1.27%
controls:0.56%
cases:0.83%
controls:0.19%
—
—
—
—
—
—
cases:0.52%
controls:0.24%
cases:1.34%
controls:0.52%
23
101
1791
18004
15
35
1799
18070
—
—
—
9
42
1738
17318
20
76
1473
14659
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
5.7e-01
8.0e-01
1.1e+00
1.0e+50
1.4e+00
1.1e+00
7.4e-01
cases:8.77%
controls:5.14%
cases:2.70%
controls:1.23%
cases:0.39%
controls:0.13%
cases:0.50%
controls:0.00%
cases:0.39%
controls:0.09%
cases:2.63%
controls:0.88%
cases:6.43%
controls:3.16%
159
930
1655
17175
49
223
1765
17882
7
23
1807
18082
9
0
1805
18105
7
17
1804
18040
46
153
1701
17207
96
466
1397
14269
Extensive body CT
JN4BD [2001310899]
JN4BD [2001310899]
8.2e-01
8.4e-01
1.5e+00
—
—
1.1e+00
1.3e+00
cases:2.65%
controls:1.18%
cases:0.94%
controls:0.41%
cases:0.28%
controls:0.06%
—
—
—
—
cases:1.14%
controls:0.37%
cases:2.14%
controls:0.60%
48
214
1766
17891
17
74
1797
18031
5
11
1809
18094
—
—
20
65
1727
17295
32
89
1461
14646
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
3.2e-01
4.3e-01
6.7e-01
—
5.8e-01
6.3e-01
6.0e-01
cases:17.97%
controls:13.71%
cases:12.24%
controls:8.31%
cases:3.91%
controls:2.05%
—
—
cases:3.59%
controls:2.04%
cases:14.37%
controls:8.24%
cases:26.52%
controls:16.51%
326
2483
1488
15622
222
1505
1592
16600
71
371
1743
17734
—
65
369
1746
17688
251
1430
1496
15930
396
2433
1097
12302
Physical Medicine And Rehabilitation
25 [38004468]
25 [38004468]
3.1e-01
4.5e-01
9.0e-01
—
1.0e+00
7.7e-01
6.1e-01
cases:8.93%
controls:6.69%
cases:3.64%
controls:2.35%
cases:0.83%
controls:0.34%
—
—
cases:0.99%
controls:0.35%
cases:4.35%
controls:2.07%
cases:11.72%
controls:6.75%
162
1212
1652
16893
66
425
1748
17680
15
61
1799
18044
—
18
64
1793
17993
76
359
1671
17001
175
994
1318
13741
Besnier prurigo
L20.0 [45562534]
L20.0 [45562534]
7.7e-01
1.1e+00
1.3e+00
—
1.8e+00
1.3e+00
5.4e-01
cases:1.87%
controls:0.88%
cases:0.99%
controls:0.35%
cases:0.28%
controls:0.07%
—
—
cases:0.33%
controls:0.06%
cases:1.14%
controls:0.31%
cases:1.88%
controls:1.11%
34
159
1780
17946
18
63
1796
18042
5
13
1809
18092
—
6
10
1805
18047
20
53
1727
17307
28
163
1465
14572
Rheumatology
66 [38004491]
66 [38004491]
3.9e-01
5.2e-01
9.9e-01
—
9.4e-01
6.4e-01
6.0e-01
cases:5.18%
controls:3.56%
cases:3.47%
controls:2.09%
cases:1.05%
controls:0.39%
—
—
cases:0.83%
controls:0.33%
cases:3.72%
controls:1.99%
cases:6.16%
controls:3.50%
94
644
1720
17461
63
379
1751
17726
19
71
1795
18034
—
15
59
1796
17998
65
346
1682
17014
92
515
1401
14220
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
3.0e-01
5.9e-01
3.7e-01
1.2e+00
4.1e-01
5.2e-01
5.2e-01
cases:94.54%
controls:92.75%
cases:90.02%
controls:83.27%
cases:53.97%
controls:44.72%
cases:7.28%
controls:2.38%
cases:54.78%
controls:44.49%
cases:89.75%
controls:83.91%
cases:96.99%
controls:95.05%
1715
16792
99
1313
1633
15076
181
3029
979
8096
835
10009
132
430
1682
17675
992
8034
819
10023
1568
14567
179
2793
1448
14005
45
730
Otolaryngology
4 [38004449]
4 [38004449]
4.8e-01
5.2e-01
6.7e-01
—
1.0e+00
5.4e-01
5.2e-01
cases:16.65%
controls:10.95%
cases:5.79%
controls:3.53%
cases:1.16%
controls:0.60%
—
—
cases:1.60%
controls:0.59%
cases:6.24%
controls:3.74%
cases:17.01%
controls:10.88%
302
1983
1512
16122
105
639
1709
17466
21
108
1793
17997
—
29
107
1782
17950
109
649
1638
16711
254
1603
1239
13132
Granulocytes/Leukocytes in Blood
30395-8 [3035933]
30395-8 [3035933]
6.8e-01
7.3e-01
—
—
—
1.8e+00
1.2e+00
cases:1.10%
controls:0.56%
cases:0.28%
controls:0.13%
—
—
—
—
—
—
cases:0.46%
controls:0.07%
cases:1.21%
controls:0.37%
20
102
1794
18003
5
24
1809
18081
—
—
—
8
13
1739
17347
18
54
1475
14681
Sleep apnoea
G47.3 [45562094]
G47.3 [45562094]
1.1e-01
6.5e-02
2.0e-01
3.0e+00
4.4e-01
-7.3e-02
1.8e-01
cases:4.30%
controls:3.88%
cases:2.87%
controls:2.69%
cases:0.72%
controls:0.59%
cases:0.55%
controls:0.03%
cases:0.77%
controls:0.50%
cases:2.58%
controls:2.76%
cases:5.96%
controls:5.05%
78
703
1736
17402
52
487
1762
17618
13
106
1801
17999
10
5
1804
18100
14
90
1797
17967
45
480
1702
16880
89
744
1404
13991
Malignant melanoma of the lower extremity including the hip without histology
C43.70 [2000500761]
C43.70 [2000500761]
—
3.0e+00
1.0e+50
—
—
—
—
—
—
cases:0.55%
controls:0.03%
cases:0.55%
controls:0.00%
—
—
—
—
—
—
—
—
—
10
5
1804
18100
10
0
1804
18105
—
—
—
—
Laparoscopy
JAH01 [2001304475]
JAH01 [2001304475]
1.2e+00
1.8e+00
—
—
—
—
7.1e-01
cases:0.83%
controls:0.25%
cases:0.39%
controls:0.07%
—
—
—
—
—
—
—
—
cases:0.54%
controls:0.26%
15
45
1799
18060
7
12
1807
18093
—
—
—
—
8
39
1485
14696
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
1.9e-01
3.3e-01
4.2e-01
1.1e+00
3.6e-01
3.2e-01
1.9e-01
cases:34.40%
controls:30.25%
cases:29.16%
controls:22.89%
cases:7.22%
controls:4.88%
cases:0.83%
controls:0.27%
cases:6.52%
controls:4.66%
cases:29.65%
controls:23.51%
cases:45.68%
controls:41.07%
624
5476
1190
12629
529
4145
1285
13960
131
883
1683
17222
15
48
1799
18057
118
841
1693
17216
518
4081
1229
13279
682
6052
811
8683
Remowal of suture of skin
TQW40 [2001310146]
TQW40 [2001310146]
7.5e-01
1.3e+00
—
—
—
1.6e+00
8.6e-01
cases:1.32%
controls:0.63%
cases:0.66%
controls:0.18%
—
—
—
—
—
—
cases:0.52%
controls:0.10%
cases:1.21%
controls:0.52%
24
114
1790
17991
12
32
1802
18073
—
—
—
9
18
1738
17342
18
76
1475
14659
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
8.1e-01
8.1e-01
1.0e+00
—
1.3e+00
1.1e+00
9.6e-01
cases:2.09%
controls:0.94%
cases:0.94%
controls:0.42%
cases:0.39%
controls:0.14%
—
—
cases:0.44%
controls:0.12%
cases:1.09%
controls:0.35%
cases:2.08%
controls:0.81%
38
170
1776
17935
17
76
1797
18029
7
25
1807
18080
—
8
22
1803
18035
19
61
1728
17299
31
119
1462
14616
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
3.5e-01
4.6e-01
8.2e-01
—
4.4e-01
6.4e-01
6.4e-01
cases:13.29%
controls:9.75%
cases:11.19%
controls:7.35%
cases:3.58%
controls:1.61%
—
—
cases:2.54%
controls:1.66%
cases:12.76%
controls:7.18%
cases:22.30%
controls:13.19%
241
1766
1573
16339
203
1330
1611
16775
65
292
1749
17813
—
46
299
1765
17758
223
1246
1524
16114
333
1944
1160
12791
Melanoma in situ of trunk
D03.5 [45542675]
D03.5 [45542675]
2.9e+00
—
—
1.0e+50
1.0e+50
—
1.0e+50
cases:0.50%
controls:0.03%
—
—
—
—
cases:0.83%
controls:0.00%
cases:0.33%
controls:0.00%
—
—
cases:0.94%
controls:0.00%
9
5
1805
18100
—
—
15
0
1799
18105
6
0
1805
18057
—
14
0
1479
14735
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
57782-5 [40760892]
3.0e-01
4.7e-01
1.1e+00
—
6.4e-01
7.1e-01
5.0e-01
cases:5.95%
controls:4.46%
cases:3.86%
controls:2.44%
cases:1.38%
controls:0.45%
—
—
cases:0.83%
controls:0.44%
cases:4.69%
controls:2.36%
cases:9.98%
controls:6.31%
108
808
1706
17297
70
442
1744
17663
25
81
1789
18024
—
15
79
1796
17978
82
409
1665
16951
149
930
1344
13805
Malignant melanoma, NOS, of skin of upper limb and shoulder
8720/3-C44.6 [36552402]
8720/3-C44.6 [36552402]
2.8e+00
1.0e+50
—
—
—
—
—
cases:0.55%
controls:0.03%
cases:0.28%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
10
6
1804
18099
5
0
1809
18105
—
—
—
—
—
Other chronic renal failure
N18.8 [45534123]
N18.8 [45534123]
1.5e+00
1.2e+00
—
—
—
8.6e-01
1.3e+00
cases:0.83%
controls:0.19%
cases:0.33%
controls:0.10%
—
—
—
—
—
—
cases:0.29%
controls:0.12%
cases:0.74%
controls:0.20%
15
34
1799
18071
6
19
1808
18086
—
—
—
5
21
1742
17339
11
29
1482
14706
TREATMENT - Kidney transplant
TREATMENT-51 [2002330239]
TREATMENT-51 [2002330239]
2.8e+00
—
—
—
—
—
—
cases:0.72%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
13
8
1801
18097
—
—
—
—
—
—
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
5.9e-01
6.0e-01
8.1e-01
—
1.2e+00
6.5e-01
9.4e-01
cases:7.66%
controls:4.42%
cases:2.98%
controls:1.65%
cases:0.50%
controls:0.22%
—
—
cases:0.61%
controls:0.18%
cases:2.69%
controls:1.43%
cases:9.11%
controls:3.76%
139
800
1675
17305
54
299
1760
17806
9
40
1805
18065
—
11
33
1800
18024
47
248
1700
17112
136
554
1357
14181
Malignant tumor of the skin on another or unspecified part of the face without histology
C44.30 [2000500791]
C44.30 [2000500791]
2.8e+00
—
—
—
—
—
—
cases:0.61%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
11
7
1803
18098
—
—
—
—
—
—
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
D01AC20 [21601936]
6.2e-01
7.9e-01
1.1e+00
—
1.3e+00
7.8e-01
5.6e-01
cases:6.73%
controls:3.73%
cases:2.87%
controls:1.32%
cases:0.44%
controls:0.14%
—
—
cases:0.55%
controls:0.16%
cases:2.52%
controls:1.18%
cases:6.63%
controls:3.89%
122
676
1692
17429
52
239
1762
17866
8
26
1806
18079
—
10
28
1801
18029
44
204
1703
17156
99
573
1394
14162
Failure and rejection of transplanted organs and tissues
T86 [45561099]
T86 [45561099]
2.7e+00
—
—
—
—
—
—
cases:0.50%
controls:0.03%
—
—
—
—
—
—
—
—
—
—
—
—
9
6
1805
18099
—
—
—
—
—
—
Systolic blood pressure
8480-6 [3004249]
8480-6 [3004249]
2.6e+00
—
—
—
—
—
—
cases:0.61%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
11
8
1803
18097
—
—
—
—
—
—
Diastolic blood pressure
8462-4 [3012888]
8462-4 [3012888]
2.6e+00
—
—
—
—
—
—
cases:0.61%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
11
8
1803
18097
—
—
—
—
—
—
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
4.3e-01
6.5e-01
8.0e-01
—
5.3e-01
7.9e-01
7.4e-01
cases:8.54%
controls:5.71%
cases:5.46%
controls:2.93%
cases:0.99%
controls:0.45%
—
—
cases:0.94%
controls:0.55%
cases:6.30%
controls:2.95%
cases:14.60%
controls:7.55%
155
1033
1659
17072
99
530
1715
17575
18
81
1796
18024
—
17
100
1794
17957
110
512
1637
16848
218
1112
1275
13623
Cytology report of Tissue fine needle aspirate Cyto stain
33718-8 [3043109]
33718-8 [3043109]
4.9e-01
1.1e+00
—
—
—
1.6e+00
1.1e+00
cases:0.77%
controls:0.48%
cases:0.33%
controls:0.11%
—
—
—
—
—
—
cases:0.52%
controls:0.11%
cases:1.07%
controls:0.37%
14
86
1800
18019
6
20
1808
18085
—
—
—
9
19
1738
17341
16
55
1477
14680
Proteinase 3 Ab [Units/volume] in Serum
6968-2 [3009445]
6968-2 [3009445]
5.5e-01
1.0e+00
—
—
—
1.4e+00
1.2e+00
cases:1.38%
controls:0.80%
cases:0.61%
controls:0.22%
—
—
—
—
—
—
cases:0.69%
controls:0.17%
cases:2.34%
controls:0.70%
25
145
1789
17960
11
39
1803
18066
—
—
—
12
30
1735
17330
35
103
1458
14632
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
2.7e-01
4.2e-01
5.7e-01
6.3e-01
4.1e-01
5.0e-01
4.3e-01
cases:31.26%
controls:25.69%
cases:27.89%
controls:20.24%
cases:7.72%
controls:4.52%
cases:0.50%
controls:0.27%
cases:6.57%
controls:4.46%
cases:29.71%
controls:20.45%
cases:46.28%
controls:35.92%
567
4652
1247
13453
506
3664
1308
14441
140
819
1674
17286
9
48
1805
18057
119
806
1692
17251
519
3550
1228
13810
691
5293
802
9442
Occupational therapy
R4120 [2001310234]
R4120 [2001310234]
1.0e+00
4.6e-01
—
—
—
1.5e+00
8.4e-01
cases:1.65%
controls:0.59%
cases:0.39%
controls:0.24%
—
—
—
—
—
—
cases:0.86%
controls:0.18%
cases:1.34%
controls:0.58%
30
107
1784
17998
7
44
1807
18061
—
—
—
15
32
1732
17328
20
86
1473
14649
Social worker
Z2446 [2001311559]
Z2446 [2001311559]
1.2e+00
1.4e+00
—
—
—
—
4.8e-01
cases:1.82%
controls:0.56%
cases:0.55%
controls:0.14%
—
—
—
—
—
—
—
—
cases:0.60%
controls:0.37%
33
101
1781
18004
10
25
1804
18080
—
—
—
—
9
55
1484
14680
Ulcer of lower limb, not elsewhere classified
L97 [45591659]
L97 [45591659]
8.8e-01
1.2e+00
—
—
—
1.6e+00
9.6e-01
cases:0.66%
controls:0.28%
cases:0.55%
controls:0.17%
—
—
—
—
—
—
cases:0.46%
controls:0.09%
cases:1.07%
controls:0.41%
12
50
1802
18055
10
30
1804
18075
—
—
—
8
16
1739
17344
16
61
1477
14674
Hip joint ultrasound examination
NF1AE [2001307895]
NF1AE [2001307895]
1.1e+00
1.3e+00
—
—
—
1.1e+00
1.4e+00
cases:0.77%
controls:0.25%
cases:0.28%
controls:0.07%
—
—
—
—
—
—
cases:0.29%
controls:0.10%
cases:1.00%
controls:0.24%
14
45
1800
18060
5
13
1809
18092
—
—
—
5
17
1742
17343
15
36
1478
14699
Excision of lesion of auricle
DAB00 [2001301517]
DAB00 [2001301517]
2.6e+00
—
—
—
—
—
—
cases:0.50%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
9
7
1805
18098
—
—
—
—
—
—
other preparations, combinations; ointment
C05AX03 [21601631]
C05AX03 [21601631]
7.1e-01
9.5e-01
6.9e-01
—
1.3e+00
8.4e-01
4.0e-01
cases:4.69%
controls:2.35%
cases:2.04%
controls:0.80%
cases:0.28%
controls:0.14%
—
—
cases:0.39%
controls:0.11%
cases:1.66%
controls:0.72%
cases:3.55%
controls:2.41%
85
426
1729
17679
37
144
1777
17961
5
25
1809
18080
—
7
19
1804
18038
29
125
1718
17235
53
355
1440
14380
Other psoriatic arthropathies
M07.3*L40.5 [2000503010]
M07.3*L40.5 [2000503010]
9.9e-01
8.9e-01
—
—
—
1.3e+00
1.2e+00
cases:0.77%
controls:0.29%
cases:0.44%
controls:0.18%
—
—
—
—
—
—
cases:0.63%
controls:0.17%
cases:1.00%
controls:0.31%
14
52
1800
18053
8
33
1806
18072
—
—
—
11
30
1736
17330
15
45
1478
14690
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
OMOP4822000 [32411]
-1.7e-01
8.2e-01
1.7e+00
—
—
1.3e+00
1.2e+00
cases:0.83%
controls:0.98%
cases:0.66%
controls:0.29%
cases:0.28%
controls:0.05%
—
—
—
—
cases:0.80%
controls:0.22%
cases:2.28%
controls:0.69%
15
177
1799
17928
12
53
1802
18052
5
9
1809
18096
—
—
14
39
1733
17321
34
101
1459
14634
fluconazole; oral, parenteral
J02AC01 [21603080]
J02AC01 [21603080]
5.0e-01
4.7e-01
—
—
1.1e+00
4.3e-01
3.8e-01
cases:11.14%
controls:7.05%
cases:3.42%
controls:2.17%
—
—
—
—
cases:0.77%
controls:0.25%
cases:3.38%
controls:2.22%
cases:9.31%
controls:6.54%
202
1276
1612
16829
62
392
1752
17713
—
—
14
45
1797
18012
59
386
1688
16974
139
963
1354
13772
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
2.7e-01
3.9e-01
7.3e-01
—
8.5e-01
5.6e-01
6.9e-01
cases:9.26%
controls:7.23%
cases:5.18%
controls:3.58%
cases:1.16%
controls:0.56%
—
—
cases:1.10%
controls:0.48%
cases:5.78%
controls:3.38%
cases:16.68%
controls:9.11%
168
1309
1646
16796
94
648
1720
17457
21
102
1793
18003
—
20
86
1791
17971
101
587
1646
16773
249
1343
1244
13392
T2D - yes
T2D-2 [2002330230]
T2D-2 [2002330230]
2.5e+00
—
—
—
—
—
—
cases:0.33%
controls:0.03%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
1808
18100
—
—
—
—
—
—
Congenital non-neoplastic naevus
Q82.58 [2000503507]
Q82.58 [2000503507]
1.4e+00
2.5e+00
—
—
—
—
—
cases:0.28%
controls:0.07%
cases:0.33%
controls:0.03%
—
—
—
—
—
—
—
—
—
—
5
12
1809
18093
6
5
1808
18100
—
—
—
—
—
Senile nuclear cataract
H25.1 [45581628]
H25.1 [45581628]
3.5e-01
3.5e-01
1.7e+00
1.0e+50
1.0e+00
7.8e-01
3.6e-01
cases:3.58%
controls:2.56%
cases:1.49%
controls:1.05%
cases:0.66%
controls:0.12%
cases:0.44%
controls:0.00%
cases:0.61%
controls:0.22%
cases:2.23%
controls:1.04%
cases:4.35%
controls:3.07%
65
463
1749
17642
27
190
1787
17915
12
22
1802
18083
8
0
1806
18105
11
40
1800
18017
39
180
1708
17180
65
453
1428
14282
Abdominal ultrasound examination
JN3AE [2001305555]
JN3AE [2001305555]
7.3e-01
9.7e-01
—
—
—
4.8e-01
7.7e-01
cases:3.14%
controls:1.54%
cases:1.05%
controls:0.40%
—
—
—
—
—
—
cases:0.74%
controls:0.46%
cases:2.95%
controls:1.38%
57
279
1757
17826
19
72
1795
18033
—
—
—
13
80
1734
17280
44
204
1449
14531
Urine microscopy for crystals
167340007 [4042251]
167340007 [4042251]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.40%
controls:0.03%
—
—
—
—
—
—
6
5
1487
14730
Squamous cell carcinoma Ag [Mass/volume] in Serum or Plasma
9679-2 [3005411]
9679-2 [3005411]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.40%
controls:0.03%
—
—
—
—
—
—
6
5
1487
14730
Spinocellular carcinoma of the skin of the scalp and neck
C44.42 [2000500797]
C44.42 [2000500797]
-1.0e+50
—
—
—
—
—
2.5e+00
cases:0.00%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
cases:0.40%
controls:0.03%
0
8
1814
18097
—
—
—
—
—
6
5
1487
14730
Transplant complication
127 [2001600125]
127 [2001600125]
2.5e+00
—
—
—
—
—
—
cases:1.10%
controls:0.09%
—
—
—
—
—
—
—
—
—
—
—
—
20
17
1794
18088
—
—
—
—
—
—
General anaesthesia
WX402 [2001310806]
WX402 [2001310806]
5.4e-01
6.0e-01
—
—
1.0e+00
7.4e-01
5.9e-01
cases:4.08%
controls:2.42%
cases:2.21%
controls:1.22%
—
—
—
—
cases:0.28%
controls:0.10%
cases:2.12%
controls:1.03%
cases:6.63%
controls:3.79%
74
438
1740
17667
40
221
1774
17884
—
—
5
18
1806
18039
37
178
1710
17182
99
559
1394
14176
Knee and lower leg MRI examination with high intensity magnet
NG1BG [2001308056]
NG1BG [2001308056]
3.7e-01
1.4e+00
—
—
—
—
1.0e+00
cases:0.50%
controls:0.34%
cases:0.55%
controls:0.13%
—
—
—
—
—
—
—
—
cases:1.00%
controls:0.36%
9
62
1805
18043
10
24
1804
18081
—
—
—
—
15
53
1478
14682
sevelamer; oral
V03AE02 [21605265]
V03AE02 [21605265]
2.5e+00
—
—
—
—
—
—
cases:0.39%
controls:0.03%
—
—
—
—
—
—
—
—
—
—
—
—
7
6
1807
18099
—
—
—
—
—
—
Stomatognathic treatment, basic
SHA02 [2001310406]
SHA02 [2001310406]
4.6e-01
1.5e+00
—
—
—
8.5e-01
1.0e+00
cases:1.54%
controls:0.98%
cases:0.94%
controls:0.22%
—
—
—
—
—
—
cases:0.69%
controls:0.29%
cases:2.34%
controls:0.88%
28
178
1786
17927
17
40
1797
18065
—
—
—
12
51
1735
17309
35
129
1458
14606
Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma
7852-7 [3010130]
7852-7 [3010130]
1.4e+00
9.2e-01
—
—
—
—
1.1e+00
cases:1.21%
controls:0.31%
cases:0.28%
controls:0.11%
—
—
—
—
—
—
—
—
cases:1.00%
controls:0.35%
22
56
1792
18049
5
20
1809
18085
—
—
—
—
15
51
1478
14684
erythropoietin; parenteral
B03XA01 [21601133]
B03XA01 [21601133]
2.4e+00
—
—
—
—
—
—
cases:0.44%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
8
7
1806
18098
—
—
—
—
—
—
Abdominal extensive ultrasoudn examination with blood flow measurements after transplantation
JN3DE [2001305565]
JN3DE [2001305565]
2.4e+00
—
—
—
—
—
—
cases:0.44%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
8
7
1806
18098
—
—
—
—
—
—
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
3.1e-01
2.3e-01
1.2e+00
—
5.5e-01
5.8e-01
6.4e-01
cases:5.57%
controls:4.13%
cases:2.43%
controls:1.93%
cases:0.66%
controls:0.20%
—
—
cases:0.44%
controls:0.25%
cases:3.15%
controls:1.78%
cases:8.24%
controls:4.51%
101
748
1713
17357
44
349
1770
17756
12
36
1802
18069
—
8
46
1803
18011
55
309
1692
17051
123
665
1370
14070
Treatment of several skin areas
ZQZ00 [2001311318]
ZQZ00 [2001311318]
2.4e+00
—
—
1.0e+50
—
—
—
cases:0.50%
controls:0.04%
—
—
—
—
cases:0.28%
controls:0.00%
—
—
—
—
—
—
9
8
1805
18097
—
—
5
0
1809
18105
—
—
—
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
3.7e-01
5.7e-01
5.4e-01
—
6.1e-01
8.0e-01
6.8e-01
cases:7.33%
controls:5.18%
cases:4.24%
controls:2.45%
cases:0.66%
controls:0.39%
—
—
cases:0.61%
controls:0.33%
cases:4.75%
controls:2.20%
cases:10.78%
controls:5.80%
133
938
1681
17167
77
444
1737
17661
12
70
1802
18035
—
11
60
1800
17997
83
382
1664
16978
161
854
1332
13881
HLA Ab [Presence] in Serum
44534-6 [3042733]
44534-6 [3042733]
2.4e+00
—
—
—
—
—
—
cases:0.61%
controls:0.06%
—
—
—
—
—
—
—
—
—
—
—
—
11
10
1803
18095
—
—
—
—
—
—
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
J01EE01 [21602961]
1.2e+00
1.2e+00
—
—
—
1.1e+00
8.3e-01
cases:1.65%
controls:0.52%
cases:0.83%
controls:0.25%
—
—
—
—
—
—
cases:0.69%
controls:0.23%
cases:1.34%
controls:0.59%
30
94
1784
18011
15
45
1799
18060
—
—
—
12
40
1735
17320
20
87
1473
14648
Sedation and analgesia
WX002 [2001310758]
WX002 [2001310758]
6.3e-01
3.7e-01
—
1.0e+50
—
1.1e+00
6.0e-01
cases:4.69%
controls:2.56%
cases:0.94%
controls:0.65%
—
—
cases:0.28%
controls:0.00%
—
—
cases:1.37%
controls:0.44%
cases:3.15%
controls:1.75%
85
464
1729
17641
17
118
1797
17987
—
5
0
1809
18105
—
24
77
1723
17283
47
258
1446
14477
ursodeoxycholic acid; oral
A05AA02 [21600513]
A05AA02 [21600513]
1.1e+00
1.4e+00
—
—
—
1.2e+00
1.3e+00
cases:0.72%
controls:0.24%
cases:0.50%
controls:0.12%
—
—
—
—
—
—
cases:0.46%
controls:0.13%
cases:0.87%
controls:0.24%
13
44
1801
18061
9
22
1805
18083
—
—
—
8
23
1739
17337
13
36
1480
14699
Standard cardiac ultrasound examination
FM1AE [2001303278]
FM1AE [2001303278]
2.4e-01
6.8e-01
1.1e+00
—
—
8.1e-01
8.8e-01
cases:3.03%
controls:2.40%
cases:1.82%
controls:0.93%
cases:0.28%
controls:0.09%
—
—
—
—
cases:1.95%
controls:0.88%
cases:4.89%
controls:2.10%
55
434
1759
17671
33
169
1781
17936
5
16
1809
18089
—
—
34
152
1713
17208
73
309
1420
14426
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
2.0e-01
7.9e-01
—
—
1.5e+00
1.0e+00
5.0e-01
cases:2.76%
controls:2.28%
cases:1.87%
controls:0.86%
—
—
—
—
cases:0.33%
controls:0.07%
cases:2.06%
controls:0.74%
cases:4.42%
controls:2.73%
50
412
1764
17693
34
156
1780
17949
—
—
6
13
1805
18044
36
128
1711
17232
66
402
1427
14333
Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
7853-5 [3015635]
7853-5 [3015635]
1.2e+00
7.8e-01
—
—
—
—
1.1e+00
cases:1.21%
controls:0.36%
cases:0.28%
controls:0.13%
—
—
—
—
—
—
—
—
cases:1.07%
controls:0.36%
22
65
1792
18040
5
23
1809
18082
—
—
—
—
16
53
1477
14682
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
5.8e-01
8.6e-01
—
—
—
6.6e-01
8.8e-01
cases:6.45%
controls:3.71%
cases:1.98%
controls:0.85%
—
—
—
—
—
—
cases:1.32%
controls:0.69%
cases:4.55%
controls:1.94%
117
672
1697
17433
36
154
1778
17951
—
—
—
23
119
1724
17241
68
286
1425
14449
Other specified counselling
Z71.8 [45581061]
Z71.8 [45581061]
3.7e-01
4.7e-01
1.0e+00
—
8.3e-01
4.1e-01
4.3e-01
cases:6.34%
controls:4.45%
cases:3.69%
controls:2.34%
cases:0.94%
controls:0.34%
—
—
cases:0.77%
controls:0.34%
cases:3.55%
controls:2.39%
cases:10.85%
controls:7.33%
115
805
1699
17300
67
423
1747
17682
17
61
1797
18044
—
14
61
1797
17996
62
415
1685
16945
162
1080
1331
13655
esomeprazole; oral, parenteral
A02BC05 [21600100]
A02BC05 [21600100]
2.4e-01
4.7e-01
8.9e-01
—
5.6e-01
5.0e-01
4.5e-01
cases:10.42%
controls:8.35%
cases:6.28%
controls:4.03%
cases:2.04%
controls:0.85%
—
—
cases:1.60%
controls:0.92%
cases:6.70%
controls:4.18%
cases:12.12%
controls:8.11%
189
1512
1625
16593
114
730
1700
17375
37
153
1777
17952
—
29
166
1782
17891
117
725
1630
16635
181
1195
1312
13540
Severe anaemia associated with chronic renal failure
138 [2001600134]
138 [2001600134]
2.3e+00
—
—
—
—
—
—
cases:0.66%
controls:0.07%
—
—
—
—
—
—
—
—
—
—
—
—
12
12
1802
18093
—
—
—
—
—
—
Allogenic transplantation of kidney from cadaver donor
KAS10 [2001305738]
KAS10 [2001305738]
2.3e+00
—
—
—
—
—
—
cases:0.50%
controls:0.05%
—
—
—
—
—
—
—
—
—
—
—
—
9
9
1805
18096
—
—
—
—
—
—
HLA-DR beta [Type]
13306-6 [3024932]
13306-6 [3024932]
2.3e+00
—
—
—
—
—
—
cases:0.39%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
1807
18098
—
—
—
—
—
—
Malignant melanoma of skin
C43 [45571501]
C43 [45571501]
2.3e+00
—
—
—
—
—
—
cases:0.39%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
1807
18098
—
—
—
—
—
—
HLA-A [Type]
13298-5 [3024471]
13298-5 [3024471]
2.3e+00
—
—
—
—
—
—
cases:0.39%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
1807
18098
—
—
—
—
—
—
Basocellular carcinoma of the skin of the outer ear and the outer ear canal
C44.21 [2000500788]
C44.21 [2000500788]
2.3e+00
—
—
—
—
—
—
cases:0.39%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
1807
18098
—
—
—
—
—
—
Sentinell lymphnode SPECT with low dose CT
PJ5AQ [2001309622]
PJ5AQ [2001309622]
2.3e+00
—
—
—
—
—
—
cases:0.33%
controls:0.03%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
1808
18099
—
—
—
—
—
—
Ultrasound examination of lower part of abdomen without contrast
JN2AE [2001305537]
JN2AE [2001305537]
—
2.3e+00
—
—
—
-1.0e+50
1.4e+00
—
—
cases:0.33%
controls:0.03%
—
—
—
—
—
—
cases:0.00%
controls:0.03%
cases:0.33%
controls:0.08%
—
6
6
1808
18099
—
—
—
0
5
1747
17355
5
12
1488
14723
Demanding therapy of methastized malignancy with biomodifiers
WD325 [2001310687]
WD325 [2001310687]
—
—
—
—
—
2.1e+00
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:0.29%
controls:0.03%
cases:0.40%
controls:0.04%
—
—
—
—
—
5
6
1742
17354
6
6
1487
14729
Nutritional therapy
R4190 [2001310243]
R4190 [2001310243]
1.1e+00
9.2e-01
—
—
—
7.2e-01
1.1e+00
cases:0.83%
controls:0.27%
cases:0.39%
controls:0.15%
—
—
—
—
—
—
cases:0.34%
controls:0.17%
cases:1.61%
controls:0.52%
15
49
1799
18056
7
28
1807
18077
—
—
—
6
29
1741
17331
24
76
1469
14659
Procedure duration 60 to 89 minutes
ZXE11 [2001311402]
ZXE11 [2001311402]
9.1e-01
2.9e-01
—
—
—
—
1.4e+00
cases:1.60%
controls:0.65%
cases:0.33%
controls:0.25%
—
—
—
—
—
—
—
—
cases:1.41%
controls:0.37%
29
118
1785
17987
6
45
1808
18060
—
—
—
—
21
54
1472
14681
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
3.0e-01
3.5e-01
8.3e-01
—
7.4e-01
5.3e-01
5.9e-01
cases:9.21%
controls:6.96%
cases:5.68%
controls:4.06%
cases:1.27%
controls:0.56%
—
—
cases:1.16%
controls:0.56%
cases:6.70%
controls:4.06%
cases:16.95%
controls:10.18%
167
1260
1647
16845
103
735
1711
17370
23
101
1791
18004
—
21
101
1790
17956
117
705
1630
16655
253
1500
1240
13235
tamsulosin; oral
G04CA02 [21602669]
G04CA02 [21602669]
4.1e-01
5.9e-01
5.6e-01
—
3.7e-01
6.3e-01
6.0e-01
cases:4.74%
controls:3.20%
cases:3.53%
controls:1.99%
cases:1.10%
controls:0.64%
—
—
cases:0.77%
controls:0.54%
cases:3.89%
controls:2.10%
cases:6.03%
controls:3.41%
86
580
1728
17525
64
360
1750
17745
20
115
1794
17990
—
14
97
1797
17960
68
365
1679
16995
90
503
1403
14232
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 [3017918]
22246-3 [3017918]
1.1e+00
7.3e-01
—
—
—
—
1.1e+00
cases:1.16%
controls:0.38%
cases:0.28%
controls:0.13%
—
—
—
—
—
—
—
—
cases:1.14%
controls:0.39%
21
68
1793
18037
5
24
1809
18081
—
—
—
—
17
57
1476
14678
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
2731-8 [3000067]
4.7e-01
7.1e-01
—
—
—
7.7e-01
7.3e-01
cases:2.15%
controls:1.36%
cases:1.54%
controls:0.76%
—
—
—
—
—
—
cases:1.66%
controls:0.78%
cases:3.95%
controls:1.95%
39
246
1775
17859
28
138
1786
17967
—
—
—
29
135
1718
17225
59
287
1434
14448
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
4.4e-01
6.5e-01
6.7e-01
—
4.4e-01
7.5e-01
8.1e-01
cases:3.69%
controls:2.40%
cases:2.48%
controls:1.31%
cases:0.50%
controls:0.25%
—
—
cases:0.39%
controls:0.25%
cases:2.75%
controls:1.32%
cases:6.43%
controls:2.98%
67
435
1747
17670
45
237
1769
17868
9
46
1805
18059
—
7
45
1804
18012
48
229
1699
17131
96
439
1397
14296
Ultrsound examination of lesion close to skin
QX3HE [2001310035]
QX3HE [2001310035]
9.7e-01
—
—
—
—
—
2.2e+00
cases:0.28%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
cases:0.67%
controls:0.07%
5
19
1809
18086
—
—
—
—
—
10
11
1483
14724
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2465-3 [3005719]
7.0e-01
5.8e-01
—
—
—
8.0e-01
7.0e-01
cases:2.92%
controls:1.47%
cases:1.27%
controls:0.71%
—
—
—
—
—
—
cases:1.43%
controls:0.65%
cases:3.28%
controls:1.66%
53
266
1761
17839
23
129
1791
17976
—
—
—
25
113
1722
17247
49
244
1444
14491
Bilateral
ZXA10 [2001311348]
ZXA10 [2001311348]
6.0e-01
1.0e+00
—
1.0e+50
—
6.5e-01
5.7e-01
cases:4.08%
controls:2.28%
cases:1.49%
controls:0.54%
—
—
cases:0.28%
controls:0.00%
—
—
cases:0.92%
controls:0.48%
cases:3.08%
controls:1.77%
74
413
1740
17692
27
98
1787
18007
—
5
0
1809
18105
—
16
83
1731
17277
46
261
1447
14474
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
29760-6 [3005772]
4.0e-01
7.4e-01
8.2e-01
—
1.2e+00
7.8e-01
6.7e-01
cases:3.20%
controls:2.18%
cases:1.54%
controls:0.75%
cases:0.28%
controls:0.12%
—
—
cases:0.33%
controls:0.10%
cases:1.72%
controls:0.79%
cases:4.96%
controls:2.59%
58
394
1756
17711
28
135
1786
17970
5
22
1809
18083
—
6
18
1805
18039
30
138
1717
17222
74
382
1419
14353
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
2.1e-01
4.1e-01
6.6e-01
—
5.9e-01
4.2e-01
4.7e-01
cases:21.06%
controls:17.72%
cases:12.57%
controls:8.70%
cases:1.82%
controls:0.95%
—
—
cases:1.77%
controls:0.99%
cases:12.54%
controls:8.64%
cases:31.61%
controls:22.36%
382
3208
1432
14897
228
1575
1586
16530
33
172
1781
17933
—
32
178
1779
17879
219
1500
1528
15860
472
3295
1021
11440
Excision of other lesion extending through all layers of skin in uspecified region
QXE10 [2001310064]
QXE10 [2001310064]
2.0e+00
—
—
1.0e+50
—
—
2.2e+00
cases:0.28%
controls:0.04%
—
—
—
—
cases:1.10%
controls:0.00%
—
—
—
—
cases:0.47%
controls:0.05%
5
7
1809
18098
—
—
20
0
1794
18105
—
—
7
8
1486
14727
Very extensive MRI examination of mammary gland with high intensity magnet
HA1DG [2001303900]
HA1DG [2001303900]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.47%
controls:0.05%
—
—
—
—
—
—
7
8
1486
14727
Gas panel - Venous blood
24339-4 [3000991]
24339-4 [3000991]
8.4e-01
7.6e-01
—
—
—
5.6e-01
5.5e-01
cases:2.54%
controls:1.12%
cases:1.38%
controls:0.65%
—
—
—
—
—
—
cases:1.20%
controls:0.69%
cases:3.35%
controls:1.95%
46
202
1768
17903
25
117
1789
17988
—
—
—
21
120
1726
17240
50
288
1443
14447
Telehealth
OMOP5556618 [722455]
OMOP5556618 [722455]
6.7e-02
3.0e-01
6.2e-01
—
6.1e-01
3.6e-01
2.6e-01
cases:27.51%
controls:26.19%
cases:13.23%
controls:10.13%
cases:3.20%
controls:1.75%
—
—
cases:3.09%
controls:1.70%
cases:12.94%
controls:9.37%
cases:25.52%
controls:20.94%
499
4741
1315
13364
240
1834
1574
16271
58
317
1756
17788
—
56
307
1755
17750
226
1627
1521
15733
381
3085
1112
11650
Preparatory care for dialysis
Z49.0 [45571361]
Z49.0 [45571361]
2.1e+00
—
—
—
—
—
—
cases:0.33%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
1808
18098
—
—
—
—
—
—
Benign lipomatous neoplasm of skin and subcutaneous tissue of limbs
D17.2 [45561898]
D17.2 [45561898]
8.8e-01
2.1e+00
—
1.0e+50
—
2.1e+00
1.1e+00
cases:0.39%
controls:0.16%
cases:0.28%
controls:0.03%
—
—
cases:0.28%
controls:0.00%
—
—
cases:0.34%
controls:0.04%
cases:0.33%
controls:0.12%
7
29
1807
18076
5
6
1809
18099
—
5
0
1809
18105
—
6
7
1741
17353
5
17
1488
14718
Skin, Other therap proced/minor surg NEC
S59 [2002001023]
S59 [2002001023]
—
—
—
—
—
2.1e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:0.34%
controls:0.04%
cases:0.54%
controls:0.17%
—
—
—
—
—
6
7
1741
17353
8
25
1485
14710
Other procedure to treat skin wound, unspecified location
QXB99 [2001310054]
QXB99 [2001310054]
1.3e+00
—
—
—
1.0e+50
2.1e+00
1.1e+00
cases:0.55%
controls:0.15%
—
—
—
—
—
—
cases:0.28%
controls:0.00%
cases:0.34%
controls:0.04%
cases:0.47%
controls:0.16%
10
27
1804
18078
—
—
—
5
0
1806
18057
6
7
1741
17353
7
24
1486
14711
Hepatitis A virus IgG Ab [Presence] in Serum by Immunoassay
40724-7 [3040363]
40724-7 [3040363]
4.5e-01
-1.0e+50
—
—
—
—
2.1e+00
cases:0.28%
controls:0.18%
cases:0.00%
controls:0.03%
—
—
—
—
—
—
—
—
cases:0.40%
controls:0.05%
5
32
1809
18073
0
5
1814
18100
—
—
—
—
6
7
1487
14728
Feet X-ray examination with load
NH3EA [2001308283]
NH3EA [2001308283]
3.0e-01
—
—
—
—
—
2.1e+00
cases:0.28%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:0.40%
controls:0.05%
5
37
1809
18068
—
—
—
—
—
6
7
1487
14728
Very extensive CT of head and brain
AA1CD [2001300114]
AA1CD [2001300114]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.40%
controls:0.05%
—
—
—
—
—
—
6
7
1487
14728
Medical observation and evaluation for suspected diseases and conditions, ruled out
Z03 [45552058]
Z03 [45552058]
2.8e-01
1.2e+00
-1.0e+50
—
—
8.3e-01
9.7e-01
cases:1.27%
controls:0.96%
cases:0.72%
controls:0.23%
cases:0.00%
controls:0.05%
—
—
—
—
cases:0.63%
controls:0.28%
cases:1.88%
controls:0.72%
23
174
1791
17931
13
41
1801
18064
0
9
1814
18096
—
—
11
48
1736
17312
28
106
1465
14629
Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
3255-7 [3016407]
3255-7 [3016407]
1.0e+00
1.1e+00
—
—
—
1.2e+00
1.1e+00
cases:1.49%
controls:0.55%
cases:0.66%
controls:0.23%
—
—
—
—
—
—
cases:0.63%
controls:0.20%
cases:1.61%
controls:0.54%
27
99
1787
18006
12
41
1802
18064
—
—
—
11
34
1736
17326
24
79
1469
14656
Vascular Surgery
77 [38004496]
77 [38004496]
3.2e-01
6.0e-01
1.4e+00
1.0e+50
7.8e-01
6.1e-01
6.8e-01
cases:3.25%
controls:2.38%
cases:1.87%
controls:1.04%
cases:0.72%
controls:0.18%
cases:0.94%
controls:0.00%
cases:0.39%
controls:0.18%
cases:1.72%
controls:0.94%
cases:5.36%
controls:2.78%
59
430
1755
17675
34
188
1780
17917
13
32
1801
18073
17
0
1797
18105
7
32
1804
18025
30
164
1717
17196
80
410
1413
14325
calcium (different salts in combination); oral
A12AA20 [21600872]
A12AA20 [21600872]
3.8e-01
3.3e-01
5.8e-01
—
2.6e-01
3.5e-01
4.3e-01
cases:11.85%
controls:8.39%
cases:8.82%
controls:6.52%
cases:2.98%
controls:1.68%
—
—
cases:2.32%
controls:1.81%
cases:9.39%
controls:6.79%
cases:14.07%
controls:9.60%
215
1519
1599
16586
160
1180
1654
16925
54
305
1760
17800
—
42
326
1769
17731
164
1179
1583
16181
210
1414
1283
13321
Incision of skin of trunk
QBA10 [2001309831]
QBA10 [2001309831]
1.4e+00
—
—
—
—
—
2.1e+00
cases:0.28%
controls:0.07%
—
—
—
—
—
—
—
—
—
—
cases:0.54%
controls:0.07%
5
12
1809
18093
—
—
—
—
—
8
10
1485
14725
ispaghula (psylla seeds); oral
A06AC01 [21600555]
A06AC01 [21600555]
3.8e-01
5.8e-01
6.6e-01
—
6.6e-01
6.1e-01
4.9e-01
cases:5.35%
controls:3.71%
cases:3.64%
controls:2.08%
cases:0.72%
controls:0.37%
—
—
cases:0.66%
controls:0.34%
cases:4.06%
controls:2.24%
cases:7.17%
controls:4.50%
97
672
1717
17433
66
376
1748
17729
13
67
1801
18038
—
12
62
1799
17995
71
389
1676
16971
107
663
1386
14072
Foot/toe symptom/complaint
L17 [2002000641]
L17 [2002000641]
1.8e-01
5.9e-01
1.0e+00
—
1.5e+00
3.1e-01
2.9e-01
cases:4.91%
controls:4.11%
cases:3.03%
controls:1.70%
cases:0.50%
controls:0.18%
—
—
cases:0.88%
controls:0.20%
cases:2.23%
controls:1.65%
cases:7.57%
controls:5.76%
89
745
1725
17360
55
308
1759
17797
9
33
1805
18072
—
16
37
1795
18020
39
286
1708
17074
113
849
1380
13886
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
2.0e-01
3.3e-01
5.5e-01
—
3.2e-01
5.0e-01
4.7e-01
cases:23.04%
controls:19.62%
cases:15.55%
controls:11.70%
cases:4.02%
controls:2.37%
—
—
cases:3.09%
controls:2.27%
cases:18.20%
controls:11.85%
cases:34.56%
controls:24.76%
418
3552
1396
14553
282
2118
1532
15987
73
429
1741
17676
—
56
410
1755
17647
318
2057
1429
15303
516
3649
977
11086
Varicose veins of lower extremities with ulcer
I83.0 [45557601]
I83.0 [45557601]
—
—
—
—
—
2.0e+00
6.2e-01
—
—
—
—
—
—
—
—
—
—
cases:0.40%
controls:0.05%
cases:0.40%
controls:0.22%
—
—
—
—
—
7
9
1740
17351
6
32
1487
14703
Right side
ZXA00 [2001311346]
ZXA00 [2001311346]
4.2e-01
7.1e-01
1.7e+00
1.0e+50
1.3e+00
1.1e+00
5.1e-01
cases:5.07%
controls:3.38%
cases:1.43%
controls:0.71%
cases:0.39%
controls:0.07%
cases:0.83%
controls:0.00%
cases:0.28%
controls:0.08%
cases:2.00%
controls:0.67%
cases:3.88%
controls:2.37%
92
612
1722
17493
26
129
1788
17976
7
13
1807
18092
15
0
1799
18105
5
14
1806
18043
35
116
1712
17244
58
349
1435
14386
Fear of cancer of skin
S26 [2002000990]
S26 [2002000990]
2.0e+00
—
—
—
—
—
1.8e+00
cases:0.55%
controls:0.07%
—
—
—
—
—
—
—
—
—
—
cases:0.33%
controls:0.05%
10
13
1804
18092
—
—
—
—
—
5
8
1488
14727
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
3209-4 [3019250]
8.7e-01
8.5e-01
—
—
—
9.6e-01
1.2e+00
cases:1.38%
controls:0.58%
cases:0.55%
controls:0.24%
—
—
—
—
—
—
cases:0.57%
controls:0.22%
cases:1.74%
controls:0.55%
25
105
1789
18000
10
43
1804
18062
—
—
—
10
38
1737
17322
26
81
1467
14654
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
SPAT1148 [2001700249]
-5.5e-02
8.6e-01
9.2e-01
—
1.2e+00
1.2e+00
3.3e-01
cases:1.54%
controls:1.63%
cases:1.32%
controls:0.56%
cases:0.33%
controls:0.13%
—
—
cases:0.66%
controls:0.20%
cases:1.77%
controls:0.56%
cases:2.21%
controls:1.60%
28
295
1786
17810
24
102
1790
18003
6
24
1808
18081
—
12
37
1799
18020
31
98
1716
17262
33
236
1460
14499
Exposure to unspecified factor
X59 [45756412]
X59 [45756412]
2.4e-01
5.9e-01
-1.0e+50
—
2.0e+00
1.3e-01
4.0e-01
cases:2.87%
controls:2.26%
cases:1.05%
controls:0.59%
cases:0.00%
controls:0.06%
—
—
cases:0.50%
controls:0.07%
cases:0.74%
controls:0.66%
cases:3.82%
controls:2.59%
52
410
1762
17695
19
106
1795
17999
0
10
1814
18095
—
9
12
1802
18045
13
114
1734
17246
57
382
1436
14353
Disorder of skin and subcutaneous tissue, unspecified
L98.9 [45562566]
L98.9 [45562566]
2.0e+00
—
—
—
—
—
—
cases:0.33%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
1808
18097
—
—
—
—
—
—
Active surveillance of a diagnosed cancer
XZZ00 [2001311159]
XZZ00 [2001311159]
1.4e+00
2.0e+00
—
—
—
1.6e+00
1.3e+00
cases:0.50%
controls:0.13%
cases:0.33%
controls:0.04%
—
—
—
—
—
—
cases:0.29%
controls:0.06%
cases:0.54%
controls:0.15%
9
23
1805
18082
6
8
1808
18097
—
—
—
5
10
1742
17350
8
22
1485
14713
Benign neoplasm: Skin of upper limb, including shoulder
D23.6 [45586094]
D23.6 [45586094]
2.0e+00
—
—
—
—
—
2.0e+00
cases:0.33%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
cases:0.33%
controls:0.05%
6
8
1808
18097
—
—
—
—
—
5
7
1488
14728
Laparoscopically assisted vaginal hysterectomy
LCD11 [2001306588]
LCD11 [2001306588]
2.0e+00
—
—
—
—
—
—
cases:0.33%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
1808
18097
—
—
—
—
—
—
Construction of arteriovenous fistula from radial artery
PBL10 [2001308892]
PBL10 [2001308892]
2.0e+00
—
—
—
—
—
—
cases:0.33%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
1808
18097
—
—
—
—
—
—
Procollagen type I.N-terminal propeptide [Mass/volume] in Serum
47255-5 [3049714]
47255-5 [3049714]
—
—
—
—
—
2.0e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:0.34%
controls:0.05%
cases:0.33%
controls:0.06%
—
—
—
—
—
6
8
1741
17352
5
9
1488
14726
Ultrasound examination of thorax
GA1AE [2001303415]
GA1AE [2001303415]
—
—
—
—
—
-1.0e+50
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.07%
cases:0.40%
controls:0.05%
—
—
—
—
—
0
12
1747
17348
6
8
1487
14727
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
3.4e-01
4.7e-01
6.5e-01
—
3.6e-01
6.0e-01
5.9e-01
cases:12.18%
controls:8.99%
cases:7.33%
controls:4.71%
cases:1.32%
controls:0.70%
—
—
cases:1.16%
controls:0.81%
cases:8.47%
controls:4.86%
cases:19.09%
controls:11.61%
221
1627
1593
16478
133
853
1681
17252
24
126
1790
17979
—
21
147
1790
17910
148
843
1599
16517
285
1711
1208
13024
Other disorders resulting from impaired renal tubular function
N25.8 [45582397]
N25.8 [45582397]
2.0e+00
—
—
—
—
—
1.7e+00
cases:0.44%
controls:0.06%
—
—
—
—
—
—
—
—
—
—
cases:0.33%
controls:0.06%
8
11
1806
18094
—
—
—
—
—
5
9
1488
14726
Deposits [accretions] on teeth betel
K03.65 [2000502690]
K03.65 [2000502690]
1.0e-01
6.5e-01
—
—
—
7.3e-01
5.9e-01
cases:3.64%
controls:3.30%
cases:1.87%
controls:0.99%
—
—
—
—
—
—
cases:2.23%
controls:1.09%
cases:5.89%
controls:3.35%
66
597
1748
17508
34
179
1780
17926
—
—
—
39
189
1708
17171
88
494
1405
14241
Lymphnode ultrasound examination
PJ2AE [2001309620]
PJ2AE [2001309620]
2.0e+00
—
—
—
—
—
—
cases:0.55%
controls:0.08%
—
—
—
—
—
—
—
—
—
—
—
—
10
14
1804
18091
—
—
—
—
—
—
Hemodialysis
TK800 [2001305768]
TK800 [2001305768]
2.0e+00
1.8e+00
—
—
—
1.4e+00
1.2e+00
cases:0.94%
controls:0.13%
cases:0.33%
controls:0.06%
—
—
—
—
—
—
cases:0.29%
controls:0.07%
cases:0.54%
controls:0.17%
17
24
1797
18081
6
10
1808
18095
—
—
—
5
12
1742
17348
8
25
1485
14710
Extracorporeal dialysis
Z49.1 [45537649]
Z49.1 [45537649]
2.0e+00
1.8e+00
—
—
—
—
1.4e+00
cases:0.66%
controls:0.09%
cases:0.28%
controls:0.04%
—
—
—
—
—
—
—
—
cases:0.40%
controls:0.10%
12
17
1802
18088
5
8
1809
18097
—
—
—
—
6
15
1487
14720
desloratadine; oral
R06AX27 [21603526]
R06AX27 [21603526]
3.9e-01
4.8e-01
2.9e-01
—
5.0e-01
5.8e-01
5.0e-01
cases:7.72%
controls:5.34%
cases:4.52%
controls:2.85%
cases:0.55%
controls:0.41%
—
—
cases:0.72%
controls:0.44%
cases:4.87%
controls:2.78%
cases:9.85%
controls:6.24%
140
967
1674
17138
82
516
1732
17589
10
75
1804
18030
—
13
79
1798
17978
85
482
1662
16878
147
919
1346
13816
Toxoplasma gondii IgG Ab avidity [Ratio] in Serum by Immunoassay
56990-5 [40760109]
56990-5 [40760109]
1.9e+00
—
—
—
—
—
1.2e+00
cases:0.39%
controls:0.06%
—
—
—
—
—
—
—
—
—
—
cases:0.40%
controls:0.12%
7
10
1807
18095
—
—
—
—
—
6
18
1487
14717
Toxoplasma gondii IgA Ab [Units/volume] in Serum
22578-9 [3018921]
22578-9 [3018921]
1.9e+00
—
—
—
—
—
1.2e+00
cases:0.39%
controls:0.06%
—
—
—
—
—
—
—
—
—
—
cases:0.33%
controls:0.10%
7
10
1807
18095
—
—
—
—
—
5
15
1488
14720
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
41
68
6.14
23.79
30.0
34.4
88.70
116.77
ug/l
2.67
33
57
937
7208
1.60
21.68
7.3
5.0
36.88
36.09
g/l
5.26
883
6802
299
1776
1.81
18.06
7.8
4.4
233.12
244.61
u/l
0.61
290
1699
424
2826
1.65
16.79
3.8
2.9
2.13
1.09
e6/l
0.44
232
1468
1166
9766
1.52
16.23
12.9
9.6
3.85
4.03
e9/l
2.05
1028
8550
619
4560
1.54
15.83
4.9
3.2
0.25
0.41
e6/l
2.02
463
3322
967
7825
1.49
15.67
3.0
2.5
79.73
76.46
nmol/l
2.98
906
7182
1545
13945
1.64
13.95
24.6
18.3
13.49
13.53
%
0.68
1529
13768
684
5265
1.47
13.66
5.2
3.3
38.81
82.29
e6/l
1.29
527
4007
567
4214
1.50
13.45
5.7
4.1
90.77
91.96
%
0.57
552
4124
382
2609
1.58
13.34
4.2
3.0
3.14
2.93
e6/l
0.13
188
1246
27
53
5.15
13.17
2.6
3.0
0.61
0.62
mmol/l
0.18
27
53
86
360
2.46
13.15
10.5
6.1
2563.89
237.51
iu/ml
0.45
18
43
1483
13323
1.56
12.92
5.2
4.6
14.65
14.64
pmol/l
0.06
1389
12401
228
1384
1.74
12.56
12.8
7.8
10.04
9.04
mmol/l
1.27
221
1339
1408
12540
1.50
12.47
11.5
8.1
75.98
77.98
u/l
1.18
1361
11949
972
8115
1.41
11.95
10.1
7.2
1.22
1.21
mmol/l
1.73
867
7060
1385
12340
1.48
11.82
5.4
4.3
10.41
11.35
mm/h
1.91
1315
11600
1660
15411
1.71
11.68
6.3
5.6
1.81
1.87
mu/l
1.14
1578
14480
916
7588
1.41
11.67
14.7
11.1
0.00
0.00
e9/l
0.10
756
6220
718
5747
1.41
10.94
4.7
3.4
2.36
2.35
mmol/l
0.31
657
5279
1062
9103
1.39
10.63
4.7
3.8
0.00
0.18
estimate
0.54
199
1811
1012
8613
1.38
10.53
8.9
6.5
11.47
11.28
umol/l
0.15
968
8226
1044
8949
1.38
10.29
4.6
3.8
0.00
0.00
estimate
0.80
201
1876
542
4169
1.42
10.21
3.8
2.7
333.22
331.75
umol/l
0.12
488
3720
1242
10968
1.40
10.14
5.3
4.6
3034.45
1746.42
e6/l
0.25
11
146
434
3211
1.46
10.07
3.7
2.8
2.44
2.44
mmol/l
0.32
390
2897
1050
9039
1.37
9.91
4.6
3.8
7.00
4.37
estimate
0.14
208
1909
113
604
1.93
9.41
2.9
2.3
3.67
3.72
g/l
0.10
108
562
113
604
1.93
9.41
2.9
2.3
4.04
4.26
g/l
2.48
108
562
113
604
1.93
9.41
2.9
2.3
6.99
7.39
g/l
1.75
108
562
101
524
1.98
9.17
3.0
2.4
9.71
10.39
g/l
0.97
96
478
863
7272
1.35
9.00
9.1
6.6
1.22
1.21
mmol/l
1.70
810
6744
1514
13951
1.46
8.94
25.4
19.0
332.26
332.32
g/l
0.10
1508
13876
1721
16314
1.73
8.92
21.5
17.0
139.68
139.63
mmol/l
0.36
1695
16002
107
572
1.92
8.92
3.0
2.4
2.87
2.95
g/l
0.37
102
530
196
1251
1.63
8.88
6.2
3.9
99.82
83.08
ng/l
1.24
180
1104
1782
17076
2.03
8.86
15.6
11.7
24.84
25.59
u/l
1.33
1759
16665
472
3622
1.41
8.80
4.2
2.7
5.28
6.47
e6/l
1.18
436
3296
72
336
2.19
8.67
1.9
1.4
139.60
154.19
au/ml
0.34
17
98
1830
17743
2.88
8.58
29.5
22.7
90.84
90.77
fl
0.26
1824
17595
1830
17746
2.87
8.52
29.6
22.8
4.48
4.49
e12/l
0.35
1804
17415
1830
17746
2.87
8.52
30.2
23.3
40.27
40.54
%
0.48
1824
17589
1830
17749
2.86
8.46
29.7
22.8
6.52
6.71
e9/l
3.65
1804
17411
1721
16347
1.70
8.41
22.0
17.2
3.94
3.95
mmol/l
0.93
1695
16001
1829
17737
2.81
8.40
29.7
22.8
255.37
255.89
e9/l
0.13
1810
17447
710
5855
1.34
8.36
4.7
3.3
28.42
31.49
u/l
2.31
674
5569
1830
17754
2.85
8.35
29.8
22.9
134.66
134.85
g/l
0.24
1825
17603
90
465
1.98
8.30
3.0
2.4
0.01
0.01
g/l
0.05
82
424
373
2783
1.43
8.08
3.8
2.6
13.92
13.44
umol/l
0.69
361
2602
298
2132
1.47
8.07
10.5
6.1
1.06
1.04
mmol/l
0.56
281
1978
364
2705
1.43
8.06
5.2
3.7
0.82
0.82
mmol/l
0.17
343
2570
88
456
1.98
8.05
3.0
2.4
0.00
0.00
g/l
-0.00
80
403
99
536
1.89
7.97
3.4
2.5
0.55
1.00
g/l
0.74
88
471
27
79
3.45
7.95
1.2
1.2
—
—
—
0
0
1704
16178
1.63
7.91
6.1
5.5
2.71
2.74
mmol/l
0.79
1628
15232
238
1640
1.52
7.73
2.9
2.4
33.88
66.85
u/l
0.58
207
1377
336
2479
1.43
7.72
2.7
2.1
29.39
29.44
s
0.06
328
2409
249
1736
1.50
7.65
3.2
2.1
375.14
381.10
nmol/l
0.22
236
1622
397
3027
1.40
7.55
4.4
3.7
477.89
485.55
ng/l
0.01
296
2194
34
119
2.89
7.49
2.3
2.8
—
—
—
0
0
319
2349
1.43
7.38
4.0
2.6
23.81
23.00
%
0.51
307
2201
343
2566
1.41
7.26
3.9
2.5
2.32
2.35
g/l
0.50
329
2386
836
7159
1.30
7.21
2.3
2.1
99.39
97.14
pmol/l
0.74
450
3812
990
8677
1.30
7.15
4.2
3.2
106.32
103.54
ug/l
0.16
934
8188
1683
15989
1.55
7.12
5.4
4.9
4.66
4.68
mmol/l
0.40
1615
15116
913
7936
1.30
6.94
3.1
2.8
—
—
estimate
—
0
0
1606
15131
1.45
6.90
4.5
4.1
1.21
1.27
mmol/l
2.87
1520
14120
269
1957
1.44
6.62
4.7
2.7
7.77
7.43
umol/l
0.14
237
1716
17
41
4.18
6.55
1.0
1.7
1.51
1.85
ug/l
—
8
20
1673
15923
1.50
6.47
5.3
4.8
1.52
1.48
mmol/l
2.85
1601
14967
189
1292
1.52
6.37
1.5
1.3
170.81
210.47
u/ml
0.49
180
1198
200
1384
1.50
6.35
3.4
3.0
10.44
10.63
g/l
0.27
183
1280
170
1144
1.53
6.16
2.3
2.3
11.63
12.28
nmol/l
0.48
158
1035
99
584
1.73
6.08
1.4
1.4
10.65
9.87
u/l
0.19
80
467
10
8
12.56
6.08
4.5
2.5
—
—
—
0
0
1629
15459
1.43
6.05
5.2
4.8
5.78
5.85
mmol/l
1.23
1545
14366
1776
17173
1.75
6.02
24.7
18.7
77.69
73.84
umol/l
3.60
1763
16999
1698
16252
1.51
5.93
20.1
14.9
21.05
22.43
mg/l
1.06
1374
13337
182
1256
1.50
5.87
3.1
2.5
66.21
69.60
ml/min/173m2
0.47
78
530
1240
11332
1.28
5.85
3.5
3.3
—
—
—
0
0
183
1265
1.50
5.85
1.6
1.4
—
—
—
0
0
183
1268
1.49
5.78
3.2
2.9
66.05
66.85
g/l
0.82
175
1183
802
6971
1.26
5.70
2.0
1.9
1.28
1.35
mmol/l
1.88
713
6003
468
3804
1.31
5.66
1.7
1.5
2.18
2.33
g/l
1.16
300
2398
77
433
1.81
5.59
2.2
3.0
1.85
1.99
index
0.10
39
227
83
479
1.77
5.53
1.2
1.2
—
—
—
0
0
190
1341
1.46
5.48
3.7
2.9
64.35
72.12
e9/l
2.89
132
974
159
1083
1.51
5.46
2.4
1.8
1.50
1.35
g/l
0.30
148
1005
1631
15533
1.40
5.44
19.0
14.0
82.86
84.60
ml/min/173m2
2.68
1504
14281
806
7048
1.25
5.32
16.6
13.3
1.23
1.21
inr
0.52
658
5873
414
3337
1.31
5.28
1.6
1.5
—
—
—
0
0
1058
9568
1.25
5.07
6.3
5.2
6.47
6.60
mmol/l
1.22
998
8996
54
281
1.95
5.00
1.1
1.1
—
—
—
0
0
580
4920
1.26
4.89
2.4
2.2
199.02
203.40
u/l
0.05
546
4695
81
482
1.71
4.88
1.2
1.2
—
—
—
0
0
10
13
7.73
4.85
4.6
2.2
17.19
26.77
mg/l
—
10
13
497
4146
1.27
4.81
2.8
2.3
—
—
—
0
0
166
1172
1.46
4.80
3.8
3.5
4.54
4.53
pmol/l
0.03
153
1054
194
1412
1.42
4.76
1.3
1.2
95.15
143.22
u/ml
1.76
78
546
219
1629
1.39
4.74
5.7
3.7
5.88
5.82
kpa
0.39
213
1585
153
1066
1.47
4.73
8.2
9.4
24.68
24.91
mmol/l
0.38
153
1060
312
2459
1.32
4.64
2.9
2.4
93.87
118.15
ug/g
1.18
263
1962
9
11
8.21
4.56
2.4
3.0
4.02
2.90
mg/l
—
9
11
83
508
1.66
4.53
3.0
2.7
—
—
—
0
0
353
2844
1.30
4.47
4.9
4.5
24.69
21.33
%
2.61
162
1329
162
1156
1.44
4.44
1.4
1.4
22.52
25.96
iu/l
0.73
138
991
1578
15049
1.32
4.39
6.4
6.0
38.26
38.66
mmol/mol
1.15
1498
14231
9
12
7.53
4.35
2.0
1.1
—
—
—
0
0
42
211
2.01
4.33
1.4
1.6
18.38
30.07
ng/l
1.32
42
211
210
1576
1.37
4.31
6.1
3.8
1.62
1.86
mmol/l
0.54
190
1353
66
387
1.73
4.23
1.6
1.3
297.47
247.91
u/ml
0.51
50
227
161
1162
1.42
4.16
1.8
1.7
—
—
—
0
0
272
2139
1.32
4.10
3.4
3.2
0.68
0.75
ug/l
0.90
180
1348
133
931
1.46
4.05
1.7
1.7
—
—
—
0
0
24
99
2.44
3.97
9.2
7.1
4.80
194.29
ug/l
0.56
18
62
205
1564
1.35
3.80
4.3
4.4
13.20
22.45
ug/l
0.37
165
1270
35
173
2.04
3.80
7.0
4.8
304.94
57.62
u/ml
0.40
15
54
321
2610
1.28
3.75
2.1
1.9
—
—
—
0
0
165
1222
1.38
3.69
2.5
2.4
16.66
20.53
au/ml
0.28
11
131
467
3979
1.23
3.62
4.3
3.9
1.02
1.78
kg/l
0.80
311
2642
74
468
1.61
3.61
1.6
2.1
11.99
11.71
mg/l
0.11
68
438
247
1954
1.30
3.57
2.1
1.8
—
—
—
0
0
153
1126
1.39
3.56
1.4
1.3
59.66
45.82
au/ml
—
7
76
56
333
1.70
3.47
1.7
1.4
—
—
—
0
0
24
106
2.28
3.46
1.2
1.1
1366.38
1528.38
miu/ml
0.29
24
106
179
1365
1.34
3.35
4.9
3.3
4.66
4.56
kpa
0.25
174
1330
100
689
1.48
3.34
2.6
1.9
1.23
1.47
g/l
1.99
90
610
20
83
2.42
3.30
1.3
2.0
—
—
—
0
0
20
83
2.42
3.30
1.3
2.0
—
—
—
0
0
235
1867
1.30
3.29
2.2
1.9
—
—
—
0
0
513
4454
1.21
3.26
2.7
2.3
2.53
2.77
mg/l
2.22
453
3860
500
4336
1.21
3.21
3.4
3.1
1457.97
1104.71
ng/l
0.77
424
3666
9
20
4.52
3.11
3.2
1.6
—
—
—
0
0
63
399
1.60
3.10
1.7
1.4
—
—
—
0
0
68
440
1.57
3.06
1.3
1.2
—
—
—
0
0
453
3908
1.21
3.06
2.3
1.7
0.95
1.09
mg/l
0.68
341
3007
96
672
1.45
2.99
1.6
1.6
7.54
12.34
u/ml
1.14
23
155
69
451
1.55
2.98
1.8
1.7
—
—
—
0
0
84
573
1.49
2.98
4.5
3.6
108.84
960.20
u/ml
1.84
69
498
76
508
1.52
2.97
1.2
1.1
3.71
4.27
—
7
68
112
809
1.41
2.95
1.6
1.6
351.71
296.21
mu/l
0.31
104
727
39
220
1.79
2.94
1.7
1.7
—
—
—
0
0
84
575
1.48
2.94
1.4
1.5
0.61
0.17
iu/ml
0.33
17
88
68
445
1.55
2.93
1.7
1.7
—
—
—
0
0
46
273
1.70
2.92
1.1
1.1
2.17
2.33
eliau/ml
0.06
25
119
28
142
1.99
2.90
2.4
1.7
—
—
—
0
0
96
677
1.44
2.89
1.7
1.7
—
—
—
0
0
413
3556
1.21
2.83
6.0
5.4
1.98
2.37
ug/l
1.36
377
3216
67
445
1.52
2.72
1.3
1.3
—
—
—
0
0
502
4419
1.19
2.68
1.5
1.3
0.76
1.58
u/ml
2.92
145
1215
177
1394
1.30
2.68
1.7
2.0
—
—
—
0
0
104
756
1.40
2.67
1.8
2.0
40.89
39.44
u/l
0.32
90
683
112
826
1.38
2.64
5.0
2.9
1.14
1.24
%
0.52
112
821
749
6820
1.16
2.63
4.4
3.7
0.19
0.05
estimate
0.43
164
1573
39
229
1.72
2.60
1.2
1.3
—
—
—
0
0
584
5221
1.17
2.58
3.8
2.6
64.68
75.09
u/l
0.28
544
4854
520
4620
1.17
2.47
1.8
1.7
21.32
20.58
nmol/l
0.53
453
3971
151
1181
1.30
2.43
2.4
2.3
7.49
7.54
ug/l
0.01
131
1059
70
483
1.47
2.41
5.4
3.7
35.88
48.00
mg/l
0.59
59
416
70
483
1.47
2.41
5.4
3.7
61.57
58.74
mg/l
0.04
59
415
44
274
1.62
2.38
1.4
1.3
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
66
451
1.48
2.38
3.2
3.3
0.28
0.37
iu/ml
2.05
34
238
296
2509
1.21
2.38
1.7
1.7
1216.24
1175.79
nmol/l
0.30
228
1927
14
58
2.42
2.37
2.3
1.4
—
—
—
0
0
151
1899
0.78
2.32
4.9
4.7
32.43
32.33
%
0.04
115
1320
26
140
1.87
2.32
1.6
1.1
356.00
210.91
titre
—
5
22
163
1297
1.28
2.31
3.2
2.4
0.32
0.44
e6/l
0.44
155
1237
21
105
2.01
2.31
1.2
1.2
—
—
—
0
0
19
92
2.08
2.27
2.9
1.5
160.09
94.67
ng/l
0.79
19
92
194
1584
1.25
2.23
7.1
9.6
96.02
95.65
%
0.29
185
1533
36
217
1.67
2.23
1.3
1.3
—
—
—
0
0
389
3403
1.18
2.21
1.4
1.3
33.41
29.43
iu/ml
0.12
116
1026
361
3142
1.18
2.18
1.3
1.3
11.86
10.93
u/ml
0.08
125
1235
1218
11583
1.15
2.16
4.0
3.3
40.51
43.75
u/l
1.00
1163
11014
205
1692
1.24
2.14
1.9
2.1
—
—
—
0
0
10
36
2.79
2.13
1.2
1.3
—
—
—
0
0
207
1711
1.24
2.13
6.1
6.4
—
—
—
0
0
15
68
2.22
2.11
3.3
2.0
69.67
64.14
ug/l
0.06
15
68
211
1755
1.23
2.06
7.0
9.1
0.52
0.92
mmol/l
0.88
172
1455
50
334
1.51
2.05
2.0
1.5
—
—
—
0
0
62
433
1.45
2.05
5.3
3.5
11.47
3.12
ratio
0.63
31
237
69
492
1.42
2.04
1.1
1.1
3.74
6.40
eliau/ml
0.40
14
62
62
434
1.44
2.02
1.8
1.6
—
—
—
0
0
181
1484
1.24
2.02
7.5
10.0
119.24
121.26
g/l
0.63
174
1448
44
287
1.55
2.01
2.0
1.8
—
—
—
0
0
46
304
1.53
1.99
1.3
1.4
—
—
—
0
0
46
304
1.53
1.99
1.3
1.4
—
—
—
0
0
74
537
1.39
1.99
1.6
2.2
2.62
4.28
iu/l
2.90
21
232
78
572
1.38
1.97
1.4
1.3
—
—
—
0
0
11
45
2.45
1.93
1.2
1.2
—
—
—
0
0
136
1086
1.27
1.91
3.0
3.0
124.32
166.90
ng/l
1.75
129
994
211
1772
1.22
1.89
7.0
9.1
5.02
5.10
kpa
0.68
200
1704
57
399
1.44
1.88
1.1
1.1
3.43
1.68
u/ml
0.42
34
205
25
144
1.75
1.85
1.2
1.1
—
—
—
0
0
18
93
1.94
1.85
1.1
1.1
—
—
—
0
0
30
183
1.65
1.82
1.1
1.1
—
—
—
0
0
210
1772
1.21
1.80
7.0
9.1
12.87
12.45
kpa
0.55
199
1706
121
961
1.28
1.79
1.4
1.4
—
—
—
0
0
415
3709
1.15
1.79
1.8
1.6
—
—
—
0
0
123
980
1.27
1.78
9.6
11.3
0.65
0.65
%
0.02
123
974
9
36
2.51
1.74
2.8
1.1
80.11
98.39
%
—
9
36
43
291
1.49
1.70
1.3
1.3
2.19
5.09
u/ml
1.74
21
128
95
737
1.30
1.69
1.5
1.5
—
—
—
0
0
39
259
1.52
1.69
1.4
1.6
331.09
352.21
mu/l
0.14
34
211
126
1016
1.26
1.66
9.5
11.1
93.86
93.87
%
0.00
126
1010
6
19
3.16
1.66
1.3
1.4
—
—
—
0
0
51
360
1.43
1.64
1.4
1.7
—
—
—
0
0
26
158
1.65
1.62
6.2
3.8
—
—
—
0
0
24
143
1.69
1.61
1.4
1.2
—
—
—
0
0
110
877
1.27
1.61
7.7
12.4
15.57
15.89
%
0.53
103
840
126
1021
1.25
1.61
9.3
10.9
1.23
1.32
%
0.66
126
1015
17
91
1.88
1.60
1.1
1.1
—
—
—
0
0
117
940
1.26
1.60
2.7
2.3
4413.47
6516.78
u/l
0.39
50
387
25
151
1.66
1.60
1.3
1.1
11.79
10.91
iu/ml
—
7
41
10
43
2.33
1.58
1.2
1.1
—
—
—
0
0
10
44
2.28
1.55
1.2
1.1
—
—
—
0
0
26
161
1.62
1.53
2.0
1.2
—
—
—
0
0
45
316
1.43
1.51
1.6
1.7
—
—
—
0
0
57
418
1.38
1.50
1.3
1.5
17.35
40.91
e6/l
0.58
43
311
16
86
1.87
1.50
3.2
3.0
658.63
936.71
u/ml
0.63
16
86
20
116
1.73
1.49
3.1
3.1
487.47
505.28
e6/l
0.06
15
99
103
824
1.26
1.48
1.7
1.5
—
—
—
0
0
9
37
2.44
1.48
1.2
1.1
—
—
—
0
0
94
746
1.27
1.45
1.3
1.2
0.24
1.19
u/ml
—
7
47
57
422
1.36
1.43
1.4
1.6
179.07
1370.70
e6/l
0.99
44
330
10
46
2.18
1.40
1.2
1.2
—
—
—
0
0
33
222
1.50
1.39
1.8
1.6
—
—
—
0
0
42
297
1.42
1.38
1.3
1.2
4.60
3.85
u/ml
0.08
15
98
6
23
2.61
1.36
1.3
1.1
—
—
—
0
0
62
470
1.33
1.35
1.1
1.1
3.28
2.42
u/ml
0.17
32
252
6
24
2.50
1.30
1.3
1.1
—
—
—
0
0
47
345
1.37
1.27
1.1
1.1
4.20
3.80
u/ml
0.07
26
174
9
44
2.05
1.27
1.2
1.1
—
—
—
0
0
20
123
1.63
1.24
1.3
1.2
0.52
0.60
ratio
0.92
12
71
80
637
1.27
1.23
1.5
1.3
—
—
—
0
0
22
139
1.59
1.23
1.8
2.5
16.82
32.91
mg/l
2.66
15
100
23
147
1.57
1.23
2.7
2.8
14.64
12.57
index
0.35
14
92
45
330
1.37
1.23
1.4
1.4
2.60
3.01
ug/l
0.34
40
301
86
693
1.25
1.21
1.7
1.5
—
—
—
0
0
0
34
0.00
1.16
0.0
3.4
—
1.26
—
0
23
528
4913
1.10
1.15
4.9
3.9
0.00
0.01
estimate
1.54
188
1774
5
112
0.44
1.13
1.2
1.3
—
—
—
0
0
26
176
1.48
1.10
1.3
1.1
—
—
—
0
0
184
1611
1.16
1.09
2.9
2.3
0.23
0.21
g/l
1.75
178
1511
44
329
1.35
1.09
1.5
1.6
—
—
—
0
0
7
32
2.19
1.08
1.0
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
15
89
1.69
1.07
1.1
1.2
—
—
—
0
0
592
5563
1.09
1.04
4.5
3.5
7.29
7.56
mmol/l
0.80
528
4799
94
782
1.21
1.02
3.3
3.3
1.02
1.02
ratio
2.39
83
713
5
23
2.18
0.98
1.6
1.6
—
—
—
0
0
50
389
1.29
0.97
1.7
1.4
0.37
0.40
nmol/l
0.17
36
314
38
284
1.35
0.97
1.1
1.1
—
—
—
0
0
534
5013
1.09
0.96
3.8
3.2
0.34
0.07
estimate
0.41
166
1525
44
337
1.31
0.96
3.6
2.4
68.58
111.66
ug/min
0.68
32
202
20
134
1.50
0.91
1.7
1.4
—
—
—
0
0
22
151
1.46
0.90
1.1
1.0
—
—
—
0
0
92
775
1.20
0.90
3.4
1.9
23.36
7.49
iu/ml
0.80
22
175
44
341
1.30
0.89
1.5
1.4
—
—
—
0
0
25
177
1.42
0.88
3.1
3.1
2.80
35.86
nmol/l
0.54
25
172
25
177
1.42
0.88
1.8
1.7
—
—
—
0
0
31
229
1.36
0.87
1.5
1.4
421.31
336.33
pmol/l
0.50
26
198
52
417
1.25
0.82
1.1
1.1
3.96
5.57
u/ml
0.39
30
232
176
1573
1.13
0.82
3.5
3.2
—
—
—
0
0
15
97
1.55
0.81
1.1
1.4
—
72.31
—
0
13
0
24
0.00
0.79
0.0
1.0
—
—
—
0
0
52
420
1.24
0.79
1.7
1.4
—
—
—
0
0
9
150
0.60
0.78
1.0
2.0
—
—
—
0
0
11
66
1.67
0.78
1.1
1.5
82.00
95.84
%
—
5
38
63
520
1.22
0.78
1.6
1.5
277.87
289.24
ug/g
0.17
39
309
40
313
1.28
0.78
1.8
1.4
29.56
24.43
u/l
0.37
35
261
619
5893
1.08
0.78
3.9
3.5
24.99
54.79
ng/l
1.69
373
3852
21
148
1.42
0.78
1.2
1.1
—
—
—
0
0
18
123
1.47
0.77
1.8
1.6
23.00
34.28
%
0.83
12
78
539
5111
1.08
0.75
5.6
4.2
9.92
8.76
mg/mmol
0.30
351
3187
23
167
1.38
0.73
1.3
1.3
0.71
2.46
u/ml
0.76
14
88
22
159
1.39
0.72
1.8
1.8
—
—
—
0
0
14
92
1.53
0.72
2.2
2.9
1.07
0.78
index
0.56
14
92
13
84
1.55
0.72
2.2
1.7
3.13
2.85
u/field
—
8
65
11
68
1.62
0.71
1.0
1.2
78.00
93.10
%
—
5
39
21
151
1.40
0.71
1.3
1.1
—
—
—
0
0
18
126
1.43
0.70
1.2
1.2
—
—
—
0
0
85
731
1.17
0.70
1.3
1.3
261.35
233.65
miu/ml
0.29
47
358
18
127
1.42
0.68
1.2
1.2
—
—
—
0
0
49
403
1.22
0.66
2.1
1.7
7739.29
12169.87
e6/l
0.67
31
287
49
403
1.22
0.66
1.1
1.1
0.39
1.22
u/ml
1.47
22
173
33
260
1.27
0.64
1.7
1.3
0.24
0.41
nmol/l
—
5
17
39
314
1.25
0.64
3.5
4.2
5.20
5.01
kpa
1.15
39
309
21
155
1.36
0.63
1.3
1.1
—
—
—
0
0
21
155
1.36
0.63
1.3
1.1
—
—
—
0
0
12
79
1.52
0.62
1.2
1.4
99.44
171.92
mmol/24h
6.32
12
79
17
121
1.41
0.62
1.2
1.0
0.92
1.08
u/l
—
6
53
119
1061
1.13
0.62
4.2
4.0
5.16
5.16
kpa
0.02
108
1030
28
218
1.29
0.60
1.8
1.3
0.15
0.26
nmol/l
0.70
20
166
0
23
0.00
0.58
0.0
1.0
—
—
—
0
0
6
35
1.72
0.57
1.0
1.1
—
—
—
0
0
70
605
1.16
0.57
4.0
4.3
24.62
24.76
mmol/l
0.16
65
566
257
2397
1.08
0.57
2.0
2.1
—
—
—
0
0
37
301
1.23
0.57
2.9
4.1
17.97
30.42
u/ml
1.62
37
292
32
256
1.25
0.56
3.6
3.4
0.70
0.83
nmol/l
0.98
26
215
23
176
1.31
0.56
1.3
1.7
—
—
—
0
0
348
3289
1.07
0.55
1.7
1.7
16832136.57
33812347.66
pmol/l
0.42
303
2786
6
39
1.54
0.53
1.0
1.1
—
—
—
0
0
13
91
1.43
0.53
1.5
1.4
11.62
13.43
u/l
0.51
13
84
103
922
1.12
0.52
4.1
3.9
1.58
1.70
mmol/l
0.12
76
688
33
268
1.24
0.52
1.4
1.5
—
—
—
0
0
31
250
1.24
0.52
1.7
1.4
0.61
7.78
nmol/l
0.50
31
238
21
161
1.31
0.51
1.3
1.1
—
—
—
0
0
6
40
1.50
0.51
1.0
1.1
—
—
—
0
0
11
75
1.47
0.50
1.6
1.7
0.47
0.47
e9/l
0.01
11
75
56
648
0.86
0.50
1.4
1.5
—
—
—
0
0
52
445
1.17
0.50
1.5
1.2
56.43
48.86
u/ml
—
6
43
10
67
1.50
0.49
1.4
1.1
111.00
107.36
%
—
10
56
62
711
0.87
0.49
1.5
1.6
68.91
60.35
ug/l
0.54
51
603
90
803
1.13
0.49
1.5
1.5
—
—
—
0
0
60
521
1.16
0.48
1.7
1.8
—
—
—
0
0
82
729
1.13
0.48
1.4
1.7
5.55
4.72
mg/l
0.18
56
531
7
47
1.49
0.47
1.4
1.0
73.40
42.18
iu/ml
—
7
47
231
2167
1.08
0.46
1.7
1.8
1.38
1.45
%
0.96
202
1925
104
941
1.11
0.46
5.9
7.7
24.06
24.45
mmol/l
0.62
96
895
63
715
0.88
0.45
1.1
1.1
1.52
1.55
g/l
0.49
63
715
58
507
1.15
0.44
1.4
1.3
—
—
—
0
0
16
121
1.33
0.44
2.2
2.1
1.44
2.03
u/field
—
9
71
38
321
1.19
0.43
1.1
1.1
6.73
5.35
u/ml
0.14
18
146
36
303
1.19
0.43
1.1
1.0
0.02
0.27
u/ml
1.85
12
97
5
31
1.61
0.43
1.0
2.3
—
—
—
0
0
54
471
1.15
0.43
1.4
1.4
81.15
184.42
pmol/l
1.61
54
460
276
2615
1.07
0.42
2.1
2.3
—
—
—
0
0
8
56
1.43
0.42
1.0
1.3
—
—
—
0
0
58
658
0.88
0.42
1.4
1.5
1.11
1.21
ratio
0.39
32
410
58
658
0.88
0.42
1.4
1.5
0.99
0.96
ratio
0.32
32
409
44
379
1.16
0.41
2.8
2.3
127.72
130.59
g/l
0.28
29
305
52
454
1.15
0.41
1.6
1.6
58.85
58.76
ug/l
0.01
52
454
58
657
0.88
0.41
1.4
1.5
1.29
1.13
ratio
0.43
32
408
0
17
0.00
0.40
0.0
1.0
—
5.85
—
0
10
24
195
1.23
0.40
1.2
1.1
—
—
—
0
0
5
34
1.47
0.40
2.4
1.6
0.18
0.14
nmol/l
—
5
21
34
287
1.19
0.40
1.2
1.1
0.44
2.94
—
5
49
8
61
1.31
0.39
1.3
1.1
41.99
48.37
u/ml
—
8
61
7
104
0.67
0.39
3.9
1.8
—
—
—
0
0
5
35
1.43
0.39
2.0
3.3
5.60
5.57
ug/l
—
5
35
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
9
66
1.37
0.38
1.4
1.3
—
—
—
0
0
5
36
1.39
0.38
3.2
1.4
—
—
—
0
0
10
135
0.74
0.36
1.2
1.5
0.86
1.14
promille
—
5
109
217
2058
1.06
0.34
2.0
1.9
3.38
3.42
ratio
0.19
167
1573
64
576
1.12
0.34
1.8
2.0
—
—
—
0
0
41
359
1.15
0.33
1.2
1.1
12.34
18.48
au/ml
0.55
11
95
20
166
1.21
0.30
2.2
6.4
6.73
7.09
mmol/l
0.23
15
138
37
325
1.14
0.29
1.4
1.6
—
—
—
0
0
7
56
1.25
0.29
1.3
1.8
40.79
41.27
g/l
—
7
56
64
584
1.10
0.28
1.6
1.6
—
—
—
0
0
42
375
1.12
0.27
2.8
2.9
1.37
1.56
mmol/l
1.27
42
365
13
104
1.25
0.26
1.1
1.2
—
—
—
0
0
8
67
1.19
0.26
1.5
1.6
144.00
498.00
nmol/24h
—
8
67
59
539
1.10
0.26
1.6
1.3
3.80
12.87
u/ml
—
8
80
9
75
1.20
0.25
2.1
2.4
—
—
—
0
0
58
534
1.09
0.23
1.6
1.2
15.33
2.57
u/ml
—
6
46
5
39
1.28
0.23
1.0
1.2
117.80
70.18
ug/l
—
5
39
5
41
1.22
0.22
1.4
1.3
0.44
0.33
ug/l
—
5
30
14
167
0.84
0.21
3.3
2.0
-0.17
0.65
mmol/l
0.79
14
161
0
11
0.00
0.21
0.0
8.7
—
—
—
0
0
(46236287) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Pleural fluid by Immunoassay
0
10
0.00
0.21
0.0
1.2
—
4981.20
—
0
5
23
201
1.15
0.21
1.6
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
6.0
—
—
—
0
0
28
249
1.13
0.20
1.2
1.3
—
—
—
0
0
38
346
1.10
0.19
1.3
1.3
—
—
—
0
0
22
194
1.14
0.18
1.2
1.5
282.29
280.20
mosm/kgh2o
0.12
17
147
7
58
1.21
0.18
1.3
1.3
—
—
—
0
0
7
58
1.21
0.18
2.4
1.9
—
—
—
0
0
7
58
1.21
0.18
2.4
1.9
—
—
—
0
0
7
58
1.21
0.18
1.3
1.3
—
—
—
0
0
7
59
1.19
0.18
2.4
1.9
—
—
—
0
0
7
60
1.17
0.17
4.9
4.0
—
—
—
0
0
133
1276
1.05
0.17
6.2
3.7
1.23
1.23
mmol/l
0.26
116
1101
7
61
1.15
0.17
1.3
1.0
—
—
—
0
0
41
378
1.09
0.17
3.1
2.2
0.89
0.91
nmol/l
0.04
33
320
16
139
1.15
0.16
1.6
1.4
91737.50
101477.93
e6/l
—
8
68
9
79
1.14
0.15
1.2
1.3
—
—
—
0
0
9
80
1.13
0.15
1.2
1.3
—
—
—
0
0
15
131
1.15
0.14
1.1
1.5
—
—
—
0
0
22
198
1.11
0.14
1.6
1.5
—
—
—
0
0
63
665
0.95
0.14
1.1
1.1
0.65
0.64
ratio
—
10
75
23
208
1.11
0.14
2.2
2.2
31.70
32.29
pg
0.25
23
208
8
96
0.83
0.13
1.5
1.2
12.25
8.82
mm/h
—
8
96
9
107
0.84
0.13
1.6
1.3
78.89
75.11
umol/l
—
9
107
107
1031
1.04
0.13
1.0
1.1
—
—
—
0
0
76
794
0.96
0.12
1.7
1.6
0.26
0.31
mg/l
0.33
34
362
10
85
1.18
0.12
2.0
1.3
182.78
164.78
pmol/l
—
10
85
30
323
0.93
0.12
2.4
3.4
19.44
24.67
mg/l
0.47
16
223
18
162
1.11
0.12
1.6
1.4
2274.80
1987.53
e6/l
—
10
103
22
201
1.10
0.11
1.6
1.5
—
—
—
0
0
12
105
1.14
0.11
1.2
1.2
—
—
—
0
0
12
105
1.14
0.11
1.3
1.5
—
—
—
0
0
21
192
1.09
0.10
1.7
1.5
—
—
—
0
0
21
192
1.09
0.10
1.7
1.5
—
—
—
0
0
72
693
1.04
0.10
3.0
6.2
1.59
1.57
%
0.05
67
652
21
193
1.09
0.10
1.7
1.5
—
—
—
0
0
33
310
1.07
0.10
3.2
3.0
7.00
7.37
mmol/l
0.34
33
301
13
145
0.90
0.09
2.3
2.7
—
—
—
0
0
20
184
1.09
0.09
1.6
2.3
25.25
24.42
mg/l
—
8
76
30
319
0.94
0.09
3.9
9.9
105.48
105.34
mmol/l
0.07
25
286
6
57
1.05
0.08
1.2
1.0
—
—
—
0
0
7
66
1.06
0.08
1.1
1.2
136.04
121.91
nmol/l
—
7
49
8
74
1.08
0.07
1.1
1.1
117.62
193.18
iu/ml
—
8
74
8
75
1.07
0.07
2.4
1.8
—
—
—
0
0
8
75
1.07
0.07
2.4
1.8
—
—
—
0
0
8
75
1.07
0.07
2.4
1.8
—
—
—
0
0
8
75
1.07
0.07
2.4
1.8
—
—
—
0
0
55
530
1.04
0.07
1.7
1.8
—
—
—
0
0
8
78
1.03
0.07
1.1
1.9
—
—
—
0
0
158
1552
1.02
0.07
1.7
1.7
3.45
3.46
mmol/l
0.01
111
1084
15
163
0.92
0.07
1.1
1.1
12.61
16.34
u/ml
—
7
70
13
142
0.91
0.06
1.9
1.1
—
43.20
—
0
5
125
1228
1.02
0.05
1.6
1.6
1530.90
1015.39
mu/l
0.95
105
1043
11
100
1.10
0.05
1.4
1.5
—
—
—
0
0
32
308
1.04
0.04
3.0
2.2
19.68
5.84
umol/l
0.56
22
227
16
151
1.06
0.03
1.3
1.1
127.50
107.74
pmol/l
1.40
16
151
19
181
1.05
0.03
2.0
1.8
50.64
57.40
%
0.24
11
121
12
128
0.94
0.02
1.3
1.7
—
—
—
0
0
29
281
1.03
0.02
1.2
1.3
18.59
27.71
u/l
0.52
22
238
18
173
1.04
0.01
1.3
1.6
7.57
7.63
mmol/l
0.04
18
167
73
738
0.99
0.01
1.3
1.2
0.89
0.89
g/l
0.10
73
738
12
114
1.05
0.00
1.3
1.5
—
—
—
0
0
15
156
0.96
0.00
1.4
1.6
—
—
—
0
0
22
215
1.02
0.00
1.1
1.1
—
—
—
0
0
50
501
1.00
0.00
4.7
3.9
1.20
1.39
mmol/l
1.14
50
493
15
154
0.97
0.00
2.3
1.6
—
—
—
0
0
14
138
1.01
0.00
2.3
1.6
—
—
—
0
0
14
138
1.01
0.00
2.3
1.6
—
—
—
0
0
14
138
1.01
0.00
2.3
1.6
—
—
—
0
0
13
128
1.02
0.00
3.2
1.7
3.64
4.00
mg/l
0.15
13
123
6
68
0.88
0.00
5.0
3.2
1.33
1.28
%
—
6
68
7
76
0.92
0.00
1.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
26.50
—
0
5
6
67
0.90
-0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.2
—
419.00
—
0
6
0
6
0.00
-0.00
0.0
9.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
3.00
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
56
0.89
-0.00
1.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_MELANOCYTIC_LOWERLIMB and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_MELANOCYTIC_LOWERLIMB | 1.071 [0.91, 1.27] | 0.422 |
| Birth year | 0.999 [0.99, 1.01] | 0.838 |
During the follow-up period (1.1.1998 — 31.12.2019), 287 out of 5208 females with CD2_BENIGN_MELANOCYTIC_LOWERLIMB died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_MELANOCYTIC_LOWERLIMB | 0.987 [0.82, 1.19] | 0.889 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 228 out of 2989 males with CD2_BENIGN_MELANOCYTIC_LOWERLIMB died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_MELANOCYTIC_LOWERLIMB.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.098% | 0.19% |
| 5 | 0.626% | 1.261% |
| 10 | 1.676% | 2.956% |
| 15 | 3.351% | 5.426% |
| 20 | 6.121% | 9.002% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_MELANOCYTIC_LOWERLIMB – Melanocytic naevi of lower limb, including hip
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data